<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001288.pub4" GROUP_ID="AIRWAYS" ID="134999091011553256" MERGED_FROM="" MODIFIED="2014-08-28 15:29:54 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Abroug 2014 ICU data added- no response to 4 emails- sent final reminder 3/06/14&lt;/p&gt;&lt;p&gt;Final text reveiwed EHW&lt;/p&gt;&lt;p&gt;changes and corrections made as per Emma W notes, PRISMA updated.&lt;/p&gt;&lt;p&gt;I do not know who was the previous editor- possibly PEter Gibson?&lt;/p&gt;&lt;p&gt;&lt;b&gt;Emma W notes 23/05/2014&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Please note changes to 'what's new events'&lt;/p&gt;&lt;p&gt;Objectives - must be exactly the same in the main text and abstract. Please choose what is best and apply.&lt;/p&gt;&lt;p&gt;Background - there is a hospital at home following exacerbations of COPD Cochrane review that you might want to reference http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003573.pub2/abstract&lt;/p&gt;&lt;p&gt;Methods - this sentence is ambiguous - clarify: Other non-corticosteroid interventions e.g. bronchodilator(s), antibiotic(s) were standardised as far as possible for both treatment arms. We usually say that other co-interventions were permitted as long as they were not part of the randomised treatments - is that what you meant?&lt;/p&gt;&lt;p&gt;Data and analyses&lt;/p&gt;&lt;ul&gt;&lt;li&gt;need to turn off totals for plots with only one trial e.g. analysis 1.8, 1,9&lt;/li&gt;&lt;li&gt;Is it possible to be more consistent in how the subgroup analyses are labelled? Sometimes the length of treatment is specified in parenthesis which seems like it is helpful, but not in others. Not sure if they were not labelled for a reason!&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Risk of bias - need to add a heading in the text and information on the additional domain added in the ROB table &amp;quot;free of other potential confounders?&amp;quot;&lt;/p&gt;&lt;p&gt;Tables&lt;/p&gt;&lt;ul&gt;&lt;li&gt;there is an errant unit mg/kgm - did you mean mg/kg?&lt;/li&gt;&lt;li&gt;be consistent e.g. methylpred. and methylprednisolone both used&lt;/li&gt;&lt;li&gt;define q6h in the footnotes&lt;/li&gt;&lt;li&gt;be consistent with how you denote per: &amp;quot;.&amp;quot; or &amp;quot;/&amp;quot;&lt;/li&gt;&lt;li&gt;SOF table&lt;/li&gt;&lt;ul&gt;&lt;li&gt;I deleted the rows which had the high/moderate/low risk in the control group. I assume that these were the ones generated in GRADEpro. This is discouraged unless the different control group event rates are explained.&lt;/li&gt;&lt;li&gt;add duration of treatment to the header of the table since that defines the need for the 2 tables&lt;/li&gt;&lt;li&gt;for the control group event rates that are currently blank (e.g. VAS for breathlessness, duration of hospitalisation and PaO2) you can add the range in the means - I completed one as an example&lt;/li&gt;&lt;/ul&gt;&lt;/ul&gt;&lt;p&gt;General comment&lt;/p&gt;&lt;ul&gt;&lt;li&gt;References need to have parenthesis round them and with semicolons between them, I added some&lt;/li&gt;&lt;li&gt;there are some errors in the spell check&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;b&gt;Liz Notes 22/05/2014&lt;/b&gt; - looks like will need a pre-pub search. (last search date June 2013). Will update search and send results. Also - no PRISMA study flow diagram for update. I have inserted a template for updates. Please complete.&lt;/p&gt;&lt;p&gt;**************************************************************&lt;/p&gt;&lt;p&gt;2008 update&lt;/p&gt;&lt;p&gt;Data double checked, results and conclusions amended with Abroug data. Send to all authors, then submit.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Abroug 2014: &lt;/b&gt;Length of stay and duration of mechanical ventilation published as median and interquartile range. Mean and SD assumptions based on Cochrane handbook section 7.7.3.5. The width of the interquartile range is approximately 1.35 standard deviations. data calculated and entered into RevMan. Data sent to author abroug for confiration 13/05/14.&lt;/p&gt;&lt;p&gt;&lt;b&gt;JW 02/05/14 updated to include ICU study Abroug 2014. Data check sent to DT CW.&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;9/4/14:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;26/03/14 &lt;/b&gt;PLS and asbtract revised, validation check run, errors corrected. send to all authors for comments.&lt;/p&gt;&lt;p&gt;&lt;b&gt;28/02/14 &lt;/b&gt;JW completed update draft main review. DT to do first draft abstract and PLS.&lt;/p&gt;&lt;p&gt;28/09/13 - DT (Edit - 21/10/13)&lt;br&gt;- Data input for Alia (complete) - &lt;b&gt;Letter sent&lt;/b&gt;&lt;br&gt;- Data input for Gunen (complete - except for TF and ADE outcomes) - &lt;b&gt;Letter sent&lt;br&gt;&lt;/b&gt;- Data input for Ceviker (complete - still require clarification on Legend used, highly likely mean(SD) format though. Symptom scores have not been put in yet (SE/SD?). In addition to clarification, early (Day 2) PaO2 and PaCO2 requested. - &lt;b&gt;Letter sent&lt;/b&gt;)&lt;br&gt;- Data input for de Jong (complete)&lt;/p&gt;&lt;p&gt;- Data input for Willaert (complete)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;9/08/13 letters request to cordero, Ridha, Zheng&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Moved Bafhadel to excluded studies RCT biodirected tx. Use in discussion.&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;10/09/12&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Plant ongoing trial- ask AG for 1999 abstract publication- not obtainiable moveto excuded studies&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Abroug OGT-emailed&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;5/9/12 updating table studies and ROB for all existing studies- see log&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;4/09/12&lt;/b&gt;Imported refs, studies awaiting classificiation&lt;/p&gt;&lt;p&gt;Alia,&lt;/p&gt;&lt;p&gt;Bafhadel, Discuss authors design?&lt;/p&gt;&lt;p&gt;Cordero, &lt;b&gt;emailed 20/09/12 returned to sender, try Morales&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Gunen,&lt;/p&gt;&lt;p&gt;Ridha,&lt;/p&gt;&lt;p&gt;Roede- exc&lt;/p&gt;&lt;p&gt;&lt;b&gt;To do Write to Cordero, &lt;/b&gt;no paper found in scopus for this author&lt;/p&gt;&lt;p&gt;&lt;b&gt;Ridha- emailed 4/09/12 &lt;/b&gt;Professeur Ali BEN KHEDER, H&amp;#244;pital ARIANA , TUNISIE&lt;br&gt;Je vous &amp;#233;cris en r&amp;#233;f&amp;#233;rence &amp;#224; votre &amp;#233;tude &amp;quot;Effet de la corticoth&amp;#233;rapie syst&amp;#233;mique dans les exacerbations aigu&amp;#235;s de BPCO&amp;quot;, pr&amp;#233;sent&amp;#233; en 2006 au 16&amp;#232;me European Respiratory Society congr&amp;#232;s annuel. Munich, Allemagne.&lt;br&gt;Nous aimerions inclure votre &amp;#233;tude dans une revue syst&amp;#233;matique Cochrane.&lt;br&gt;Pourriez-vous nous faire savoir si les r&amp;#233;sultats ont &amp;#233;t&amp;#233; publi&amp;#233;s dans un journal et si oui, quelle est la r&amp;#233;f&amp;#233;rence.&lt;br&gt;Si les r&amp;#233;sultats n'ont pas &amp;#233;t&amp;#233; publi&amp;#233;s, pourriez-vous fournir les r&amp;#233;sultats dans les 3 groupes: 1. intraveineuse (IV) d'hydrocortisone, 2. prednisone par voie orale et 3. contr&amp;#244;le / placebo, pour les r&amp;#233;sultats:&lt;br&gt;&amp;#233;chec du traitement, VEMS, effets ind&amp;#233;sirables Sympt&amp;#244;mes d'autres r&amp;#233;sultats&lt;br&gt;&lt;/p&gt;&lt;p&gt;23/08/12 OGCT registers searched.&lt;/p&gt;&lt;p&gt;1 study in ICU &lt;b&gt;Abroug&lt;/b&gt;, emailed for update progress&lt;/p&gt;&lt;p&gt;1 completed study oral pred versus IVS dejong. &lt;b&gt;de Jong&lt;/b&gt; Y P, Uil S M, Grotjohan H P, Postma D S, Kerstjens H A, van den Berg J W. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study.[see comment]. Comment in: Chest. 2007 Dec;132(6):1728-9; PMID: 18079214. 2007;132(6):1741-7 include&lt;/p&gt;&lt;p&gt;Consider separate comparison modes delivery SCS. Check all excluded studies for this comparison&lt;/p&gt;&lt;p&gt;&lt;b&gt;Willaert W&lt;/b&gt;, Daenen M, Bomans P, Verleden G, Decramer M. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? European Respiratory Journal 2002;19:928-35. &lt;b&gt;Compares intravenous steroids and aerosol bronchodilators (group I) is superior to oral steroids and multiple dose inhaler (MDI) bronchodilators with a spacer (group II). NO placebo Include in IV v Oral&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Shortall&lt;/b&gt; SP, Blum J, Oldenburg FA, Rodgerson L, Branscombe JM, Harrow EM. Treatment of patients hospitalised for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regime and an intravenous/nebulizer regimen. Respiratory Care 2002;47(2):154-8. &lt;b&gt;compares therapeutic efficacy, of Oral CS/metered-dose inhaler BD antibiotics with intravenous CS (till wheeze free then oral CS)/nebulizer regimen BD + IV cefuroxime in COPD exacerbations. No placebo control. Co-intervention delivery differs by group-&lt;/b&gt; exclude&lt;/p&gt;&lt;p&gt;&lt;b&gt;Rizzato &lt;/b&gt;G.. Effects of Deflazacort Hemisuccinate vs Methylprednisolone Succinate in COPD exacerbations.. L'internista 1998;6:35-40.GOTexclude compares 2 CS by IV administration&lt;/p&gt;&lt;p&gt;&lt;b&gt;Li&lt;/b&gt; H, He G, Chu H, Zhao L, Yu H. A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD. Respirology 2003;8(2):199-204. &lt;b&gt;compares 3 step IV/oral/inh mpred with dexamethasone and matched cointernventions. No placebo group exclude&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Kocks &lt;/b&gt;JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respiratory Research 2006;7:62. [DOI: 10.1186/1465-9921-7-62. 2nd citation Same study as de Jong. partial publication of CRG QOL results for MCID, same hospital same recruitment dates.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Ghanei&lt;/b&gt; M, Khalili A, Arab M, Mojtahedzadeh M, Aslani J, Lessan-Pezeshki M, et al. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic &amp;amp; Clinical Pharmacology &amp;amp; Toxicology 97;5:302-5&lt;/p&gt;&lt;p&gt;22/08/12 Emailed authors re update. propose amending the PICO to include studies in which participants received assisted ventilation, as a separate comparison, previously we excluded them. Alia study. &lt;/p&gt;&lt;p&gt;Check author affiliations RWB. EHW, JW&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;21/08/12 August 2011search for OS in COPD. 2 possible studies found for AE&lt;/p&gt;&lt;p&gt;1&lt;b&gt;.Alia &lt;/b&gt;I, De La Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Archives of Internal Medicine. 2011;171:1939-1946. Include- change incl criteria to look at ICU patients. GOT&lt;br&gt;2.&lt;b&gt;Bafadhel&lt;/b&gt; M, McKenna S, Terry S, et al. A double-blind randomised control trial of peripheral blood eosinophils to direct prednisolone use in COPD exacerbations [Abstract]. European Respiratory Society Annual Congress, Amsterdam, The Netherlands, September 24-28. 2011;38:38s [357]. Got, 2nd citation, main paper Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. 2012;186(1):48-55. ? Include&lt;/p&gt;&lt;p&gt;also get-email request to Liz Stovold 1-4 21/08/12&lt;/p&gt;&lt;p&gt;1.&lt;b&gt;Alia &lt;/b&gt;I, De La Cal MA, Esteban A, Ferrer R, Molina F, Pier R, et al. Evaluation of the efficacy of corticosteroids in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support: A prospective, international, randomized double blind clinical trial [Abstract]. Intensive Care Medicine. 2010;36(Suppl 2):S205.&lt;br&gt;2&lt;b&gt;.Cao&lt;/b&gt; GQ, Li J, Li L, Li HD, Chen HY, Wang FW, et al. Current status of the use of drugs without authorization by state food and drug administration of China in patients with chronic obstructive pulmonary disease in southwest chinese city of chongqing and the evaluation of interference effect [Abstract]. Congress of the Asian Pacific Society of Respirology, Manila, Philippines. 2010.&lt;br&gt;3.&lt;b&gt;Cordero &lt;/b&gt;PJ, Benlloch E, Sol&amp;#200; A, Morales P, Men&amp;#200;ndez R, Cebri&amp;#183;n J. Corticosteroid therapy for COPD exacerbations at inpatient settings: a controlled-randomized study. Archivos de Bronconeumolog&amp;#204;a. 1996;32(Suppl.2):17.&lt;br&gt;4.&lt;b&gt;Cordero&lt;/b&gt; PJ, Sole A, Benlloch E, Morales P, Vallterra J, Menendez R, et al. A randomized controlled study of prednisone in outpatients with acute exacerbation of COPD. European Respiratory Journal. 1996;9(Suppl 23):110s-1s.&lt;br&gt;5.&lt;b&gt;Ridha &lt;/b&gt;M, Ferdaous Y, Sofia T, Amel C, Ali B. Effect of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal. 2006;28(Suppl 50):624s [E3652]. Got but written in french to Ali Tunisian again&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;+++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;Abstracts for cordero 1996 obtained, refs added to waiting classification. Need letter to authors for full details.&lt;/p&gt;&lt;p&gt;13/08/09 search CCTR 2009- 77 references. 7 to evaluate&lt;/p&gt;&lt;p&gt;? inc 1- ordered paper copy of Cordero PJ; Benlloch E; Sol? A; Morales P; Men?ndez R, and Cebri?n J. Corticosteroid therapy for COPD exacerbations at inpatient settings: a controlled-randomized study [Tratamiento con corticoides en la reagudizaci?n de la EPOC en el ambiente extrahospitalario: estudio controlado y randomizado.]. CN-00662349. Archivos De Bronconeumolog&amp;#213;a. 1996; 32(Suppl.2):&lt;/p&gt;&lt;p&gt;eXCL 6: Albert (editorial) Stallberg (ICS v OS) Gomma (OS short v long), Sirichana (OS short v long), Mortimer (not rCT of OS v control), Kunter 2008 (not rCT)&lt;/p&gt;&lt;p&gt;Oct 27th&lt;/p&gt;&lt;p&gt;Dear Julia,&lt;/p&gt;&lt;p&gt;The best data is that found from ANCOVA. However this is a secondary outcome and may not alter the pooled result so I am happy to proceed with the review in its current format, as it would mean changing all the trials to GIV and I do not think this is worth the additional labour.&lt;/p&gt;&lt;p&gt;I am happy to proceed with this update in its present format.&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;Dear Chris and Toby, see responses below. I have rechecked review in with changes made&lt;/p&gt;&lt;p&gt;Astra zeneca supplied results following direct request to Maltais in 03/04 (attached)&lt;/p&gt;&lt;p&gt;Paco2: the lower SD entered were an error. the correct SD are 5 and 6. other data has been checked. Astra supplied absolute values for Paco2 for each group. Using these figures with change results in other study, gives similar effect size as in current version, -0.65 [-0.90, -0.41]&lt;/p&gt;&lt;p&gt;FEV1 72hrs-Data supplied by astrazeneca in 2004. Using absolute group values of post BD feV1 72 hours the effect size is 0.25 [0.08, 0.42]. Paper gives mean diference for change in FEV1 PRED-PLAc of 0.16 (0.09, 0.24) page 700. The stats section says anaylsis was by Ancova with ajustment for baseline values as covariates which may explains the difference. which to use? &amp;#160;MD 0.14 [0.09, 0.19]&lt;/p&gt;&lt;p&gt;Ferguson 1993 deleted, other refs linked to text.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;CJC checking on Oct 13th&lt;/p&gt;&lt;p&gt;Could Liz run an updated search as the last search date is in 2007?&lt;/p&gt;&lt;p&gt;Dear Julia,&lt;/p&gt;&lt;p&gt;Thanks for responding to the previous comments.&lt;/p&gt;&lt;p&gt;Maltais PaCO2 results altered by CJC: SD of 5 and 6 reported in the paper on page 701. Could you check this and discuss as previous SD was much lower? Where did the previous SD entries come from? Where does the data entered for Maltais early and late FEV1 come from in the paper. The effect size does not match Figure 2 in the paper? Does this mean other data will need to be checked?&lt;/p&gt;&lt;p&gt;The unlinked studies are listed below - please link to text.&lt;/p&gt;&lt;table cols=&quot;2&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Schermer 2002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Ferguson 1993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Groenewegen 2001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Wise 2005&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Jones 1997&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Singh 2002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Reference: Wilkinson 2004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p&gt;+++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;CJC edit Sept 22nd.&lt;/p&gt;&lt;p&gt;I have made a few minor edits and used the new version of Visual Rx to generate plots for both the treatment failures and adverse events. I have followed the text in stating the follow up was for 30 days (although one study was 6 months?) How did you decide which arm of the Chen trial to use?&lt;/p&gt;&lt;p&gt;Can Julia recheck this and if happy we can proceed.&lt;/p&gt;&lt;p&gt;Chris&lt;/p&gt;&lt;p&gt;+++++++++++++++++++++++++++++++++++++&lt;/p&gt;&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;04.01.08 RWB comments on first draft, edited text.&lt;br&gt;03.01.08 sent review to Mairi Hannay&lt;br&gt;6.12.07 Spell check, Export review. Send to RWB for comments on draft. Autho list needs reviewing. PG remaining as author to give overall comment?&lt;br&gt;5.12.07 Kunter 2005 published Respiration online. states that participants not randomised therefore excluded study JW. 11 studies in this update.&lt;br&gt;29.11.07 Kunter reply. Study prednisolone versu standard treatment no placebo. RWB JW agree included with sensitivity analysis. No data in abstract. Emailed request.&lt;br&gt;Imported new review into primary version. now 12 studies.&lt;br&gt;19.11.07 Vestergaard 2007 OS and fracture risk additional reference added&lt;br&gt;Second letter (emial) re Ilvan/Kunter 2005 and ST nature sent&lt;br&gt;Chen 2005 data extraction, study data. Sent Melanie Sung for second check. Data added to review&lt;/p&gt;&lt;p&gt;Update 2007: studies excluded 7 (Mirici, Rahman, De Jong, Ghanei, GSKFLIT98, Ilvan, Kocks )&lt;br&gt;Studies Included 1 (Chen 2005)&lt;br&gt;Feb 2007 Search update reviewed on 20.04.07- 70 refs&lt;br&gt;AE COPD_OS 5 refs to obtain (, 12 not OS, 47 stable COPD, 6 not COPD&lt;br&gt;1. Chen 2005 previously found&lt;br&gt;2. Ghanei 2005 -previously found&lt;br&gt;3.Ghanei 2005-previously found&lt;br&gt;4.Ilvan 2005- previously found&lt;br&gt;5.Kocks 2006 IV versus OS in AE COPD - no mention of placebo group, get full text- reviewed no placebo group, IVS versus OS in AE COPD: exclude&lt;/p&gt;&lt;p&gt;Feb 2006 Search: 77 refs 5 for assessment&lt;br&gt;1.Ilvan 2005: Letter study information request re placebo group sent 3.8.06, no reply by 20.04.07. Excluded as comparision was standard treatment no mention placebo.&lt;br&gt;2. Bingol 2005 COPD patients undergoing cardiopulmonary bypass OS v Placebo-exc&lt;br&gt;3. Ghanei 2005 no placebo group AE mustard gas induced chronic bronchitis IVS v OS- excluded&lt;br&gt;4. Chen 2005 Chen 2005: Letter study information request sent 3.8.06, reply 20.01.07 with data.&lt;br&gt;5. FLIT98 GSK trials register: exc- ICS v placebo&lt;br&gt;6. Rahman 2004 7d v 14 d OS in AECOPD no placebo&lt;br&gt;7. Mirici 2002- OS versus nebuised budesonide in AE COPD, no placebo- exclude&lt;br&gt;8. de Jong 2004 IVS versus OS in AE COPD- exclude&lt;/p&gt;&lt;p&gt;&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;new studies:&lt;br&gt;Gross data into results new&lt;br&gt;singh 2002- comment in background&lt;br&gt;ROWE- background&lt;br&gt;Old title: Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease&lt;/p&gt;&lt;p&gt;Liz Arnold has read, revised and approved the search strategy 051104.&lt;br&gt;______________________________________________________________________________________&lt;br&gt;CJC Edit of Update 4/11/2004&lt;br&gt;Authors' Contribution: fine&lt;/p&gt;&lt;p&gt;What's new: Names of new studies added. Fine to specify primary outcomes.&lt;/p&gt;&lt;p&gt;Objectives: Unchanged.&lt;/p&gt;&lt;p&gt;References: Fine&lt;/p&gt;&lt;p&gt;Table of included studies: great - good to see the detail on allocation concealment&lt;/p&gt;&lt;p&gt;Metaview Labels: Fine&lt;/p&gt;&lt;p&gt;Synopsis: fine&lt;/p&gt;&lt;p&gt;Abstract: : &amp;quot;The last search was carried out in August 2004.&amp;quot; added. Some changes made in red. FEV1 is % predicted in Metaview. NNT changed to round up using Visual Rx from the Pooled OR and baseline risk in placebo group. Minor differences. All shown in red.&lt;/p&gt;&lt;p&gt;Methods: NNT is better calcuated using the pooled OR and its confidence interval and applying this to a specified baseline risk. this can be done online at www.nntonline.net using Visual Rx. I have done this and amended the results. I have also included figures 1 and 2 to represent these pictorially.&lt;/p&gt;&lt;p&gt;Results: Fine with NNT alterations.&lt;/p&gt;&lt;p&gt;Discussion: Fine&lt;/p&gt;&lt;p&gt;Contentious issues: Why is the Aaron hyperglycaemia ratio not raised compared to the others?&lt;/p&gt;&lt;p&gt;Next action: To Toby to check authors are happy. Then off for copy editing please.&lt;br&gt;3.3.06 revwied 2005 search 112 references. excluded 25 not AE COPD, 71 intervention not OS, 4 not RCT. Getting 11 for possible inclusion and 1 for background.&lt;br&gt;One RCT comparing 2 lengths of treatment period&lt;br&gt;One RCT comparing IV versus oral&lt;br&gt;One ongoing RCT oral versus inhaled&lt;/p&gt;&lt;p&gt;Consider widening comparisons to extend the scope of the review to include other comparisons.&lt;br&gt;ie OS V placebo, OS v parenteral S, OS at different lengths treatment, OS v ICS.&lt;br&gt;There are no protocols for either as a separate review as far as I can see but checking with Toby L/RWB -emailed 3.3.06&lt;br&gt;[jw check those excuded already for above comparisons- Check Li 2003,Shortall 2002, Willaert 2002 ]&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 15:24:33 +0100" NOTES_MODIFIED_BY="Emma J Welsh" REVIEW_NO="EXA-COP" REVMAN_SUB_VERSION="5.3.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2014-08-28 15:29:54 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease</TITLE>
<CONTACT MODIFIED="2014-08-28 15:29:54 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="12527" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julia</FIRST_NAME><MIDDLE_INITIALS>AE</MIDDLE_INITIALS><LAST_NAME>Walters</LAST_NAME><POSITION>NHMRC Primary Care Research Fellow</POSITION><EMAIL_1>Julia.Walters@utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>MS1, 17 Liverpool Street</ADDRESS_1><ADDRESS_2>PO Box 23</ADDRESS_2><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6226 4798</PHONE_1><PHONE_2>+61 422 266 158</PHONE_2><FAX_1>+61 3 6226 7704</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-08-28 15:29:54 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="12527" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julia</FIRST_NAME><MIDDLE_INITIALS>AE</MIDDLE_INITIALS><LAST_NAME>Walters</LAST_NAME><POSITION>NHMRC Primary Care Research Fellow</POSITION><EMAIL_1>Julia.Walters@utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>MS1, 17 Liverpool Street</ADDRESS_1><ADDRESS_2>PO Box 23</ADDRESS_2><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6226 4798</PHONE_1><PHONE_2>+61 422 266 158</PHONE_2><FAX_1>+61 3 6226 7704</FAX_1></ADDRESS></PERSON><PERSON ID="z1305141514585849521955509509908" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Daniel</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Tan</LAST_NAME><POSITION>5th Year Medical Student</POSITION><EMAIL_1>dtan1@postoffice.utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><CITY>Hobart</CITY><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="z1305141510544590685970942900195" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Clinton</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>White</LAST_NAME><POSITION>5th Year Medical Student</POSITION><EMAIL_1>cjwhite@utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>MS1, 17 Liverpool Street</ADDRESS_1><ADDRESS_2>PO Box 23</ADDRESS_2><CITY>Hobart</CITY><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="4647" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Gibson</LAST_NAME><EMAIL_1>Peter.Gibson@hnehealth.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Respiratory and Sleep Medicine</DEPARTMENT><ORGANISATION>John Hunter Hospital</ORGANISATION><ADDRESS_1>Lookout Road</ADDRESS_1><CITY>New Lambton</CITY><ZIP>2305</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 498555766</PHONE_1><FAX_1>+ 61 2 49855850</FAX_1></ADDRESS></PERSON><PERSON ID="12536" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><LAST_NAME>Wood-Baker</LAST_NAME><POSITION>Clinical Professor</POSITION><EMAIL_1>Richard.WoodBaker@utas.edu.au</EMAIL_1><MOBILE_PHONE>0407641077</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 3 6226 4805</PHONE_1><PHONE_2>0407 641 077</PHONE_2></ADDRESS></PERSON><PERSON ID="DA990F8082E26AA2005DA36437887272" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>E. Haydn</FIRST_NAME><LAST_NAME>Walters</LAST_NAME><EMAIL_1>Haydn.Walters@utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>NHMRC CRE for Chronic Respiratory Disease</DEPARTMENT><ORGANISATION>School of Medicine, University of Tasmania</ORGANISATION><CITY>Hobart</CITY><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6226 4805</PHONE_1><FAX_1>+61 3 6226 7704</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-07-28 12:00:21 +0100" MODIFIED_BY="Emma J Welsh">
<UP_TO_DATE>
<DATE DAY="23" MONTH="5" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="5" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="7" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-08-28 15:23:39 +0100" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-08-28 15:23:39 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="23" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>Literature search run.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-07-28 12:22:39 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="23" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>Objectives of review amended. Participants: to include studies in which participants received assisted ventilation.</P>
<P>Interventions: Comparison 1- corticosteroids, parenteral or oral administration versus placebo control injections or tablets as appropriate; Comparison 2- corticosteroids, parenteral versus oral administration.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-08-19 14:30:06 +0100" MODIFIED_BY="Emma Jackson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-06-02 02:55:13 +0100" MODIFIED_BY="Julia A.E. Walters">
<DATE DAY="22" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Review updated. Changes to criteria for study inclusion; studies with participants requiring assisted ventilation included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-05-23 15:37:00 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="1" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Literature searches re-run</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-05-23 15:37:03 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="11" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-08-19 14:30:06 +0100" MODIFIED_BY="Emma Jackson">
<DATE DAY="2" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>This review, originally published in 1999 was updated in 2004 and for this version in 2007. One additional study (<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>) has been added and additional data have been received from two authors (<LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK> and <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>).</P>
<P>The conclusions of the previous version on the beneficial effect of treatment with systemic corticosteroids in acute exacerbations of COPD on the primary outcome of treatment failure have been strengthened. This update of the review found a significant reduction in length of hospital stay for treatment with systemic corticosteroids.<BR/>The beneficial effects of treatment with systemic corticosteroids on the secondary outcomes of dyspnoea, blood gases and lung function, previously only significant at an early time point, have also been confirmed at the end of treatment.</P>
<P>The increased risk of adverse effects associated with treatment, particularly the risk of hyperglycaemia, with systemic corticosteroids was confirmed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-03-26 01:03:58 +0000" MODIFIED_BY="Julia A.E. Walters">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Tasmania</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-03-26 01:03:58 +0000" MODIFIED_BY="Julia A.E. Walters">
<SOURCE MODIFIED="2014-03-26 01:03:58 +0000" MODIFIED_BY="Julia A.E. Walters">
<NAME>Commonwealth Department of Health and Aged Care</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION>
<P>Through the National Health and Medical Research Council Cochrane funding (2013-2016)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-08-28 15:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<SUMMARY MODIFIED="2014-08-19 17:46:31 +0100" MODIFIED_BY="Emma J Welsh">
<TITLE MODIFIED="2014-08-19 14:44:42 +0100" MODIFIED_BY="Emma Jackson">Do systemic corticosteroids improve treatment outcomes in flare-ups of chronic obstructive pulmonary disease?</TITLE>
<SUMMARY_BODY MODIFIED="2014-08-19 17:46:31 +0100" MODIFIED_BY="Emma J Welsh">
<P>
<B>Why is this question important?</B>
</P>
<P>Chronic obstructive pulmonary disease (COPD), also referred to as emphysema or chronic bronchitis, is a long-term lung condition commonly associated with smoking. People with COPD usually have persistent symptoms of breathlessness and may experience flare-ups (exacerbations) on occasion, often precipitated by infection, in which symptoms become markedly worse and further medical intervention is required beyond regular treatment by inhalers.</P>
<P>Systemic (i.e. not inhaled corticosteroids) such as prednisolone, prednisone and cortisone, are anti-inflammatory drugs commonly used in the treatment of exacerbations. We wanted to assess the effectiveness of systemic corticosteroids and whether different routes of administration have impacts on response to treatment of COPD exacerbations.</P>
<P>
<B>How did we answer the question?</B>
</P>
<P>We looked for all studies that compared corticosteroid, given either by injections (parenterally) or tablets (orally), with matching dummy injections or tablets and all studies that compared corticosteroid given by injections with corticosteroid given by tablets.</P>
<P>
<B>What did we find?</B>
</P>
<P>We found 16 studies including over 1700 people with COPD who experienced a flare-up that required additional medical treatment that compared corticosteroid given by injections or tablets with dummy treatment. Four studies with nearly 300 people compared corticosteroid injections with corticosteroid tablets. More men than women took part in the studies and they were usually in their late 60s, with moderately severe symptoms of COPD. Most studies took place in hospitals, two in intensive care units with people who needed breathing support, and three studies involved people who were treated at home. The last search for studies to include in the review was done in May 2014.</P>
<P>There were three studies where people knew which treatment they were getting, but otherwise studies were generally well designed.</P>
<P>People treated with either corticosteroid injections or tablets compared with dummy treatment were less likely to experience treatment failure, 122 fewer people per 1000 treated, with a lower rate of relapse by one month. They had shorter stays in hospital if they did not require assisted ventilation in an intensive care unit, and their lung function and breathlessness improved more quickly during treatment. However, they had more adverse events while taking treatment, especially a temporary increase in glucose levels in blood. Corticosteroid treatment did not reduce the number of people who died within one month of their flare-up.</P>
<P>In studies comparing two ways of giving corticosteroid, either by injections or tablets, there were no differences in treatment failure, the time in hospital or number of deaths after discharge; however, a temporary increase in glucose levels in blood was more likely with injections than tablets.</P>
<P>
<B>Conclusion</B>
</P>
<P>There is high-quality evidence that is unlikely to be changed by future research that people who experience flare-ups of COPD benefit from treatment with corticosteroid given by injections or tablets with the increased risk of some temporary side effects.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-08-28 14:33:06 +0100" MODIFIED_BY="Emma J Welsh">
<ABS_BACKGROUND MODIFIED="2014-08-28 14:33:05 +0100" MODIFIED_BY="Emma J Welsh">
<P>Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity and quality of life. The most common causes are infective, and treatment includes antibiotics, bronchodilators and systemic corticosteroids as anti-inflammatory agents.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-08-28 14:33:06 +0100" MODIFIED_BY="Emma J Welsh">
<P>To assess the effects of corticosteroids administered orally or parenterally for treatment of acute exacerbations of COPD, and to compare the efficacy of parenteral versus oral administration.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-08-19 14:43:51 +0100" MODIFIED_BY="Emma Jackson">
<P>We carried out searches using the Cochrane Airways Group Specialised Register of Trials, MEDLINE and CENTRAL (Cochrane Central Register of Controlled Trials), and checked references of included studies and trials registries. We conducted the last search in May 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-08-19 14:43:51 +0100" MODIFIED_BY="Emma Jackson">
<P>Randomised controlled trials comparing corticosteroids administered orally or parenterally with an appropriate placebo, or comparing oral corticosteroids with parenteral corticosteroids in the treatment of people with acute exacerbations of COPD. Other interventions (e.g. bronchodilators and antibiotics) were standardised for both groups. We excluded clinical studies of acute asthma.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-08-19 14:43:51 +0100" MODIFIED_BY="Emma Jackson">
<P>We used standard methodological procedures expected by The Cochrane Collaboration.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-08-28 14:33:06 +0100" MODIFIED_BY="Emma J Welsh">
<P>Sixteen studies (n = 1787) met inclusion criteria for the comparison systemic corticosteroid versus placebo and 13 studies contributed data (n = 1620). Four studies (n = 298) met inclusion criteria for the comparison oral corticosteroid versus parenteral corticosteroid and three studies contributed data (n = 239). The mean age of participants with COPD was 68 years, median proportion of males 82% and mean forced expiratory volume in one second (FEV<SUB>1</SUB>) per cent predicted at study admission was 40% (6 studies; n = 633). We judged risk of selection, detection, attrition and reporting bias as low or unclear in all studies. We judged risk of performance bias high in one study comparing systemic corticosteroid with control and in two studies comparing intravenous corticosteroid versus oral corticosteroid.</P>
<P>Systemic corticosteroids reduced the risk of treatment failure by over half compared with placebo in nine studies (n = 917) with median treatment duration 14 days, odds ratio (OR) 0.48 (95% confidence interval (CI) 0.35 to 0.67). The evidence was graded as high quality and it would have been necessary to treat nine people (95% CI 7 to 14) with systemic corticosteroids to avoid one treatment failure. There was moderate-quality evidence for a lower rate of relapse by one month for treatment with systemic corticosteroid in two studies (n = 415) (hazard ratio (HR) 0.78; 95% CI 0.63 to 0.97). Mortality up to 30 days was not reduced by treatment with systemic corticosteroid compared with control in 12 studies (n = 1319; OR 1.00; 95% CI 0.60 to 1.66).</P>
<P>FEV<SUB>1</SUB>, measured up to 72 hours, showed significant treatment benefits (7 studies; n = 649; mean difference (MD) 140 mL; 95% CI 90 to 200); however, this benefit was not observed at later time points. The likelihood of adverse events increased with corticosteroid treatment (OR 2.33; 95% CI 1.59 to 3.43). Overall, one extra adverse effect occurred for every six people treated (95% CI 4 to 10). The risk of hyperglycaemia was significantly increased (OR 2.79; 95% CI 1.86 to 4.19). For general inpatient treatment, duration of hospitalisation was significantly shorter with corticosteroid treatment (MD -1.22 days; 95% CI -2.26 to -0.18), with no difference in length of stay the intensive care unit (ICU) setting.</P>
<P>Comparison of parenteral versus oral treatment showed no significant difference in the primary outcomes of treatment failure, relapse or mortality or for any secondary outcomes. There was a significantly increased rate of hyperglycaemia in one study (OR 4.89; 95% CI 1.20 to 19.94).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-08-19 14:44:42 +0100" MODIFIED_BY="Emma Jackson">
<P>There is high-quality evidence to support treatment of exacerbations of COPD with systemic corticosteroid by the oral or parenteral route in reducing the likelihood of treatment failure and relapse by one month, shortening length of stay in hospital inpatients not requiring assisted ventilation in ICU and giving earlier improvement in lung function and symptoms. There is no evidence of benefit for parenteral treatment compared with oral treatment with corticosteroid on treatment failure, relapse or mortality. There is an increase in adverse drug effects with corticosteroid treatment, which is greater with parenteral administration compared with oral treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-08-28 15:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<BACKGROUND MODIFIED="2014-08-19 17:46:37 +0100" MODIFIED_BY="Emma J Welsh">
<CONDITION MODIFIED="2014-08-19 17:46:35 +0100" MODIFIED_BY="Emma J Welsh">
<P>Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lungs to noxious particles or gases (<LINK REF="REF-GOLD-2013" TYPE="REFERENCE">GOLD 2013</LINK>). A diagnosis of COPD is considered on a clinical basis in the presence of symptoms such as dyspnoea, chronic cough or sputum production and exposure to known risk factors. Confirmation of COPD diagnosis is based on demonstration of persistent airflow limitation with spirometry, according to the criterion post-bronchodilator forced expiratory volume in one second (FEV<SUB>1</SUB>)/forced vital capacity (FVC) ratio less than 0.7, as specified in guidelines including GOLD: Global Strategy for Diagnosis, Management, and Prevention of COPD (<LINK REF="REF-GOLD-2013" TYPE="REFERENCE">GOLD 2013</LINK>).</P>
<P>COPD is an important and increasing cause of mortality, estimated to be the fifth leading cause of death in 2000, responsible for 2.75 million deaths (<LINK REF="REF-Lopez-2006" TYPE="REFERENCE">Lopez 2006</LINK>). Worldwide mortality due to COPD is projected to rise to 4.5 million deaths in 2020, and become the third leading cause (<LINK REF="REF-Murray-1997" TYPE="REFERENCE">Murray 1997</LINK>). Morbidity is high and worldwide in 2000 COPD resulted in 16.5 million years of life lost, almost 10 million years lived with disability and 26.5 million disability-adjusted life years (<LINK REF="REF-Lopez-2006" TYPE="REFERENCE">Lopez 2006</LINK>).</P>
<P>COPD prevalence measured in a worldwide study to estimate the Burden of Lung Disease (BOLD) showed the prevalence of stage II or higher severity (FEV<SUB>1</SUB> less than 80% predicted) is 10.1% (standard error (SE) 4.8%) overall, 11.8% (SE 7.9%) for men and 8.5% (SE 5.8%) for women (<LINK REF="REF-Buist-2007" TYPE="REFERENCE">Buist 2007</LINK>). International variation in prevalence and severity stage of COPD is partially explained by variation in smoking prevalence and other risk factors (<LINK REF="REF-Buist-2007" TYPE="REFERENCE">Buist 2007</LINK>
<I>)</I>.</P>
<P>Exacerbations and co-morbidities contribute to the varying natural history of COPD in individual people (<LINK REF="REF-GOLD-2013" TYPE="REFERENCE">GOLD 2013</LINK>
<I>).</I> Exacerbations contribute to long-term decline in lung function (<LINK REF="REF-Donaldson-2002" TYPE="REFERENCE">Donaldson 2002</LINK>), and reduced physical activity (<LINK REF="REF-Donaldson-2005" TYPE="REFERENCE">Donaldson 2005</LINK>)<I>,</I> and are associated with increased risk of death (<LINK REF="REF-Soler_x002d_Cataluna-2005" TYPE="REFERENCE">Soler-Cataluna 2005</LINK>). They also have a profound and long-lasting effect on quality of life (QoL) (<LINK REF="REF-Seemungal-1998" TYPE="REFERENCE">Seemungal 1998</LINK>; <LINK REF="REF-Groenewegen-2001" TYPE="REFERENCE">Groenewegen 2001</LINK>; <LINK REF="REF-Wilkinson-2004" TYPE="REFERENCE">Wilkinson 2004</LINK>); in 10% of exacerbations, pre-exacerbation QoL was not recovered after three months (<LINK REF="REF-Seemungal-2000" TYPE="REFERENCE">Seemungal 2000</LINK>).</P>
<P>COPD exacerbations may require hospitalisation, although exacerbations with less severe symptoms and signs are often managed as an outpatient (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). Hospital-at-home, or early discharge services if available, may be used as an alternative way of caring for people with exacerbations of COPD who would otherwise need to be admitted or stay in hospital (<LINK REF="REF-Jeppesen-2012" TYPE="REFERENCE">Jeppesen 2012</LINK>; <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). The treatment of exacerbations is a large contributor to the economic burden of COPD (<LINK REF="REF-Sullivan-2000" TYPE="REFERENCE">Sullivan 2000</LINK>; <LINK REF="REF-Schermer-2002" TYPE="REFERENCE">Schermer 2002</LINK>), with a high proportion of costs being due to hospitalisations (<LINK REF="REF-Crockett-2001" TYPE="REFERENCE">Crockett 2001</LINK>; <LINK REF="REF-Oostenbrink-2004" TYPE="REFERENCE">Oostenbrink 2004</LINK>).</P>
<P>Studies on the frequency of exacerbations usually use an 'event-based' definition  based on healthcare utilisation (<LINK REF="REF-Effing-2009" TYPE="REFERENCE">Effing 2009</LINK>), and different events may be a proxy for severity, with unscheduled clinic or emergency department visits rated 'moderate' and those requiring hospitalisation labelled 'severe' (<LINK REF="REF-Rodriguez_x002d_Roisin-2000" TYPE="REFERENCE">Rodriguez-Roisin 2000</LINK>). However, the clinical onset of an acute exacerbation is defined according to symptoms, although there is no universally agreed definition (<LINK REF="REF-Rodriguez_x002d_Roisin-2000" TYPE="REFERENCE">Rodriguez-Roisin 2000</LINK>). Type 1 exacerbations were defined by Anthonisen on the basis of three major symptoms; increased dyspnoea, sputum volume and sputum purulence; Type 2 exacerbations had only two of the major symptoms and Type 3 exacerbations had  one major symptom plus cough, wheeze or symptoms of an upper respiratory tract infection (<LINK REF="REF-Anthonisen-1987" TYPE="REFERENCE">Anthonisen 1987</LINK>). A later definition required an increase in two of the 'major symptoms' of dyspnoea, sputum volume or sputum purulence, or one major symptom with an increase in one 'minor symptom' for two days (wheeze, sore throat, cough or common cold symptoms) (<LINK REF="REF-Seemungal-2000" TYPE="REFERENCE">Seemungal 2000</LINK>). More recently, a standardised measure for assessing the frequency, severity and duration of exacerbations of COPD using participant-reported outcomes has been developed for use in clinical studies (<LINK REF="REF-Leidy-2010" TYPE="REFERENCE">Leidy 2010</LINK>).</P>
<P>COPD exacerbations can be precipitated by several factors, the most common causes being infective, with bacterial pathogens identified in just over 50% and viral causes in around 25% of people (<LINK REF="REF-Sherk-2000" TYPE="REFERENCE">Sherk 2000</LINK>). Non-infective causes such as air pollution and other environmental conditions that increase airway inflammation may account for 15% to 20% of exacerbations (<LINK REF="REF-Sethi-2008" TYPE="REFERENCE">Sethi 2008</LINK>). Exacerbations become more frequent and more severe as the severity of COPD increases (<LINK REF="REF-Suissa-2012" TYPE="REFERENCE">Suissa 2012</LINK>), although the rate at which they occur may reflect an independent susceptibility phenotype, the 'frequent exacerbator' (<LINK REF="REF-Hurst-2010" TYPE="REFERENCE">Hurst 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-08-19 14:45:17 +0100" MODIFIED_BY="Emma Jackson">
<P>The acute inflammatory response to airway infection is influenced by both pathogenic and host factors, resulting in increased airway and systemic inflammation (<LINK REF="REF-Sethi-2008" TYPE="REFERENCE">Sethi 2008</LINK>). Airway inflammation is significantly increased during exacerbations of COPD, with evidence of increased neutrophils, lymphocytes and eosinophils seen in airways and in sputum (<LINK REF="REF-Papi-2006" TYPE="REFERENCE">Papi 2006</LINK>; <LINK REF="REF-Bathoorn-2008" TYPE="REFERENCE">Bathoorn 2008</LINK>; <LINK REF="REF-Falk-2008" TYPE="REFERENCE">Falk 2008</LINK>). Systemic inflammation is also present in COPD; many circulating inflammatory mediators are elevated both in stable COPD and during exacerbations. C-reactive protein is a known marker of systemic inflammation whose levels are elevated during exacerbations and it is a likely participant in the inflammatory cascade (<LINK REF="REF-Falk-2008" TYPE="REFERENCE">Falk 2008</LINK>).<I> </I>
</P>
</INTERVENTION>
<THEORY MODIFIED="2014-08-19 14:45:17 +0100" MODIFIED_BY="Emma Jackson">
<P>Theoretical mechanisms for clinical improvement in lung function in people treated with corticosteroids during exacerbations may include reduction in airway inflammation or a decrease in airway oedema (<LINK REF="REF-Wedzicha-2000" TYPE="REFERENCE">Wedzicha 2000</LINK>)<I>.</I>
</P>
<P>Corticosteroid use may be associated with a number of adverse effects, including fluid retention, hypertension, diabetes mellitus, adrenal suppression, osteoporosis and increased fracture risk (<LINK REF="REF-Vestergaard-2007" TYPE="REFERENCE">Vestergaard 2007</LINK>). Although the risks are greater with longer-term use than short-term use (<LINK REF="REF-Henzen-2000" TYPE="REFERENCE">Henzen 2000</LINK>), their benefits in the management of acute COPD exacerbations must be balanced against adverse effects (<LINK REF="REF-McEvoy-1997" TYPE="REFERENCE">McEvoy 1997</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-08-19 17:46:37 +0100" MODIFIED_BY="Emma J Welsh">
<P>Previous versions of this systematic review showed beneficial effects of treatment with systemic corticosteroids in acute exacerbations of COPD on treatment failure (<LINK REF="REF-Wood_x002d_Baker-2001" TYPE="REFERENCE">Wood-Baker 2001</LINK>; <LINK REF="REF-Walters-2009" TYPE="REFERENCE">Walters 2009</LINK>), and reduced length of hospital stay, reduced dyspnoea, improved oxygen saturation and improved lung function measures (<LINK REF="REF-Walters-2009" TYPE="REFERENCE">Walters 2009</LINK>). The findings of these systematic reviews (based on searches of the literature to 2008) are reflected in current guidelines for the treatment of acute exacerbations of COPD that recommend the use of systemic corticosteroids (<LINK REF="REF-GOLD-2013" TYPE="REFERENCE">GOLD 2013</LINK>), both within and outside hospital (<LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>).</P>
<P>Long-term follow-up of a population-based inception cohort of people with COPD suggested the need to investigate the effects of systemic corticosteroids in severe exacerbations requiring non-invasive ventilation (<LINK REF="REF-Suissa-2012" TYPE="REFERENCE">Suissa 2012</LINK>). However, in previous versions of this systematic review, studies in which participants received assisted ventilation for a severe exacerbation were excluded and we wish to update the evidence and extend the review to include the setting of assisted ventilation. With the finding of increased risk of subsequent exacerbations following first hospitalisation (<LINK REF="REF-Suissa-2012" TYPE="REFERENCE">Suissa 2012</LINK>), and observation of higher individual risk of exacerbations in frequent exacerbators (<LINK REF="REF-Hurst-2010" TYPE="REFERENCE">Hurst 2010</LINK>), we wished to include subgroup analysis by frequency and severity of exacerbations in this version of the review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-08-19 17:46:40 +0100" MODIFIED_BY="Emma J Welsh">
<P>To assess the effects of corticosteroids administered orally or parenterally for treatment of acute exacerbations of COPD, and to compare the efficacy of parenteral versus oral administration.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-08-19 17:46:41 +0100" MODIFIED_BY="Emma J Welsh">
<SELECTION_CRITERIA MODIFIED="2014-08-19 14:45:44 +0100" MODIFIED_BY="Emma Jackson">
<CRIT_STUDIES MODIFIED="2014-08-19 14:45:33 +0100" MODIFIED_BY="Emma Jackson">
<P>We included randomised controlled trials (RCTs) in which treatment with oral or parenteral corticosteroids was compared with appropriate placebo, or in which treatment with oral corticosteroids was compared with parenteral corticosteroid for acute exacerbations of COPD.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-08-19 14:45:33 +0100" MODIFIED_BY="Emma Jackson">
<P>We included studies that recruited people with a guideline-typical clinical diagnosis of COPD of any severity (<LINK REF="REF-GOLD-2013" TYPE="REFERENCE">GOLD 2013</LINK>), based on persistent (post-bronchodilator) airflow limitation, confirmed for example by FEV<SUB>1</SUB>/FVC ratio less than 0.7 and history of exposure to risk factors (tobacco smoke, smoke from home cooking and heating fuels, occupational dusts and chemicals).</P>
<P>Participants must have experienced an acute functional deterioration, thus allowing a wide definition of an acute exacerbation, which could include any combination of increased breathlessness or sputum volume, sputum purulence, cough or wheeze and symptoms or overt respiratory tract infection. Participants could be treated in primary care, or hospital secondary care, including when requiring assisted ventilation. We excluded trials of people with acute asthma.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-08-19 14:45:32 +0100" MODIFIED_BY="Emma Jackson">
<P>We included studies comparing:</P>
<UL>
<LI>corticosteroid, administered either parenterally or orally with placebo-control injections or tablets as appropriate;</LI>
<LI>oral corticosteroid with parenteral corticosteroid.</LI>
</UL>
<P>We permitted other non-corticosteroid co-interventions (e.g. bronchodilators and antibiotics) as long as they were not part of the randomised treatments.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-08-19 14:45:44 +0100" MODIFIED_BY="Emma Jackson">
<P>We divided outcome data into early (defined as up to and including 72 hours from study entry) and late (occurring after 72 hours and up to the last available measurement during study treatment) time points.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-08-19 14:45:44 +0100" MODIFIED_BY="Emma Jackson">
<OL>
<LI>Treatment failure: defined as necessity to intensify pharmacological treatment, hospital admission during outpatient treatment or return to emergency department during outpatient treatment.</LI>
<LI>Relapse: defined as treatment or hospital admission for a COPD exacerbation after completion of study treatment.</LI>
<LI>Mortality.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-08-19 14:45:44 +0100" MODIFIED_BY="Emma Jackson">
<OL>
<LI>Adverse drug effects.</LI>
<LI>Arterial blood gas (ABG) measurements (partial pressure of oxygen dissolved in arterial blood (PaO<SUB>2</SUB>)<SUB> </SUB>and partial pressure of carbon dioxide dissolved in arterial blood (PaCO<SUB>2</SUB>)).</LI>
<LI>Symptom scores: measuring breathlessness, symptoms of cough, wheeze, sputum production&#8232;; preferably using validated scales.</LI>
<LI>Lung function, pre- and post-bronchodilator including FEV<SUB>1</SUB>, FVC), peak expiratory flow (PEF).</LI>
<LI>Health status: QoL assessments using validated scales.</LI>
<LI>Physical capacity: timed walking tests, endurance tests,</LI>
<LI>Duration of hospitalisation.</LI>
<LI>Duration of assisted ventilation.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-08-19 14:45:52 +0100" MODIFIED_BY="Emma Jackson">
<ELECTRONIC_SEARCHES MODIFIED="2014-08-19 14:45:52 +0100" MODIFIED_BY="Emma Jackson">
<P>We identified trials using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/AIRWAYS/frame.html">Airways Group Module</A> for further details). We searched all records in the Specialised Register coded as 'COPD' (Airways Trials Search Co-ordinator) most recently in June 2013 using the following terms:</P>
<P>"adrenal cortex hormone*" or steroid* or glucocorticoid* or corticoid* or corticosteroid* or beclomethasone or betamethasone or fluticasone or cortisone or dexamethasone or hydrocortisone or prednisolone or prednisone or methylprednisolone or methylprednisone or triamcinolone.</P>
<P>We performed the most recent search (DT/CW) of MEDLINE for the period 12 months from June 2012 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and of EMBASE for the period 2010 to June 2013 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<P>We ran previous searches of these databases for the review published in 1999, and updated versions in 2004 and in 2007.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-08-19 14:45:52 +0100" MODIFIED_BY="Emma Jackson">
<P>In addition, we searched the bibliographies of each RCT and any review articles identified for additional papers. We searched the registers of ongoing clinical trials ClinicalTrials.gov (<A HREF="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</A>) and the World Health Organization (WHO) trials portal (<A HREF="http://www.who.int/ictrp/en/">www.who.int/ictrp/en/</A>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-08-19 17:46:41 +0100" MODIFIED_BY="Emma J Welsh">
<STUDY_SELECTION MODIFIED="2014-08-19 14:46:11 +0100" MODIFIED_BY="Emma Jackson">
<P>At least two review authors (DT, CW) assessed all potentially relevant trials for relevance. We screened the full text to independently select trials for inclusion and identify and record reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third person (JW). We identified and excluded duplicates and collated multiple reports of the same study so that each study (rather than each report) was the unit of interest in the review. We recorded the selection process as a PRISMA flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-08-19 14:46:19 +0100" MODIFIED_BY="Emma Jackson">
<P>We used a data collection form for study characteristics and outcome data. Two review authors (DT, CW) independently extracted the following study characteristics from included studies.</P>
<OL>
<LI>Methods: study design, total duration of study, number of study centres and location, study setting, withdrawals and date of study.</LI>
<LI>Participants: n, mean age, age range, gender, diagnostic criteria for exacerbation, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria.</LI>
<LI>Interventions: study treatment, comparison, concomitant medications and excluded medications.</LI>
<LI>Outcomes: primary and secondary outcomes specified and collected, and time points reported.</LI>
<LI>Notes: funding for trial and notable conflicts of interest of trial authors.</LI>
</OL>
<P>Two review authors (two of JW, DT, CW) independently extracted outcome data from included studies. We entered data into the Review Manager 5 (JW, DT, CW) and a second review author double-checked entries. We checked that data were entered correctly by comparing the data presented in the systematic review with the study reports.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-08-19 17:46:41 +0100" MODIFIED_BY="Emma J Welsh">
<P>Two review authors independently assessed the risk of bias for each study (two of JW, CW, DT) using criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreements by discussion or by involving another review author. We assessed the risk of bias according to the following domains.</P>
<OL>
<LI>Random sequence generation.</LI>
<LI>Allocation concealment.</LI>
<LI>Blinding of participants and personnel.</LI>
<LI>Blinding of outcome assessment.</LI>
<LI>Incomplete outcome data.</LI>
<LI>Selective outcome reporting.</LI>
<LI>Other bias(es).</LI>
</OL>
<P>We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table.</P>
<P>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome.</P>
<P>In addition, we assessed each study for the basis of the diagnosis of COPD using the following criteria.<BR/>
</P>
<OL>
<LI>Was the age of participants over 45 years?</LI>
<LI>Was the smoking history greater than 10 pack-years?</LI>
<LI>Were participants with a previous physician diagnosis of asthma excluded?</LI>
<LI>Was there evidence of fixed airflow obstruction?</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-08-19 17:44:58 +0100" MODIFIED_BY="Emma J Welsh">
<P>For continuous variables, we analysed data as mean difference (MD), with 95% confidence interval (CI). We used standardised mean difference (SMD) with 95% CI if different scales of measurement had been used for an outcome. The SMD is a statistic that expresses the difference in means between treatment groups in units of the pooled standard deviation (SD). We analysed dichotomous outcomes using Mantel-Haenszel odds ratio (OR) with a 95% CI. Where events were rare, we employed the Peto OR. We entered scale data with a consistent direction of effect.</P>
<P>We undertook meta-analyses only where it was meaningful; when treatments, participants and the underlying clinical question were similar.</P>
<P>When skewed data were available (reported as medians and interquartile ranges), we described them narratively.</P>
<P>For 'time-to-event' outcomes such as log hazard ratios (HR), we used the fixed-effect generic inverse variance outcome to combine results. This method gives a weighted mean of the effect estimates of separate studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We calculated number needed to treat for an additional beneficial outcome (NNTB) from the pooled OR and its CI using the baseline risk in the control group.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-03-26 00:41:26 +0000" MODIFIED_BY="Emma J Welsh">
<P>We analysed dichotomous data using participants as the unit of analysis. For continuous data, the MD based on change from baseline was preferred over MD based on absolute when both were available.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-08-19 14:46:35 +0100" MODIFIED_BY="Emma Jackson">
<P>We contacted investigators to obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results using a sensitivity analysis<B>. </B>
</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-08-19 14:46:35 +0100" MODIFIED_BY="Emma Jackson">
<P>We carried out an assessment of possible heterogeneity, where the null hypothesis is that all studies are evaluating the same effect, for pooled effects using a Breslow-Day test of heterogeneity; a P value &gt; 0.05 was considered to indicate a significant difference between studies. In addition, we used the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Interpretation of statistical heterogeneity was as follows: 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed clinical and methodological heterogeneity by recording differences in study design and participant characteristics between individual studies. When we found substantial heterogeneity, we reported it and explored possible causes by pre-specified subgroup analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-03-26 00:40:51 +0000" MODIFIED_BY="Emma J Welsh">
<P>We tried to minimise reporting bias from non-publication of studies or selective outcome reporting by using a broad search strategy, checking references of included studies and relevant systematic reviews, and contacting authors for additional outcome data. We visually inspected funnel plots when 10 or more studies contributed to analysis for an outcome.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-08-19 14:46:48 +0100" MODIFIED_BY="Emma Jackson">
<P>We used a fixed-effect model, and, in addition, we performed a sensitivity analysis with a random-effects model if there was unexplained heterogeneity. We presented the findings of our primary outcomes in a 'Summary of findings' table according to recommendations provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (generated with the use of GRADEPRO software).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-08-19 14:46:48 +0100" MODIFIED_BY="Emma Jackson">
<P>Subgroup analyses were performed by:</P>
<UL>
<LI>duration of corticosteroid treatment (number of days' treatment is reported in the user-defined order in analysis tables);</LI>
<LI>setting (i.e. primary care, hospital secondary care or requiring assisted ventilation).</LI>
</UL>
<P>Analysis by frequency and severity of exacerbations was not possible owing to lack of data in studies.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-08-19 14:46:47 +0100" MODIFIED_BY="Emma Jackson">
<P>In the assessment of heterogeneity, we considered possible causes arising from details of study design. We performed sensitivity analyses using random-effects models versus fixed-effect models, by risk of bias and by other potential confounders.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-08-27 08:28:20 +0100" MODIFIED_BY="Julia A.E. Walters">
<STUDY_DESCRIPTION MODIFIED="2014-08-19 14:47:25 +0100" MODIFIED_BY="Emma Jackson">
<SEARCH_RESULTS MODIFIED="2014-08-19 14:47:08 +0100" MODIFIED_BY="Emma Jackson">
<P>We carried out an initial search in 1996, using the Cochrane Airways Group COPD RCT register and MEDLINE; the search retrieved 108 references and we subsequently identified 85 papers as suitable for consideration in the review, with eight RCTs included in the original review. We located two additional studies in searches up to August 2004 and included them in the 2005 update of the review (<LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>). In the 2009 review update, from searches to August 2008, we identified 10 studies for potential inclusion of which <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK> was included.</P>
<P>For this review update in 2014, we undertook searches on 28 June 2013 and 23 May 2014 (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). The 2003 search yielded 140 and the 2014 search yielded 148 references after duplicates were removed and we identified two studies for the new comparison of route of treatment from those previously excluded. We excluded 278 references on title or abstract. We excluded three references as they did not randomise participants to corticosteroid treatment or did not use placebo control (<LINK REF="STD-Roede-2008" TYPE="STUDY">Roede 2008</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Bafadhel-2012" TYPE="STUDY">Bafadhel 2012</LINK>). We included five additional studies comparing systemic corticosteroids with placebo (<LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>; <LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>: <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>; <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>). We included two studies comparing oral and parenteral corticosteroids (<LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>; <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>), with two studies for this treatment comparison that had previously been excluded now included (<LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-08-19 14:47:25 +0100" MODIFIED_BY="Emma Jackson">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table for details. </P>
<P>For the comparison <U>systemic corticosteroid versus placebo</U>, we included 16 studies in the review. Four were published in abstract form only (<LINK REF="STD-Rostom-1994" TYPE="STUDY">Rostom 1994</LINK>; <LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK>; <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>; <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>). Three studies contained no data that could be included and no responses to requests for data have been received (<LINK REF="STD-Rostom-1994" TYPE="STUDY">Rostom 1994</LINK>; <LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK>; <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>). Unpublished data were available for <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK> and data were sought and supplied by the authors for <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>. Authors of eight published studies supplied additional data (<LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>; <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>; <LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>). Thus, 13 studies contribute some outcome data for this comparison.</P>
<P>For the comparison <U>parenteral corticosteroid versus oral corticosteroid</U>, we included three published studies in the review that contributed outcome data (<LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>; <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>), while one study was only published as an abstract and no response has been received to a request for data for inclusion in the review (<LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>). We requested additional data for <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>, but we received no response.</P>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> summarises across the 20 studies: setting; exclusion of people with asthma, prior inhaled corticosteroid use, exacerbation definition, duration of study treatment, participants per cent male, mean age, FEV<SUB>1</SUB>, pack-years' smoking history, number of withdrawals.</P>
<P>The setting for participant recruitment and intervention delivery was hospital inpatients in 12 studies (<LINK REF="STD-Albert-1980" TYPE="STUDY">Albert 1980</LINK>; <LINK REF="STD-Rostom-1994" TYPE="STUDY">Rostom 1994</LINK>; <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>; <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>
<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>; <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>; <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>), hospital intensive care units (ICU) in two studies (<LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>; <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>), and, in two studies, the intervention was initiated in the emergency department with subsequent admission only if required clinically (<LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>). In <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>, participants were kept in the emergency department for six hours, and 26 of 113 participants were discharged within 24 hours. In <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>, a single intravenous infusion of methylprednisolone was given in the emergency department and participants were observed over a minimum of four hours. Subsequently 30 of 96 participants required admission and for some participants allocation to treatment group was not maintained after re-admission. Three studies recruited outpatients (<LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK>; <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>), and the setting was not specified for <LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>.</P>
<P>We attempted to verify the diagnosis of COPD using the criteria age of people over 40 years, smoking history greater than 10 pack-years, exclusion of people with a previous physician diagnosis of asthma and evidence of fixed airflow obstruction for all studies (see notes in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The important criterion of irreversible airflow obstruction determined by spirometry was specified in 12 studies (<LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; <LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK>; <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>; <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>; <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>; <LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>; <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>). Where specified, the mean length of smoking history ranged from 32 to 80 pack-years. The demographics of participants in these studies, particularly age, smoking history and severity of airflow obstruction suggests low likelihood of contamination with people with asthma, although this cannot be verified in <LINK REF="STD-Rostom-1994" TYPE="STUDY">Rostom 1994</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>; <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>; and <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>, as they made no reference to the exclusion of people with asthma or the smoking history of participants. Of 2078 participants randomised to treatment in the 20 included studies, the mean age was 68 years and median proportion of males included was 82% (range 52% to 100%). For six studies reporting lung function, the mean FEV<SUB>1</SUB> per cent predicted at study admission was 40% (range 27% to 64%).</P>
<SUBSECTION>
<HEADING LEVEL="4">Definition of an exacerbation of chronic obstructive pulmonary disease</HEADING>
<P>In 11 studies, some combination of worsening symptoms was specified, including dyspnoea or cough, or increase in sputum volume or purulence. <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK> and <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK> used a clinical diagnosis of an exacerbation of COPD without specifying the criteria. <LINK REF="STD-Albert-1980" TYPE="STUDY">Albert 1980</LINK>; <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; and <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK> specified acute respiratory insufficiency as an inclusion criterion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>For studies included in the comparison systemic corticosteroid versus placebo, systemic corticosteroid treatment varied. Two studies used only short intravenous courses (less than four days' length) (<LINK REF="STD-Albert-1980" TYPE="STUDY">Albert 1980</LINK>; <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>), four studies used intravenous administration followed by oral treatment (<LINK REF="STD-Rostom-1994" TYPE="STUDY">Rostom 1994</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>), and two studies used intravenous administration (<LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>; <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>). Among the seven studies using oral corticosteroids throughout treatment, the initial dose of prednisolone used varied from 30 mg to 60 mg fixed dose daily or 1 mg/kg in <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>, with higher initial doses being tapered in <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK> and <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>. The length of treatment with oral corticosteroids varied from five to 15 days although <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK> included an arm in which treatment was continued for eight weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The primary outcome, treatment failure occurring during the treatment period, met the review definition in a variety of ways during periods varying in length from two to 30 days (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Five studies used attendance or return to the emergency department or doctor's clinic (<LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>). Eight studies used deterioration leading to intensification of pharmacological treatment (<LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>; <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>; <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; and <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>). Six studies used the requirement for assisted ventilation or ICU admission (<LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>; and <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>).</P>
<P>Relapse occurred at a later time point to treatment failure, after completion of treatment during varied periods of follow-up from one to four months, and was based on treatment for an acute exacerbation in two studies (<LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>), or hospital re-admission for COPD in four studies (<LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>), and hospital admission for which the cause was not specified in three studies (<LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-08-19 14:47:25 +0100" MODIFIED_BY="Emma Jackson">
<P>We excluded 18 studies from this review; reasons for exclusion are shown in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-08-19 14:47:35 +0100" MODIFIED_BY="Emma Jackson">
<P>Full details of our judgements for the included studies, with supporting information for each judgement, can be found in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table. A summary of risk of bias across all studies is shown in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. We rated all studies either low or unclear risk of selection bias. We rated risk of performance bias as either low or unclear in all studies comparing systemic corticosteroid versus placebo, with the exception of <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>, which was an open-label study without placebo control that we judged at high risk. We judged two of three studies comparing intravenous corticosteroid versus oral corticosteroid at high risk of performance bias. Detection bias was either low or unclear in 19 studies. Attrition bias risk was low in 60% of studies and high in 15% of studies. We rated all studies as either low or unclear risk of reporting bias.</P>
<ALLOCATION MODIFIED="2014-08-19 14:47:35 +0100" MODIFIED_BY="Emma Jackson">
<P>All 20 studies were described as randomised; in 14 studies assessment of random sequence generation indicated low risk of bias and in the remaining six studies information was lacking and risk of bias was unclear. In 10 studies, concealment of allocation was assessed at low risk of bias, with lack of information in 10 studies considered at unclear risk.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-08-19 14:47:35 +0100" MODIFIED_BY="Emma Jackson">
<P>Blinding of participants and treating personnel was adequate with low risk of bias in 13 of 19 studies; in three studies, risk of bias was unclear and we judged four studies at high risk of bias due to lack of blinding (<LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>; <LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>; <LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>; <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>). Blinding for outcome assessment indicated low risk of bias in six studies, unclear risk in 13 studies and high risk of bias one study (<LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-08-19 14:47:34 +0100" MODIFIED_BY="Emma Jackson">
<P>We rated 12 studies as low risk of bias due to incomplete outcome data because the number of drop-outs per group was low and even. In five studies, bias risk was unclear and three studies only published as abstracts were rated at high risk (<LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK>; <LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK>; <LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-08-19 14:47:34 +0100" MODIFIED_BY="Emma Jackson">
<P>We rated 12 studies as low risk of bias due to selective reporting as all likely outcomes were reported. The risk of bias was unclear in eight studies when there was insufficient information.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-08-27 08:28:20 +0100" MODIFIED_BY="Julia A.E. Walters">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: systemic corticosteroid versus placebo</HEADING>
<P>Twelve studies with 1620 participants contribute outcome data for systemic corticosteroids versus placebo (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure (Analysis 1.1)</HEADING>
<P>Definition of treatment failure and the time period during which an event occurred varied across studies (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Systemic corticosteroids reduced the risk of treatment failure by over half when compared with placebo in nine studies (n = 917), of which seven studies contributed data, with median treatment duration of 14 days (OR 0.48; 95% CI 0.35 to 0.67; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). There was only minor heterogeneity between studies (Chi<SUP>2</SUP> = 11.75; degrees of freedom (df) = 8; P value = 0.16); I<SUP>2</SUP> = 32%). It would have been necessary to treat nine people (95% CI 7 to 14) with systemic corticosteroids to avoid one treatment failure during the treatment period. The funnel plot did not indicate a strong likelihood of publication bias (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). We rated the quality of evidence for this outcome as high.</P>
<P>In subgroup analyses, the reduction in likelihood of treatment failure between seven and 30 days for six inpatient studies (n = 680) with treatment duration greater than three days, was similar to the pooled overall result (OR 0.46; 95% CI 0.30 to 0.69), with no heterogeneity. For two outpatient studies (n = 167), the likelihood of treatment failure between 14 and 30 days with systemic corticosteroid compared with placebo was also lower (OR 0.37; 95% CI 0.19 to 0.72) (<LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>; <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>. There was substantial heterogeneity in the fixed-effect analysis (Chi<SUP>2</SUP> = 3.47; df = 1; P value = 0.06; I<SUP>2</SUP> = 71%). Oral corticosteroid treatment differed in these studies, with the dose used being higher in <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>.</P>
<P>In the <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK> study (n = 70), which used a single intravenous dose of systemic corticosteroid and assessed treatment failure over two days, the likelihood of treatment failure was not lower with systemic corticosteroid treatment (OR 1.87; 95% CI 0.51 to 6.89).</P>
<P>When <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK> was excluded from the meta-analysis, the test for subgroup differences showed no difference between inpatient and outpatient studies (Chi<SUP>2</SUP> = 0.28, df = 1; P value = 0.59; I<SUP>2</SUP> = 0%). However, the result with <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK> included indicated some difference although it was not statistically significant (Chi<SUP>2</SUP> = 4.77, df = 2; P value = 0.09); I<SUP>2</SUP> = 58.1%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relapse (Analyses 1.2 and 1.3)</HEADING>
<P>The HR for relapse up to 30 days in two large studies (n = 415) showed a significant reduction for treatment with systemic corticosteroid with no heterogeneity (HR 0.78; 95% CI 0.63 to 0.97; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>). However, the reduced likelihood of relapse on treatment with systemic corticosteroid in five studies (n = 596) over periods of one to four months was not statistically significant with no heterogeneity between studies (OR 0.67; 95% CI 0.42 to 1.07; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). We rated the quality of evidence for this outcome as moderate, which was downgraded once as wide CI values include significant benefit and harm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality (Analysis 1.4)</HEADING>
<P>Mortality up to 30 days was not reduced by treatment with systemic corticosteroid compared with placebo in 11 studies (n = 1319; OR 1.00; 95% CI 0.60 to 1.66; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). There were four subgroups, inpatient studies greater or less than three days' treatment, ICU treatment and outpatient treatment. No heterogeneity was found overall or in any subgroup analysed. The funnel plot did not indicate a strong likelihood of publication bias (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). We rated the quality of evidence for this outcome as moderate, which was downgraded once as wide CI values include significant benefit and harm.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Early outcomes: 72 hours or less</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Lung function (Analyses 1.5 to 1.10)</HEADING>
<P>FEV<SUB>1</SUB> was significantly increased with corticosteroid treatment in seven studies (n = 649), with no heterogeneity between studies (MD 140 mL; 95% CI 90 to 200; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). This effect size is thought to be clinically meaningful (<LINK REF="REF-Donohue-2005" TYPE="REFERENCE">Donohue 2005</LINK>). The FEV<SUB>1</SUB> per cent predicted was also greater at this time point in three studies, with no significant heterogeneity (n = 231; MD 3.85%; 95% CI 0.18 to 7.52; Chi<SUP>2</SUP> = 2.62; df = 2; P value = 0.27; I<SUP>2</SUP> = 24%; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). There was no increase in FVC with corticosteroid treatment in three studies (n = 123; MD 200 mL; 95% CI -50 to 450). PEF was significantly increased with corticosteroid treatment in two studies with significant heterogeneity (n = 137; MD 22.52 L/minute; 95% CI 5.02 to 40.03; Chi<SUP>2</SUP> = 4.48, df = 1; P value = 0.03; I<SUP>2</SUP> = 78%; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom scores (Analysis 1.11)</HEADING>
<P>Breathlessness was assessed using the Borg dyspnoea scale (<LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>), and visual analogue scales (VAS) for overall dyspnoea (<LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>; <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>), and dyspnoea related to specific activities (talking, dressing, washing, walking) (<LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>). Corticosteroid treatment significantly decreased dyspnoea when results were pooled using the SMD in three studies, with some heterogeneity that might not be important (n = 178; SMD 0.35; 95% CI 0.05 to 0.64; Chi<SUP>2</SUP> = 2.89; df = 2; P value = 0.24; I<SUP>2</SUP> = 31%; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). This equates to an effect size on the Borg scale of 0.93 units (95% CI 0.18 to 1.7) or on the VAS scale of 5.24 (95% CI 0.75 to 9.59). The effect sizes are less than the suggested minimal clinically important differences of 2 units for the Borg scale and 10 units for the VAS (<LINK REF="REF-Ries-2005" TYPE="REFERENCE">Ries 2005</LINK>). We rated the quality of evidence for this outcome as moderate, being downgraded once as the upper CI crossed an effect size of 0.5.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Arterial blood gas measurements (Analyses 1.12 and 1.13)</HEADING>
<P>Conditions for measurement of ABGs varied across studies. In <LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK> and <LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>, ABGs were measured while breathing room air at rest and, in <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>, conditions were variable, with some participants using supplementary oxygen and some breathing room air. Corticosteroid treatment compared with placebo significantly increased arterial oxygenation in three studies, with no heterogeneity (n = 233; PaO<SUB>2</SUB> MD 3.71 mmHg; 95% CI 0.55 to 6.88; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). In these three studies of inpatients and one study in ICU (<LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>), PaCO<SUB>2</SUB> was decreased with corticosteroid treatment compared with placebo, with moderate heterogeneity between studies in different settings (n = 316; MD -2.21 mmHg; 95% CI -3.84 to -0.58; Chi<SUP>2</SUP> = 7.23, df = 3; P value = 0.06; I<SUP>2</SUP> = 58%; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Late outcomes: end of treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Lung function (Analyses 1.14 to 1.18)</HEADING>
<P>FEV<SUB>1</SUB> was not significantly increased with corticosteroid treatment compared with placebo in seven studies (n = 669; MD 90 mL; 95% CI -10 to 190; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). There was little heterogeneity between inpatient studies (Chi<SUP>2</SUP> = 6.21, df = 4; P value = 0.18; I<SUP>2</SUP> = 36%) and moderate heterogeneity in pooled inpatient and outpatient studies (Chi<SUP>2</SUP> = 11.28; df = 6; P value = 0.08; I<SUP>2</SUP> = 47%). There was an increase in FEV<SUB>1</SUB> per cent predicted in two studies with corticosteroid treatment, with no significant heterogeneity (n = 129; MD 6.14; 95% CI 1.32 to 10.96; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). PEF improved with corticosteroid treatment in two studies, with moderate heterogeneity (n = 112; MD 119.06 L/minute; 95% CI 64.39 to 173.73; Chi<SUP>2</SUP> = 2.27; df = 1; P value = 0.13; I<SUP>2</SUP> = 56%; <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>). There was no increase in FVC, FVC per cent predicted or the ratio of FEV<SUB>1</SUB>/FVC with corticosteroid treatment compared with placebo at the end of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom scores (Analyses 1.20 to 1.22)</HEADING>
<P>Dyspnoea was measured using the transitional dyspnoea index (<LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>), with a positive score indicating improvement and a change of one unit considered clinically significant (<LINK REF="REF-Mahler-1984" TYPE="REFERENCE">Mahler 1984</LINK>). There was a significant benefit with corticosteroid treatment in <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK> (effect size MD 1.88 units; 95% CI 0.23 to 3.53; <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>). VAS symptom scores were reported by <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>; <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; and <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>. The improvement in dyspnoea with corticosteroid treatment in four studies was not significant, with no heterogeneity (n = 301; SMD 0.18; 95% CI -0.05 to 0.41; <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Arterial blood gas measurements (Analyses 1.23 and 1.24)</HEADING>
<P>Corticosteroid treatment significantly improved PaO<SUB>2</SUB> compared with placebo in four inpatient studies, with no heterogeneity between studies (n = 200; PaO<SUB>2</SUB> MD 6.86 mmHg; 95% CI 2.75 to 10.96; <LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>). There was no significant decrease in PaCO<SUB>2</SUB> with corticosteroid treatment in three studies, with moderate heterogeneity: (n = 188; MD -1.81 mmHg; 95% CI -5.06 to 1.44; Chi<SUP>2</SUP> = 4.89; df = 2; P value = 0.09; I<SUP>2</SUP> = 59%; <LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Health-related quality of life (Analysis 1.25)</HEADING>
<P>Only <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK> (n = 147) reported data on quality of life with the total Chronic Respiratory Disease index and did not find a significant improvement with corticosteroid treatment after 10 days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Functional capacity (Analysis 1.26)</HEADING>
<P>
<LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK> reported data on six-minute walk tests in 18 participants at 14 days and found no improvement with corticosteroid treatment (<LINK REF="REF-Wise-2005" TYPE="REFERENCE">Wise 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Length of stay and duration of ventilation (Analyses 1.27 and 1.28)</HEADING>
<P>There was substantial heterogeneity in the outcome 'length of stay' between studies in a general inpatient setting versus an ICU setting for people who required assisted ventilation. The test for subgroup differences was significant (P value = 0.04; I<SUP>2</SUP> = 75.4%) and we decided not to pool the subgroups. In the general inpatient setting, there was a shorter duration of hospital stay for corticosteroid treatment compared with placebo in two studies, with no heterogeneity (n = 296; MD -1.22 days; 95% CI -2.26 to -0.18). <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK> also reported a lower median stay of seven days for corticosteroid treatment and nine days for placebo, while in <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>, the corticosteroid treatment group median length of stay was six days and eight days for placebo. We rated the quality of evidence for this outcome as high. However, in the ICU setting for people requiring assisted ventilation, there was no difference in length of ICU stay for corticosteroid treatment compared with control, with moderate heterogeneity (n=300; MD 0.65 days; 95% CI -0.84 to 2.15; P value = 0.17; I<SUP>2</SUP> = 46%; <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>).</P>
<P>The duration of assisted ventilation in two studies in an ICU setting was not significantly reduced with corticosteroid treatment compared with control (n = 300; MD -1.03 days; 95% CI -3.44 to 1.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects (Analyses 1.29 to 1.41)</HEADING>
<P>An adverse drug reaction was more than twice as likely with corticosteroid treatment compared with placebo in eight studies (n = 736; OR 2.33; 95% CI 1.59 to 3.43; <LINK REF="CMP-001.29" TYPE="ANALYSIS">Analysis 1.29</LINK>). Overall, one extra adverse effect occurred for every six people treated (95% CI 4 to 10). Six studies reported data specifically on hyperglycaemia (<LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>; <LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>; <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>). There was an increased likelihood of hyperglycaemia with corticosteroid compared with placebo treatment, with no significant heterogeneity (n = 804; OR 2.79; 95% CI 1.86 to 4.19; P value = 0.25; I<SUP>2</SUP> = 24%; <LINK REF="CMP-001.30" TYPE="ANALYSIS">Analysis 1.30</LINK>). Overall, one extra participant developed hyperglycaemia for every seven treated with systemic corticosteroids (95% CI 5 to 12). We rated the quality of evidence for this outcome as high.</P>
<P>The risk of hypertension did not differ with corticosteroid treatment compared with placebo in two studies in inpatients and ICU, although there was moderate heterogeneity (n = 274; OR 1.20; 95% CI 0.44 to 3.25; Chi<SUP>2</SUP> = 2.06; df = 1; P value = 0.15; I<SUP>2</SUP> = 51%; <LINK REF="CMP-001.31" TYPE="ANALYSIS">Analysis 1.31</LINK>). The risk of gastrointestinal bleeding did not differ with corticosteroid treatment compared with placebo in two studies in ICU (n = 300; OR 0.93; 95% CI 0.12 to 6.91; <LINK REF="CMP-001.32" TYPE="ANALYSIS">Analysis 1.32</LINK>).</P>
<P>In the ICU-based studies of <LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK> and <LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>, there was no increased likelihood of ventilator-associated pneumonia with corticosteroid treatment (n = 300; OR 1.23; 95% CI 0.44 to 3.40).</P>
<P>There was a non-significant two-fold increase in likelihood of an adverse psychiatric event with corticosteroid treatment compared with placebo in two studies (n = 331; OR 2.15; 95% CI 0.95 to 4.88; <LINK REF="CMP-001.37" TYPE="ANALYSIS">Analysis 1.37</LINK>).</P>
<P>The outpatient study of <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK> and the inpatient study of <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK> reported incidences of other specific adverse effects. In single studies, there were significantly increased risks of weight gain and insomnia with corticosteroid treatment compared with placebo. In these studies, there were no significantly increased risks with corticosteroid treatment compare with placebo for anxiety, depression, dyspepsia, delirium or secondary infection.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: intravenous corticosteroid versus oral corticosteroid</HEADING>
<P>Three studies with 298 participants contributed outcome data for intravenous corticosteroids versus oral corticosteroids (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Treatment failure (Analysis 2.1)</HEADING>
<P>There was no significant reduction in risk of treatment failure with intravenous corticosteroid treatment and oral corticosteroid treatment in three studies in inpatients, with no heterogeneity (n = 298; OR 0.67; 95% CI 0.34 to 1.30; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). We rated the quality of evidence for this outcome as moderate, being downgraded once as wide CI values included significant benefit and harm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Relapse (Analysis 2.2)</HEADING>
<P>The odds of relapse after completion of treatment was not significantly reduced by treatment with intravenous corticosteroid compared with oral corticosteroid in three studies, with no heterogeneity between studies (n = 298; OR 0.95; 95% CI 0.50 to 1.80; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). We rated the quality of evidence for this outcome as moderate, being downgraded once as wide CI values included significant benefit and harm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality (Analysis 2.3)</HEADING>
<P>Mortality after discharge between one and three months was not reduced by treatment with intravenous corticosteroid compared with oral corticosteroid in three studies, with no significant heterogeneity (n = 298; OR 1.40; 95% CI 0.44 to 4.51; Chi<SUP>2</SUP> = 2.41; df = 2; P value = 0.30; I<SUP>2</SUP> = 17%; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). We rated the quality of evidence for this outcome as moderate, being downgraded once as wide CI values included significant benefit and harm.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Early outcomes: 72 hours or less</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Lung function (Analyses 2.4 and 2.5)</HEADING>
<P>Only one study reported lung function measures at the early time point, and neither FEV<SUB>1</SUB> nor FVC was significantly increased with intravenous corticosteroid treatment compared with oral corticosteroid.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom scores (Analyses 2.5 to 2.8)</HEADING>
<P>Dyspnoea was not significantly decreased with intravenous corticosteroid treatment compared with oral corticosteroid in two inpatient studies using a VAS measure, with no heterogeneity (n = 75; MD 0.62; 95% CI -0.55 to 1.78; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). We rated the quality of evidence for this outcome as low, being downgraded twice as wide CI values included significant benefit and harm and participants and physicians were not blinded to treatment in the two studies. In one single study (n = 38), there were no differences in VAS scores for cough or sputum volume.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Late outcomes: end of treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Lung function (Analyses 2.9 to 2.11)</HEADING>
<P>FEV<SUB>1</SUB> did not differ significantly at the end of treatment with intravenous corticosteroid compared with oral corticosteroid treatment in three studies, with no heterogeneity present (n = 285; MD -20 mL; 95% CI -80 to 30; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). There was no difference in FVC in two studies with intravenous corticosteroid compared with oral corticosteroid treatment, with no heterogeneity present (n = 75; MD -50 mL; 95% CI -33 to 22; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom scores (Analyses 2.12 to 2.14)</HEADING>
<P>Dyspnoea was not significantly improved with intravenous corticosteroid treatment compared with oral corticosteroid in two inpatient studies using a VAS measure, with no heterogeneity (n = 75; MD 1.28; 95% CI -0.24 to 2.80; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>), and in one single study (n = 38) there were no differences in VAS scores for cough or sputum volume.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Arterial blood gas measurements (Analyses 2.15 and 2.16)</HEADING>
<P>There were no significant differences in between intravenous corticosteroid compared with oral corticosteroid treatment in a single study in PaO<SUB>2</SUB> (n = 38; MD -1.20 mmHg; 95% CI -8.61 to 6.21; <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>) or PaCO<SUB>2 </SUB>(MD 5.50 mmHg; 95% CI -0.79 to 11.79; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Health status and quality of life (Analyses 2.17 to 2.22)</HEADING>
<P>The Clinical COPD Questionnaire (CCQ) measuring health status (symptoms, functional state and mental state) and the St George's Hospital Respiratory Questionnaire (SGRQ) measuring respiratory-related QoL were reported in one study (n = 210), with no differences between intravenous corticosteroid and oral corticosteroid treatment found for either measure after one week (n = 210; CCQ: MD 0.10; 95% CI -0.17 to 0.37; <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>; SGRQ: MD -0.70; 95% CI -4.33 to 2.93; <LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>). There were no differences in the Dyspnoea, Fatigue, Mastery or Emotion domains of the Chronic Respiratory Questionnaire (CRQ) between intravenous corticosteroid and oral corticosteroid treatment in one study (n = 21) after four weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Length of stay (Analysis 2.23)</HEADING>
<P>There was a non-significant increase in duration of hospital stay for intravenous corticosteroid compared with oral corticosteroid treatment in three studies, with no significant heterogeneity (n = 298; MD 1.54 days; 95% CI -0.09 to 3.17; Chi<SUP>2</SUP> = 2.93; df = 2; P value = 0.23; I<SUP>2</SUP> = 32%; <LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>). We rated the quality of evidence for this outcome as low, being downgraded twice as wide CI values included significant benefit and harm and participants and physicians were not blinded to treatment in the two studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events (Analyses 2.24 and 2.25)</HEADING>
<P>In one single inpatient study, there was an increased likelihood of hyperglycaemia with intravenous corticosteroid compared with oral corticosteroid treatment (n = 40; OR 4.89; 95% CI 1.20 to 19.94; <LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>) (<LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>). We rated the quality of evidence for this outcome as moderate, being downgraded once for indirectness based on a single study. The risk of hypertension was not significantly increased in this study (OR 8.20; 95% CI 0.40 to 169.90; <LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-08-28 15:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<SUMMARY_OF_RESULTS MODIFIED="2014-08-19 14:50:18 +0100" MODIFIED_BY="Emma Jackson">
<P>This updated review addressed the use of systemic corticosteroid (oral or parenteral) in the treatment of acute exacerbations of COPD. The review included 16 studies with 1787 participants, mostly conducted with inpatients, that compared systemic corticosteroid with placebo and four studies with 298 inpatients comparing parenteral corticosteroid versus oral corticosteroid.</P>
<P>Systemic corticosteroid treatment compared with placebo significantly decreased treatment failure up to one month and relapse after treatment for inpatients and outpatients, and improved lung function (FEV<SUB>1</SUB>, per cent predicted FEV<SUB>1</SUB>, PEF), symptoms of breathlessness and blood gases (PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>) within three days. At the end of treatment, systemic corticosteroid treatment compared with placebo significantly improved some lung function measures (per cent predicted FEV<SUB>1</SUB>, PEF) and blood gases (PaO<SUB>2</SUB>) and reduced the length of hospital stay by around one to two days in people who did not require treatment with assisted ventilation in an ICU. In terms of adverse events, no significant difference was observed in rates of mortality up to one month but there was at least a two-fold increase in adverse drug effects, especially for hyperglycaemia, which showed a four-fold increase.</P>
<P>Parenteral corticosteroid treatment compared with oral corticosteroid treatment did not significantly decrease treatment failure, or improve lung function, QoL, respiratory symptoms or blood gases. There was no significant difference in the rate of mortality between one and three months of follow-up but parenteral corticosteroid treatment was associated with a significantly increased rate of the adverse drug effect hyperglycaemia compared with oral treatment.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-08-28 15:22:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>The criteria for an acute exacerbation were explicit in most studies, either an increase in respiratory symptoms or respiratory insufficiency. Most studies used accepted criteria for COPD diagnosis. There was imbalance in the gender ratio of participants in the included studies, ranging from 52% to 100% males. This reflects the historically higher incidence of COPD in men; however, the increasing smoking rates among women means that the incidence of COPD is increasing in women (<LINK REF="REF-Chapman-2001" TYPE="REFERENCE">Chapman 2001</LINK>). There seems to be no good reason to expect a different response to treatment in women based on studies in asthma and corticosteroid use, so the findings are applicable to all people with COPD.</P>
<P>Most studies explicitly excluded participants with asthma, as is generally the case in efficacy studies in COPD. However, excluding participants with a history of asthma excludes a population with increased risk of developing COPD. There is an association between fixed airflow obstruction in adults aged 40 to 44 years and early-onset current clinical asthma, equivalent to a 33 pack-year history of smoking (OR 3.7; 95% CI 1.5 to 9.3) (<LINK REF="REF-Perret-2013" TYPE="REFERENCE">Perret 2013</LINK>). This may limit the generalisability of the findings.</P>
<P>The current review expanded and updated a previous version of the review that excluded people requiring assisted ventilation treated in ICU and additionally compared the route of delivery of systemic corticosteroid, parenteral or oral. The decision to treat an acute exacerbation of COPD at home or admit for inpatient treatment is related to clinical assessment of severity of the person's condition. The findings of this review may be generalisable to both outpatient and inpatient settings and thus to exacerbations of a range of severity. Two studies of inpatients requiring assisted ventilation in ICU contributed data. We did not pool data on length of stay in participants who required assisted ventilation in ICU with data from studies in the general hospital setting.</P>
<P>Randomised trials in this review do not provide data on the use of repeated treatment with systemic corticosteroid in people with COPD and we were unable to perform subgroup analysis by frequency and severity of exacerbations.</P>
<P>The sensitivity analysis removing studies in which a significant proportion of participants were crossed over to active treatment (i.e. <LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>; <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>), gave results that were very similar to those of the original pooled analysis for treatment failure, mortality and lung function.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-08-19 14:50:29 +0100" MODIFIED_BY="Emma Jackson">
<P>The methodological quality of the included trials that contributed data was good, and the three conference abstracts of unknown quality did not contribute any data to the analysis. In the comparison of systemic corticosteroid and placebo treatment, only one study was not double blind. This study contributed to analysis of objectively measured outcomes and results were unlikely to be compromised by detection or performance biases. Two studies comparing routes of administration of systemic corticosteroid were not double blind, and results for objective outcomes such as mortality were unlikely to be compromised by detection or performance biases. The evidence for symptoms and duration of hospitalisation was downgraded for possible detection or performance bias. The studies judged at high risk of attrition bias did not contribute data to any analyses.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-03-26 00:23:06 +0000" MODIFIED_BY="Julia A.E. Walters">
<P>Review authors made every effort to identify all relevant published and unpublished studies by using additional methods to identify studies that might not have been found in the main electronic search (e.g. searching drug company databases and clinical trial registration sites, checking reference lists). We did not routinely contact individual trial authors for additional data unless outcomes were clearly selectively reported. All authors adhered to the most recent best practice guidelines in terms of study selection, resolution of disagreements, data extraction and analysis to reduce bias and errors.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-08-19 14:50:39 +0100" MODIFIED_BY="Emma Jackson">
<P>The results of one cohort study, conducted at 414 US hospitals in 2006 to 2007 in a non-intensive care setting, showed oral corticosteroid treatment for acute exacerbations of COPD was not associated with worse outcomes than when high-dose intravenous corticosteroid treatment was given during the first two hospital days (<LINK REF="REF-Lindenauer-2010" TYPE="REFERENCE">Lindenauer 2010</LINK>). Another Cochrane review comparing systemic corticosteroid treatment for seven days or less with longer treatment in acute exacerbations of COPD concluded there were insufficient data to base firm conclusions on the optimal duration of corticosteroid therapy (<LINK REF="REF-Walters-2011" TYPE="REFERENCE">Walters 2011</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-08-19 14:50:39 +0100" MODIFIED_BY="Emma Jackson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-08-19 14:50:39 +0100" MODIFIED_BY="Emma Jackson">
<P>This updated review and meta-analysis provide high-quality evidence to support the use of systemic corticosteroid by the oral or parenteral route for exacerbations of chronic obstructive pulmonary disease (COPD). Treatment reduces the likelihood of treatment failure, shortens hospital stay when assisted ventilation is not required, and improves lung function and symptoms. There is no evidence that corticosteroid administration by a parenteral route is more effective than oral treatment. There is an increase in adverse drug effects with corticosteroid treatment, which is greater with parenteral administration compared with oral treatment. The specific adverse drug effects are known pharmacological effects of corticosteroids and are unlikely to persist after treatment ceases.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-08-19 14:50:38 +0100" MODIFIED_BY="Emma Jackson">
<P>Future studies of systemic corticosteroid use for exacerbation of COPD should report results for participants by previous exacerbation frequency to enable assessment of repeated systemic corticosteroid treatment. There is a need for more studies in severe exacerbations of COPD in people who require assisted ventilation. Data for cost-effectiveness comparisons should be collected.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-08-19 14:50:38 +0100" MODIFIED_BY="Emma Jackson">
<P>We are grateful to authors of studies, <LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>; <LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>; <LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>; <LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>; <LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>; <LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>; <LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>, who responded to our requests for data and information. We acknowledge the contribution of M Hannay to previous updates of the review in 2004 and 2008. We are also indebted to the editorial team and Cochrane Airways Group staff for performing searches, and their help and support.</P>
<P>Chris Cates was the Editor for this review and commented critically on the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-08-19 14:50:57 +0100" MODIFIED_BY="Emma Jackson">
<P>R Wood-Baker has undertaken research sponsored by a number of pharmaceutical companies including Marion Merrell Dow, ICI Australia, Pharmacia Upjohn, GlaxoSmithKline, Sanofi-Synthélabo and Novartis.</P>
<P>E H Walters has undertaken research sponsored by a number of pharmaceutical companies including Glaxo Wellcome, Novartis, Astra, Boehringer, Schering-Plough and Amgen. He has held consultancies for AstraZeneca, ICI Australia, Pfizer and GlaxoSmithKline.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-08-19 14:50:57 +0100" MODIFIED_BY="Emma Jackson">
<P>JAEW: updates 2004, 2008, 2014: study selection, grading and data management, data entry, author correspondence, analysis, 'Summary of findings' table. Primary author first draft of results, discussion and conclusions.</P>
<P>DT: 2014 update: study selection, grading and data management, data entry, author correspondence, reviewing results and discussion, drafting abstract and plain language summary.</P>
<P>CW: 2014 update: study selection, grading and data management, data entry, author correspondence, reviewing results and discussion.</P>
<P>RWB: protocol development; data extraction and entry; data verification; writing first version of review; editing updates in 2004, 2008 and 2014.</P>
<P>EHW: protocol development; data extraction and entry; writing first version of review; editing updates 2004, 2008 and 2014.</P>
<P>PG: editing review drafts 2004, 2008 and 2014.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-08-19 14:50:57 +0100" MODIFIED_BY="Emma Jackson">
<P>We amended the objectives of the review in 2014 to include studies in which participants received assisted ventilation, and interventions to include: comparison 1: corticosteroid, parenteral or oral administration versus placebo control injections or tablets as appropriate; comparison 2: corticosteroid, parenteral versus oral administration. We changed the order of the secondary outcomes. We updated the methods, including using the latest version of the Cochrane 'Risk of bias' tool and added a 'Summary of findings' table. We added a subgroup analysis on setting of the exacerbations.</P>
<P>Two new review authors joined the team, DJT and CJW, and one review author stepped down, M Hannay.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-07-11 09:23:37 +0100" MODIFIED_BY="Toby J Lasserson"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-08-28 15:24:33 +0100" MODIFIED_BY="Emma J Welsh">
<STUDIES MODIFIED="2014-08-28 15:24:09 +0100" MODIFIED_BY="Emma J Welsh">
<INCLUDED_STUDIES MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<STUDY DATA_SOURCE="MIX" ID="STD-Aaron-2003" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Aaron 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al</AU>
<TI>Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>26</NO>
<PG>2618-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;2003;167(7):A947.&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaron SD, Vandemheen KL, Wells G, Dales R, Ahuja J, Dickinson G, et al</AU>
<TI>Oral prednisone for the prevention of relapse in outpatients with acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>2003</YR>
<VL>167</VL>
<NO>7</NO>
<PG>A947</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Courtney AU</AU>
<TI>Oral prednisone prevents relapse in COPD exacerbations</TI>
<SO>Journal of Family Practice</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>10</NO>
<PG>762-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abroug-2014" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Abroug 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F, et al</AU>
<TI>Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation</TI>
<SO>European Respiratory Journal</SO>
<YR>2014</YR>
<VL>43</VL>
<NO>3</NO>
<PG>717-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albert-1980" NAME="Albert 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Albert R, Martin T, Lewis S. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Int Med 1980;92:753-758.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albert R, Martin T, Lewis S</AU>
<TI>Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1980</YR>
<VL>92</VL>
<PG>753-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Alia-2011" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Alia 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alia I, De La Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ, et al</AU>
<TI>Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2011</YR>
<VL>171</VL>
<NO>21</NO>
<PG>1939-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alia I, De La Cal MA, Esteban A, Ferrer R, Molina F, Pier R, et al</AU>
<TI>Evaluation of the efficacy of corticosteroids in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support: a prospective, international, randomized double blind clinical trial</TI>
<SO>Intensive Care Medicine</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>Suppl 2</NO>
<PG>S205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bullard-1996" NAME="Bullard 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Bullard M, Liaw S-J, Tsai Y-H, Min H. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med 1996;14:139-143.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bullard M, Liaw S-J, Tsai Y-H, Min H</AU>
<TI>Early corticosteroid use in acute exacerbations of chronic airflow obstruction</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>139-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Ceviker-2014" MODIFIED="2014-08-10 16:02:29 +0100" MODIFIED_BY="Anne Lawson" NAME="Ceviker 2014" YEAR="2013">
<REFERENCE MODIFIED="2014-08-10 16:02:29 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ceviker Y, Sayiner A</AU>
<TI>Comparison of two systemic steroid regimens for the treatment of COPD exacerbations</TI>
<SO>Pulmonary Pharmacology and Therapeutics</SO>
<YR>2014</YR>
<VL>27</VL>
<NO>2</NO>
<PG>179-83</PG>
<IDENTIFIERS MODIFIED="2014-08-10 16:02:29 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-31 16:19:13 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chen-2005" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;Chen G, Xie C. The efficacy and treatment length of oral corticosteroids in patients with acute exacerbations of chronic obstructive pulmonary disease [Abstract]. European Respiratory Journal 2005;26(Suppl 49):Abstract No.1966.&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen G, Xie C</AU>
<TI>The efficacy and treatment length of oral corticosteroids in patients with acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>Abstract No. 1966</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen G, Xie CM, Luo YF</AU>
<TI>The effects and therapeutic duration of oral corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary diseases [In Chinese]</TI>
<SO>Chinese Journal of Tuberculosis and Respiratory Diseases</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>8</NO>
<PG>577-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Cordero-1996" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Cordero 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordero PJ, Benlloch E, SolÈ A, Morales P, MenÈndez R, Cebrian J</AU>
<TI>Corticosteroid therapy for COPD exacerbations at inpatient settings: a controlled-randomized study</TI>
<SO>Archivos de Bronconeumologia</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>Suppl 2</NO>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cordero PJ, Sole A, Benlloch E, Morales P, Vallterra J, Menendez R, et al</AU>
<TI>A randomized controlled study of prednisone in outpatients with acute exacerbation of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9 Suppl 23</VL>
<PG>110s-1s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Davies-1999" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Davies 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies L, Angus RM, Calverley PMA</AU>
<TI>Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>456-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jong-2007" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="de Jong 2007" YEAR="2004">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;1.Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T</AU>
<TI>Health status measurement in COPD: the minimal clinically important difference of the Clinical COPD Questionnaire</TI>
<SO>Respiratory Research</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>62</PG>
<IDENTIFIERS MODIFIED="2014-08-10 16:04:22 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong Y, Uil M, Grotjohan P, Postma S, Kerstjens M, van den Berg J</AU>
<TI>A comparison of intravenous versus oral administration of corticosteroids in the treatment of patients admitted to the hospital with an exacerbation of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>Suppl 48</NO>
<PG>64s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW</AU>
<TI>Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>6</NO>
<PG>1741-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Emerman-1989" NAME="Emerman 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Emerman C, Connors A, Lukens T, May M, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989;95:563-567.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emerman C, Connors A, Lukens T, May M, Effron D</AU>
<TI>A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD</TI>
<SO>Chest</SO>
<YR>1989</YR>
<VL>95</VL>
<PG>563-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Gunen-2007" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Gunen 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E</AU>
<TI>The role of nebulised budesonide in the treatment of exacerbations of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>29</VL>
<NO>4</NO>
<PG>660-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G</AU>
<TI>The role of nebulised budesonide in the treatment of acute exacerbations of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>2</NO>
<PG>399-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Maltais-2002" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Maltais 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al</AU>
<TI>Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>5</NO>
<PG>698-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Niewoehner-1999" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Niewoehner 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-04-30 10:52:11 +0100" MODIFIED_BY="Emma Jackson" NOTES="&lt;p&gt;1.Erbland ML, Deupree RH, Niewoehner DE. Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Exacerbations (SCCOPE): rationale and design of an equivalence trial. Veterans Administration Cooperative Trials SCCOPE Study Group. Control Clin Trials 1998;19(4):404-17.&lt;/p&gt;" NOTES_MODIFIED="2014-04-30 10:52:11 +0100" NOTES_MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erbland ML, Deupree RH, Niewoehner DE</AU>
<TI>Systemic corticosteroids in chronic obstructive pulmonary disease exacerbations (SCCOPE): rationale and design of an equivalence trial. Veterans Administration Cooperative Trials SCCOPE Study Group</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>404-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;1.Gross N. Is there a subgroup of steroid responders in acute exacerbations of COPD (AECOPD)? Further evaluation of SCCOPE trial data. American Journal of Respiratory and Critical Care Medicine 2002;165(suppl 8):A271.&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gross N</AU>
<TI>Is there a subgroup of steroid responders in acute exacerbations of COPD (AECOPD)? Further evaluation of SCCOPE trial data</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A271</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-30 10:52:35 +0100" MODIFIED_BY="Emma Jackson" NOTES="&lt;p&gt;1.Niewoehner DE, Collins D, Erbland ML. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1201-5.&lt;/p&gt;" NOTES_MODIFIED="2014-04-30 10:52:35 +0100" NOTES_MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niewoehner DE, Collins D, Erbland ML</AU>
<TI>Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>4 pt1</NO>
<PG>1201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Niewoehner DE, Erbland ML, Duepree RH, Collins D, Gross NJ, Light RW, et al</AU>
<TI>Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>1941-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Ridha-2006" MODIFIED="2014-04-30 10:53:20 +0100" MODIFIED_BY="Emma Jackson" NAME="Ridha 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-04-30 10:53:20 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ridha M, Ferdaous Y, Sofia T, Amel C, Ali BK</AU>
<TI>Effect of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>Suppl 50</NO>
<PG>624s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rostom-1994" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Rostom 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rostom R, Mink S, Hebert P, Cardinal P</AU>
<TI>The long term efficacy of methylprednisolone in the treatment of acute exacerbation of COPD</TI>
<SO>Chest</SO>
<YR>1994</YR>
<VL>106</VL>
<NO>2</NO>
<PG>161S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Thompson-1996" MODIFIED="2014-04-30 10:53:40 +0100" MODIFIED_BY="Emma Jackson" NAME="Thompson 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-04-30 10:53:40 +0100" MODIFIED_BY="Emma Jackson" NOTES="&lt;p&gt;Thompson W, Nielson C, Carvalho P, Charan N, Crowley J. Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-412.&lt;/p&gt;" NOTES_MODIFIED="2014-04-30 10:53:40 +0100" NOTES_MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson W, Nielson C, Carvalho P, Charan N, Crowley J</AU>
<TI>Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1996</YR>
<VL>154</VL>
<PG>407-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willaert-2002" MODIFIED="2012-09-10 06:25:22 +0100" MODIFIED_BY="Julia A.E. Walters" NAME="Willaert 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-10 06:25:22 +0100" MODIFIED_BY="Julia A.E. Walters" NOTES="&lt;p&gt;1.Willaert W, Daenen M, Bomans P, Verleden G, Decramer M. Intravenous steroids and aerosol bronchodilators versus oral steroids and MDI bronchodilators in COPD exacerbations. 2000;161(3 suppl):A578.&lt;/p&gt;" NOTES_MODIFIED="2012-09-10 06:25:22 +0100" NOTES_MODIFIED_BY="Julia A.E. Walters" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willaert W, Daenen M, Bomans P, Verleden G, Decramer M</AU>
<TI>Intravenous steroids and aerosol bronchodilators versus oral steroids and MDI bronchodilators in COPD exacerbations</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>3 Suppl</NO>
<PG>A578</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-10 06:25:22 +0100" MODIFIED_BY="Julia A.E. Walters" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Willaert W, Daenen M, Bomans P, Verleden G, Decramer M</AU>
<TI>What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>928-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wood_x002d_Baker-1998" MODIFIED="2014-08-19 14:30:06 +0100" MODIFIED_BY="Emma Jackson" NAME="Wood-Baker 1998" YEAR="1997">
<REFERENCE MODIFIED="2014-08-19 14:28:48 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood-Baker R, Wilkinson J, Pearce M, Ryan G</AU>
<TI>A double-blind, randomised, placebo-controlled trial of corticosteroids for acute exacerbations of chronic obstructive pulmonary disease [Abstract]</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Zheng-2011" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Zheng 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng J, Lin J, Zhou X, Huang S, Xie C, Liang Z, et al</AU>
<TI>Nebulized budesonide in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD): a randomized, double blind, double dummy, parallel controlled, multicenter trial</TI>
<SO>Chest</SO>
<YR>2011</YR>
<VL>140</VL>
<NO>4</NO>
<PG>526A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-08-28 15:24:09 +0100" MODIFIED_BY="Emma J Welsh">
<STUDY DATA_SOURCE="PUB" ID="STD-Bafadhel-2012" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Bafadhel 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Lomas D, et al</AU>
<TI>A double-blind randomised control trial of peripheral blood eosinophils to direct prednisolone use in COPD exacerbations</TI>
<SO>European Respiratory Journal</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>55</NO>
<PG>38s [357]</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al</AU>
<TI>Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2012</YR>
<VL>186</VL>
<NO>1</NO>
<PG>48-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bingol-2005" MODIFIED="2014-08-10 19:23:24 +0100" MODIFIED_BY="Anne Lawson" NAME="Bingol 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-10 19:23:24 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bingol H, Cingoz F, Balkan A, Kilic S, Bolcal C, Demirkilic U</AU>
<TI>The effect of oral prednisolone with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>252-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahlen-2001" MODIFIED="2008-09-19 10:14:10 +0100" MODIFIED_BY="[Empty name]" NAME="Dahlen 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-19 10:14:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahlen I, Janson C, Björsson E, Stålenheim G, Peterson CG, Venge P</AU>
<TI>Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease</TI>
<SO>Respiratory Medicine</SO>
<YR>2001</YR>
<VL>95</VL>
<PG>891-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerogianni-2002" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Gerogianni 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;1.l. . 2002;165(suppl 8):A594.&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerogianni A, Mathioudakis G, Koulouris N, Orphanidou D, Malamos N, Markozannes E, et al</AU>
<TI>The effect of oral steroid treatment in patients with chronic bronchitis</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2002</YR>
<VL>165</VL>
<NO>Suppl 8</NO>
<PG>A594</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghanei-2005" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Ghanei 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ghanei M, Khalili A, Arab M, Mojtahedzadeh M, Aslani J, Lessan-Pezeshki M, et al</AU>
<TI>Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis</TI>
<SO>Basic &amp; Clinical Pharmacology and Toxicology</SO>
<YR>2005</YR>
<VL>97</VL>
<NO>5</NO>
<PG>302-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-GSK-FLIT98" MODIFIED="2008-09-19 10:15:12 +0100" MODIFIED_BY="[Empty name]" NAME="GSK FLIT98" YEAR="1995">
<REFERENCE MODIFIED="2008-09-19 10:15:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;GSK FLIT98. Inhaled fluticasone propionate in an acute exacerbation of chronic osbstructive pulmonary disease: a multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 2000 &amp;#181;g daily compared with placebo in chronic obstructive pulmonary disease (chronic bronchitis); 1995.&lt;/p&gt;" NOTES_MODIFIED="2008-09-19 10:15:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>GSK FLIT98</AU>
<TI>Inhaled fluticasone propionate in an acute exacerbation of chronic obstructive pulmonary disease: a multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 2000 µg daily compared with placebo in chronic obstructive pulmonary disease (chronic bronchitis)</TI>
<SO>GlaxoSmithKline Clinical Trial Register</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kunter-2006" MODIFIED="2014-08-19 13:50:11 +0100" MODIFIED_BY="Emma Jackson" NAME="Kunter 2006" YEAR="2005">
<REFERENCE MODIFIED="2014-08-19 13:50:11 +0100" MODIFIED_BY="Emma Jackson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilvan A, Kunter E, Demirer E, Avsar K, Kartaloglu Z, Oztosun M et al</AU>
<TI>Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>284s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-11 10:20:08 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;1.Kunter E, Ilvan A, Ozmen N, Demirer E, Ozturk A, Avsar K, et al. Effect of Corticosteroids on Hemostasis and Pulmonary Arterial Pressure during Chronic Obstructive Pulmonary Disease Exacerbation. Respiration 2006:epub DOI:10.1159/000097748&lt;/p&gt;" NOTES_MODIFIED="2014-08-11 10:20:08 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kunter E, Ilvan A, Ozmen N, Demirer E, Ozturk A, Avsar K, et al</AU>
<TI>Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation</TI>
<SO>Respiration</SO>
<YR>2006</YR>
<VL>75</VL>
<NO>2</NO>
<PG>145-54</PG>
<IDENTIFIERS MODIFIED="2014-08-11 10:20:08 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-19 10:20:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kunter E, Ilvan A, Ozturk A, Demirer E, Ozmen N, Avsar K, et al</AU>
<TI>Effects of steroid treatment on hemodynamic and haemostatic parameters in COPD exacerbation</TI>
<SO>European Respiratory Journal</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>Suppl 49</NO>
<PG>298s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003" NAME="Li 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H, He G, Chu H, Zhao L, Yu H</AU>
<TI>A step-wise application of methylprednisolone versus dexamethasone in the treatment of acute exacerbations of COPD</TI>
<SO>Respirology</SO>
<YR>2003</YR>
<VL>8</VL>
<NO>2</NO>
<PG>199-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mirici-2002" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Mirici 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mirici A, Meral M, Akgun M, Tutar U, Kiris S</AU>
<TI>Comparison of the effectiveness of parenteral and nebuliser steroid in COPD exacerbations</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 38</NO>
<PG>243s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murata-1990" MODIFIED="2008-09-19 10:20:55 +0100" MODIFIED_BY="[Empty name]" NAME="Murata 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-09-19 10:20:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD. Effect on patients with a history of multiple relapses.&lt;/p&gt;&lt;p&gt;Murata GH, Gorby MS, Chick TW, Halperin AK.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-19 10:20:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Murata GH, Gorby MS, Chick TW, Halperin AK</AU>
<TI>Intravenous and oral corticosteroids for the prevention of relapse after treatment of decompensated COPD. Effect on patients with a history of multiple relapses</TI>
<SO>Chest</SO>
<YR>1990</YR>
<VL>98</VL>
<PG>845-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Plant-1999" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Plant 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;Respiratory Medicine, 1st Floor, Chancellor Wing, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, England&lt;br&gt;PH:0113 243 3144&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Plant PK, Watson JP, Muers MF, Pearson SB</AU>
<TI>Randomised controlled trial of oral corticosteroids in acute exacerbations of COPD. Proceedings of the European Respiratory Society Annual Congress; 1999 Oct 9-13; Madrid</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rahman-2004" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Rahman 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rahman M, Rahman M, Mamun S, Abdullah A, Haque A</AU>
<TI>Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>Suppl 4</NO>
<PG>839s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rizzato-1998" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Rizzato 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rizzato G</AU>
<TI>Effects of deflazacort hemisuccinate vs methylprednisolone succinate in COPD exacerbations</TI>
<SO>L'internista</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roede-2008" MODIFIED="2014-08-28 15:24:09 +0100" MODIFIED_BY="Emma J Welsh" NAME="Roede 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-08-28 15:24:09 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Roede Berendina Maria</AU>
<TI>Treatment of COPD Exacerbations in Primary and Secondary Care</TI>
<SO>[PhD thesis]</SO>
<YR>2008</YR>
<PG>Chapter 3, 31-47</PG>
<PB>University of Amsterdam</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sayiner-2001" NAME="Sayiner 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sayiner A, Aytemur ZA, Cirit M, Unsal I</AU>
<TI>Systemic glucocorticoids in severe exacerbations of COPD</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<PG>726-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shortall-2002" MODIFIED="2008-09-19 10:21:25 +0100" MODIFIED_BY="[Empty name]" NAME="Shortall 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-19 10:21:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shortall SP, Blum J, Oldenburg FA, Rodgerson L, Branscombe JM, Harrow EM</AU>
<TI>Treatment of patients hospitalised for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regime and an intravenous/nebulizer regimen</TI>
<SO>Respiratory Care</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>2</NO>
<PG>154-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sin-2004" MODIFIED="2014-04-30 11:16:15 +0100" MODIFIED_BY="Emma Jackson" NAME="Sin 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-04-30 11:16:15 +0100" MODIFIED_BY="Emma Jackson" NOTES="&lt;p&gt;1.Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(7):760-765&lt;/p&gt;" NOTES_MODIFIED="2014-04-30 11:16:15 +0100" NOTES_MODIFIED_BY="Emma Jackson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sin DD, Lacy P, Man SF</AU>
<TI>Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2004</YR>
<VL>170</VL>
<NO>7</NO>
<PG>760-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2011" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Wang 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang PH, Cheng SL, Wang HC, Chang HT, Hsu YL, Chen YS, et al</AU>
<TI>Systemic steroids in acute exacerbation of COPD - from guidelines to bedside</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2011</YR>
<VL>49</VL>
<NO>11</NO>
<PG>705-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-01-23 05:46:13 +0000" MODIFIED_BY="Julia AE Walters"/>
<ONGOING_STUDIES MODIFIED="2014-05-02 04:14:05 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-08-28 15:24:33 +0100" MODIFIED_BY="Emma J Welsh">
<ADDITIONAL_REFERENCES MODIFIED="2014-08-28 15:24:33 +0100" MODIFIED_BY="Emma J Welsh">
<REFERENCE ID="REF-Anthonisen-1987" MODIFIED="2012-09-05 04:36:25 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Anthonisen 1987" TYPE="JOURNAL_ARTICLE">
<AU>Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA</AU>
<TI>Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987</YR>
<VL>106</VL>
<PG>196-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bathoorn-2008" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Bathoorn 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bathoorn E, Kerstjens H, Postma D, Timens W, MacNee W</AU>
<TI>Airways inflammation and treatment during acute exacerbations of COPD</TI>
<SO>International Journal of Chronic Obstructive Pulmonary Disease</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>2</NO>
<PG>217-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buist-2007" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Buist 2007" TYPE="JOURNAL_ARTICLE">
<AU>Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al</AU>
<TI>International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9589</NO>
<PG>741-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chapman-2001" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Chapman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chapman KR, Tashkin DP, Pye DJ</AU>
<TI>Gender bias in the diagnosis of COPD</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119</VL>
<NO>6</NO>
<PG>1691-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crockett-2001" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Crockett 2001" TYPE="BOOK">
<AU>Crockett AJ, Cranston JM, Moss JR</AU>
<SO>Chronic Obstructive Pulmonary Disease (COPD) - Economic Case Statement</SO>
<YR>2001</YR>
<PB>Lung Foundation Australia</PB>
<CY>Milton QLD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donaldson-2002" MODIFIED="2012-09-05 04:37:07 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Donaldson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA</AU>
<TI>Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2002</YR>
<VL>57</VL>
<NO>10</NO>
<PG>847-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donaldson-2005" MODIFIED="2014-04-30 11:22:01 +0100" MODIFIED_BY="Emma Jackson" NAME="Donaldson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA</AU>
<TI>Exacerbations and time spent outdoors in chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>171</VL>
<PG>446-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donohue-2005" MODIFIED="2014-04-30 11:22:19 +0100" MODIFIED_BY="Emma Jackson" NAME="Donohue 2005" TYPE="JOURNAL_ARTICLE">
<AU>Donohue JF</AU>
<TI>Minimal clinically important differences in COPD lung function</TI>
<SO>COPD</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>111-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Effing-2009" MODIFIED="2014-04-30 11:26:28 +0100" MODIFIED_BY="Emma Jackson" NAME="Effing 2009" TYPE="JOURNAL_ARTICLE">
<AU>Effing TW, Kerstjens HAM, Monninkhof EM, van der Valk PDLPM, Wouters EFM, Postma DS, et al</AU>
<TI>Definitions of exacerbations: does it really matter in clinical trials on COPD?</TI>
<SO>Chest</SO>
<YR>2009</YR>
<VL>136</VL>
<NO>3</NO>
<PG>918-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falk-2008" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Falk 2008" TYPE="CONFERENCE_PROC">
<AU>Falk JA, Minai OA, Mosenifar Z</AU>
<SO>Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society; 2008 May 16-20; Toronto</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GOLD-2013" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="GOLD 2013" TYPE="OTHER">
<AU>Global Initiative for Chronic Obstructive Lung Disease (GOLD)</AU>
<TI>Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease</TI>
<SO>http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html</SO>
<YR>(accessed 10 August 2014)</YR>
<IDENTIFIERS MODIFIED="2014-08-10 16:27:26 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE ID="REF-Groenewegen-2001" MODIFIED="2012-09-05 04:37:26 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Groenewegen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Groenewegen K, Schols A, Wouters EFM</AU>
<TI>Prognosis after hospitalization for acute exacerbations of COPD</TI>
<SO>European Respiratory Journal</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>Suppl 33</NO>
<PG>209s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henzen-2000" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Henzen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA</AU>
<TI>Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>542-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-10-13 14:03:06 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JD, Altman G</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurst-2010" MODIFIED="2014-04-30 11:29:19 +0100" MODIFIED_BY="Emma Jackson" NAME="Hurst 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al</AU>
<TI>Susceptibility to exacerbation in chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>12</NO>
<PG>1128-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeppesen-2012" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Jeppesen 2012" TYPE="COCHRANE_REVIEW">
<AU>Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M, et al</AU>
<TI>Hospital at home for acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2014-08-11 10:59:55 +0100" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-08-11 10:59:55 +0100" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD003573.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leidy-2010" MODIFIED="2014-04-30 11:32:29 +0100" MODIFIED_BY="Emma Jackson" NAME="Leidy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, et al</AU>
<TI>Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure</TI>
<SO>Value in Health</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>8</NO>
<PG>965-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindenauer-2010" MODIFIED="2014-04-30 11:35:27 +0100" MODIFIED_BY="Emma Jackson" NAME="Lindenauer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB</AU>
<TI>Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<PG>2359-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopez-2006" MODIFIED="2014-04-30 11:36:08 +0100" MODIFIED_BY="Emma Jackson" NAME="Lopez 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al</AU>
<TI>Chronic obstructive pulmonary disease: current burden and future projections</TI>
<SO>European Respiratory Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>2</NO>
<PG>397-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahler-1984" MODIFIED="2012-09-05 04:37:47 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mahler 1984" TYPE="JOURNAL_ARTICLE">
<AU>Mahler D, Weinberg D, Wells C, Feinstein A</AU>
<TI>The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes</TI>
<SO>Chest</SO>
<YR>1984</YR>
<VL>85</VL>
<PG>751-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEvoy-1997" MODIFIED="2014-08-10 19:27:30 +0100" MODIFIED_BY="Anne Lawson" NAME="McEvoy 1997" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy CE, Niewoehner DE</AU>
<TI>Adverse effects of corticosteroid therapy for COPD</TI>
<SO>Chest</SO>
<YR>1997</YR>
<VL>111</VL>
<PG>732-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1997" MODIFIED="2012-09-05 04:37:54 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Murray 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murray CJ, Lopez AD</AU>
<TI>Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9064</NO>
<PG>1498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="NICE 2010" TYPE="OTHER">
<AU>National Institute for Health and Care Excellence</AU>
<TI>Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update), 2010</TI>
<SO>www.guidance.nice.org.uk/cg101</SO>
<YR>(accessed 10 August 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oostenbrink-2004" MODIFIED="2012-09-05 04:38:03 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Oostenbrink 2004" TYPE="JOURNAL_ARTICLE">
<AU>Oostenbrink JB, Rutten-van Molken MP</AU>
<TI>Resource use and risk factors in high-cost exacerbations of COPD</TI>
<SO>Respiratory Medicine</SO>
<YR>2004</YR>
<VL>98</VL>
<PG>883-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papi-2006" MODIFIED="2014-04-30 11:42:34 +0100" MODIFIED_BY="Emma Jackson" NAME="Papi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al</AU>
<TI>Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2006</YR>
<VL>173</VL>
<NO>10</NO>
<PG>1114-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perret-2013" MODIFIED="2014-04-30 11:42:52 +0100" MODIFIED_BY="Emma Jackson" NAME="Perret 2013" TYPE="JOURNAL_ARTICLE">
<AU>Perret JL, Dharmage SC, Matheson MC, Johns DP, Gurrin LC, Burgess JA, et al</AU>
<TI>The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2013</YR>
<VL>187</VL>
<NO>1</NO>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ries-2005" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NAME="Ries 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ries AL</AU>
<TI>Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and visual analog scale</TI>
<SO>COPD</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez_x002d_Roisin-2000" MODIFIED="2014-04-30 11:43:42 +0100" MODIFIED_BY="Emma Jackson" NAME="Rodriguez-Roisin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez-Roisin R</AU>
<TI>Toward a consensus definition for COPD exacerbations</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<PG>398s-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schermer-2002" MODIFIED="2012-09-05 04:38:25 +0100" MODIFIED_BY="Christopher J Cates" NAME="Schermer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schermer T, Chavannes N, Saris C, Akkermans R, van Schayck C, van Weel C</AU>
<TI>Exacerbations and associated health care cost in patients with chronic obstructive pulmonary disease in general practice. Results from the COOPT trial</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>Suppl 38</NO>
<PG>398s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seemungal-1998" MODIFIED="2014-04-30 11:44:37 +0100" MODIFIED_BY="Emma Jackson" NAME="Seemungal 1998" TYPE="JOURNAL_ARTICLE">
<AU>Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA</AU>
<TI>Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1998</YR>
<VL>157</VL>
<PG>1418-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seemungal-2000" MODIFIED="2014-04-30 11:45:04 +0100" MODIFIED_BY="Emma Jackson" NAME="Seemungal 2000" TYPE="JOURNAL_ARTICLE">
<AU>Seemungal T, Donaldson G, Bhowmik A, Jefries D, Wedizicha J</AU>
<TI>Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2000</YR>
<VL>161</VL>
<NO>5</NO>
<PG>1608-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sethi-2008" MODIFIED="2014-04-30 11:45:50 +0100" MODIFIED_BY="Emma Jackson" NAME="Sethi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Sethi S, Murphy TF</AU>
<TI>Infection in the pathogenesis and course of chronic obstructive pulmonary disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>22</NO>
<PG>2355-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherk-2000" MODIFIED="2008-10-13 14:03:06 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Sherk 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sherk PA, Grossman RF</AU>
<TI>The chronic obstructive pulmonary disease exacerbation</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>2000</YR>
<VL>21</VL>
<NO>4</NO>
<PG>705-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soler_x002d_Cataluna-2005" MODIFIED="2013-11-14 01:43:06 +0000" MODIFIED_BY="Julia A.E. Walters" NAME="Soler-Cataluna 2005" TYPE="JOURNAL_ARTICLE">
<AU>Soler-Cataluna JJ, Martinnez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R</AU>
<TI>Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>11</NO>
<PG>925-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suissa-2012" MODIFIED="2013-11-14 01:53:44 +0000" MODIFIED_BY="Julia A.E. Walters" NAME="Suissa 2012" TYPE="JOURNAL_ARTICLE">
<AU>Suissa S, Dell'Aniello S, Ernst P</AU>
<TI>Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality</TI>
<SO>Thorax</SO>
<YR>2012</YR>
<VL>67</VL>
<NO>11</NO>
<PG>957-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-2000" MODIFIED="2014-04-30 11:46:15 +0100" MODIFIED_BY="Emma Jackson" NAME="Sullivan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan SD, Ramsey SD, Lee TA</AU>
<TI>The economic burden of COPD</TI>
<SO>Chest</SO>
<YR>2000</YR>
<VL>117</VL>
<PG>5s-9s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vestergaard-2007" MODIFIED="2012-09-05 04:38:46 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Vestergaard 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vestergaard P, Rejnmark L, Mosekilde L</AU>
<TI>Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids</TI>
<SO>Chest</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>5</NO>
<PG>1599-607</PG>
<IDENTIFIERS MODIFIED="2008-09-19 10:37:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-19 10:37:06 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17890464 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Walters-2011" MODIFIED="2014-05-15 10:39:25 +0100" MODIFIED_BY="Emma Jackson" NAME="Walters 2011" TYPE="COCHRANE_REVIEW">
<AU>Walters JA, Wang W, Morley C, Soltani A, Wood-Baker R</AU>
<TI>Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2014-04-30 11:47:30 +0100" MODIFIED_BY="Emma Jackson">
<IDENTIFIER MODIFIED="2014-04-30 11:47:30 +0100" MODIFIED_BY="Emma Jackson" TYPE="DOI" VALUE="10.1002/14651858.CD006897.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wedzicha-2000" MODIFIED="2013-11-14 01:59:36 +0000" MODIFIED_BY="Julia A.E. Walters" NAME="Wedzicha 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wedzicha JA</AU>
<TI>Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Thorax</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>Suppl 1</NO>
<PG>S23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2004" MODIFIED="2014-04-30 11:47:41 +0100" MODIFIED_BY="Emma Jackson" NAME="Wilkinson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA</AU>
<TI>Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2004</YR>
<VL>169</VL>
<NO>12</NO>
<PG>1298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wise-2005" MODIFIED="2012-09-05 04:39:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wise 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wise RA, Brown CD</AU>
<TI>Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test</TI>
<SO>COPD</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>125-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-23 15:43:38 +0100" MODIFIED_BY="Emma J Welsh">
<REFERENCE ID="REF-Walters-2009" MODIFIED="2014-05-23 15:43:33 +0100" MODIFIED_BY="Emma J Welsh" NAME="Walters 2009" TYPE="COCHRANE_REVIEW">
<AU>Walters JAE, Gibson PG, Wood-Baker R, Hannay M, Walters EH</AU>
<TI>Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001288.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood_x002d_Baker-2001" MODIFIED="2014-05-23 15:43:38 +0100" MODIFIED_BY="Emma J Welsh" NAME="Wood-Baker 2001" TYPE="COCHRANE_REVIEW">
<AU>Wood-Baker R, Walters E, Gibson P</AU>
<TI>Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001288"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-11-14 02:00:07 +0000" MODIFIED_BY="Julia A.E. Walters"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-08-28 15:23:21 +0100" MODIFIED_BY="Emma J Welsh">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-08-28 15:23:04 +0100" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-08-28 14:33:21 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Aaron-2003">
<CHAR_METHODS MODIFIED="2014-08-27 03:58:20 +0100" MODIFIED_BY="Julia A.E. Walters">
<P>Design: parallel group<BR/>Duration: treatment for 10 days</P>
<P>Setting: ED of 10 participating hospitals in Canada<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-27 03:58:20 +0100" MODIFIED_BY="Julia A.E. Walters">
<P>Number screened: 1087 of which 202 eligible</P>
<P>Number randomised: 147 (74 prednisone/2 withdrew, 2 hospitalised; 73 placebo/1 withdrew, 1 hospitalised, 1 lost to follow-up)</P>
<P>Number completed: 140 evaluated at 30 days</P>
<P>Baseline details:</P>
<P>Mean age (years): prednisone group: 68.9 ± 11.2; placebo group: 69.9 ± 10.4<BR/>Gender: M = 84, F = 63</P>
<P>Diagnosis COPD: evidence of irreversible airflow obstruction in the ED, with FEV<SUB>1</SUB>/FVC &lt; 0.70, an FEV<SUB>1</SUB> &lt; 70% predicted value, post-bronchodilator improvement in FEV<SUB>1</SUB> of &lt; 20%</P>
<P>AE criteria: clinical diagnosis of recent exacerbation of COPD</P>
<P>
<BR/>Inclusion criteria: age &gt; 35 years; 15 pack-years' smoking history; evidence of irreversible airflow obstruction in the ED, with FEV<SUB>1</SUB>/FVC &lt; 0.70, an FEV<SUB>1</SUB> &lt; 70% predicted value, post-bronchodilator improvement in FEV<SUB>1</SUB> of &lt; 20%<BR/>Exclusion criteria: subsequent admission to hospital from ED; diagnosis of asthma or atopy; use of oral or IV corticosteroids within the preceding 30 days; received oral or IV corticosteroids in the ED; findings on chest radiography consistent with the presence of pneumonia or congestive heart failure; adverse reactions to oral corticosteroids; severe uncontrolled diabetes mellitus or renal, hepatic or cardiac failure<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-27 08:30:14 +0100" MODIFIED_BY="Julia A.E. Walters">
<P>Experimental: prednisone 40 mg capsule (oral admin), once daily for 10 days (10D SS course)<BR/>Control: matched placebo, identical in taste and appearance once daily for 10 days<BR/>Co-interventions: trimethoprim 160 mg with sulphamethoxazole 800 mg twice daily or if allergic doxycycline 100 mg twice daily. Inhaled albuterol and inhaled ipratropium bromide</P>
<P>Confounders: inhaled corticosteroids and all other medications used by the participants at the time of enrolment were continued throughout the study in both groups<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:33:18 +0100" MODIFIED_BY="Emma J Welsh">
<P>Primary outcome: treatment failure defined as an unscheduled visit to a doctor's clinic or a return to the ED because of worsening dyspnoea within 30 days after randomisation</P>
<P>Secondary outcomes: change from day 1 to day 10 in FEV<SUB>1</SUB>, severity of dyspnoea and disease-specific QoL</P>
<P>Measurement: treatment failure participants assessed 3, 10 and 30 days after randomisation. Secondary outcomes assessed on days 1 and 10.</P>
<P>Analysed: relapse rates, FEV<SUB>1</SUB> (post-bronchodilator measurements), severity of dyspnoea (transitional dyspnoea index), disease-specific QoL (Chronic Respiratory Disease Index Questionnaire); adverse effects of prednisone<BR/>Reported: hyperglycaemia as an adverse effect<BR/>
<BR/>Mortality: 2 in prednisone group, 1 in placebo group<BR/>Adverse effects: increased appetite, weight gain, insomnia, hyperglycaemia (subjectively reported but not objectively measured as not part of protocol)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:33:21 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age &gt; 35 years, &gt; 15 pack-years' smoking history, diagnosis of asthma exclusion, evidence of fixed airflow obstruction at presentation</P>
<P>Funding: grants from the Canadian Institutes of Health Research (MCT-41545), the Ontario Ministry of Health Emergency Health Services Research Advisory Committee (13098), the Ontario Thoracic Society and the Canadian Institute of Health Research 21st Century Chairs Program (to Dr. Rowe). Authors declared previous support from pharmaceutical companies; no notable conflict</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Abroug-2014">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:08 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group open-label randomised study<BR/>Duration: conducted 2008-2011</P>
<P>Setting: ICU in 2 tertiary teaching hospitals: CHU Fattouma Bourguiba, Monastir and CHU Tahar Sfar, Mahdia, affiliated with the University of Monastir, Tunisia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:48 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 518</P>
<P>Number randomised: 217, 111 prednisone, 106 control</P>
<P>Number completed: 217</P>
<P>Baseline details:</P>
<P>Age median (IQR) (years): prednisone 70 (63-75), control 68 (63-75)</P>
<P>Gender: prednisone M = 99, F = 12; control M = 92, F = 14</P>
<P>Baseline FEV<SUB>1</SUB> median (IQR) (L): prednisone 0.82 (0.59-1.12), control 0.75 (0.57-0.95)</P>
<P>GOLD stage COPD: prednisone stage III = 30% stage IV = 70%; control stage III = 27%, stage IV = 73%</P>
<P>LTOT: prednisone 72%, control 67%</P>
<P>Diagnosis COPD: airflow obstruction post-bronchodilator ratio FEV<SUB>1</SUB>/FVC &lt; 0.7, previously documented or present on discharge from ICU</P>
<P>AE criteria: change in participant's baseline dyspnoea, cough or sputum (or both) requiring a change in regular medication with acute respiratory failure defined by severe hypoxaemia PaO<SUB>2</SUB> &lt; 60 mmHg or arterial oxygen saturation &lt; 90% on room air associated with </P>
<P>hypercapnia (or both), PaCO<SUB>2</SUB> &#8805; 45 mmHg associated with pH &#8804;<B> </B>7.35 and </P>
<P>clinical signs of excessive respiratory muscle activity (contraction of accessory respiratory muscles and respiration rate &#8805; 25 breaths<B>/</B>minute)</P>
<P>Inclusion criteria: all participants aged &gt; 40 years, &#8805; 10 pack-years' smoking history, with known or strongly suspected COPD admitted to participating ICU for AE COPD with hypercapnic </P>
<P>acute respiratory failure requiring ventilatory support</P>
<P>Exclusion criteria: evidence of pneumonia, treated for COPD, people with asthma defined by a reversible obstructive disease following nebulised bronchodilators, uncontrolled left heart failure, systemic corticosteroids for exacerbation within 30 days prior to screening, absolute contraindication to corticosteroids (active gastroduodenal ulcer, severe uncontrolled sepsis, hepatitis or other active viral disease or neuromuscular disease (or both))</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: oral prednisone 1 mg<B>/</B>kg daily either until discharge or for a maximum of 10 days, median duration 8 days (IQR 5-10)</P>
<P>Control: usual care (undefined)</P>
<P>Co-interventions: all included participants received ventilatory support (NIV or conventional) prednisone NIV 76%, conventional 24%: control NIV 76%, conventional 24%</P>
<P>Nebulised beta2-agonists (terbutaline, 5 mg every 6 hours) and ipratropium bromide (0.5 mg every 8 hours)</P>
<P>Antibiotics prescribed at discretion of physician in charge: prednisone 82%, control 79%.</P>
<P>Treatment period: up to 10 days</P>
<P>Follow-up period: maximum 30 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Primary outcome: ICU mortality<BR/>Secondary outcomes: duration of ventilator support (sum of conventional and NIV if ventilated with both); length of ICU stay; rate of NIV failure (intubation rate in participants managed initially with NIV); corticosteroidal complications: occurrence of secondary infections, hyperglycaemic episodes necessitating initiation of insulin therapy (corresponding to a blood glucose level &#8805;180 mg<B>/</B>dL in participants without pre-existing diabetes) or increase in initial insulin therapy, ICU-acquired muscular weakness, or significant gastrointestinal bleeding inducing a fall in the haemoglobin level &#8805; 2 g<B>/</B>dL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Trial registration: Clinicaltrials.gov/NCT01353235. Date of registration 17 May 2011</P>
<P>Protocol: not available. Trial approved by the ethics committee of both centres. Sample size target 300, but study was ended before completion of the planned sample size because of the slow inclusion rate</P>
<P>Length of stay and duration of mechanical ventilation published as median and IQR. Mean and SD assumptions based on <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Section 7.7.3.5. The width of the IQR is approximately 1.35 SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Albert-1980">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Setting: people with chronic airflow limitation hospitalised due to acute respiratory insufficiency from acute and chronic bronchitis, Veterans Hospital, Washington, USA</P>
<P>Duration: treatment for 72 hours</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 45</P>
<P>Number randomised: 44</P>
<P>Number completed: 40</P>
<P>Baseline details:</P>
<P>Mean age (years): 61.5</P>
<P>Gender: M = 44, F = 0</P>
<P>Diagnosis COPD: chronic bronchitis defined as cough and sputum production most days for at least 3 months of the 2 previous years, chronic airflow obstruction -FEV<SUB>1</SUB> &lt; 60% predicted or FEV<SUB>1</SUB>/FVC &lt; 60%</P>
<P>AE criteria: hospitalised with acute respiratory insufficiency, acute bronchitis defined as an increase in cough and sputum production within 5 days</P>
<P>Inclusion criteria: acute respiratory insufficiency, PaO<SUB>2</SUB> &lt; 65 mmHg on room air (after correcting for hyperventilation) or PaCO<SUB>2</SUB> &gt; 50 mmHg with pH &lt; 7.35 or alveolar-arterial oxygen difference &gt; 10 mmHg above that within the previous 2 years; chronic bronchitis defined as cough and sputum production most days for at least 3 months of the 2 previous years; FEV<SUB>1</SUB> &lt; 60% predicted or FEV<SUB>1</SUB>/FVC &lt; 60%</P>
<P>Exclusion criteria: personal or family history of asthma, increase in FEV<SUB>1</SUB> of &gt; 30% after inhaled bronchodilator when clinically stable; history of eczema or allergic rhinitis, consolidation on admission chest X-ray, corticosteroid therapy within the last 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: methylprednisolone (Upjohn) 0.5 mg/kg, IV, 6 hourly, for 72 hours (3D Systemic Steroid course)<BR/>Control: matched placebo, IV, 6 hourly, for 72 hours</P>
<P>Co-interventions: IV aminophylline, inhaled isoproterenol, IV ampicillin or oral tetracycline, supplemental oxygen to maintain SaO<SUB>2</SUB> above 85%</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed: pre- and post-bronchodilator bedside spirometry.</P>
<P>Reported: ABG, serum theophylline concentration, blood glucose concentration</P>
<P>Mortality: 2 participants in the corticosteroid group (at 30 hours and 9 days)</P>
<P>Morbidity: experimental group; psychosis (n = 1), gastrointestinal bleed (n = 1). Control group; dermatitis (n = 1), pneumonia (n = 1), gastrointestinal bleed (n = 1)</P>
<P>In comparison of treatments, the post-bronchodilator spirometric measurements at 72 hours were used for analysis. The spirometric measurements were estimated from the baseline values and graphical changes at 72 hours. The baseline SD was used for all time points</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: no age limitations, no smoking history required, history of asthma exclusion, airflow obstruction previously or 1 month after acute presentation</P>
<P>Funding: no external sources declared. In-house study assistance from the Veterans Administration Hospital, Washington</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:36:50 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Alia-2011">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group</P>
<P>Duration: recruitment began in June 2005 and concluded in July 2009. Participants were enrolled during a mean time of 19.6 months (range 5-49 months).<BR/>Setting: 8 hospitals in 4 countries (Hospital Universitario de Getafe, Hospital Fundación Alcorcón, Hospital Clinic de Barcelona, Consorci Hospitalari Parc Taulí, and Hospital Principe de Asturias in Spain; Hospital ABC in Mexico; Clinica Universitaria Bolivariana in Colombia and University of Texas Health Science Center in the USA (University Hospital and Audie L. Murphy Veterans Affairs Hospital))</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 354</P>
<P>Number randomised: 83</P>
<P>Number completed: 83</P>
<P>Baseline details: </P>
<P>Age (years): methylprednisolone 69.1 (SD 9.7), control 67.6 (SD 10.7)</P>
<P>Gender: M = methylprednisolone 32 (74%), control 34 (85%)</P>
<P>Diagnosis COPD: known COPD and hospitalised with exacerbation that required ventilator support either conventional with intubation or NIV</P>
<P>AE criteria: defined as the presence of &#8805; 2 of: worsening dyspnoea, increase in sputum purulence or increase in sputum volume</P>
<P>Inclusion criteria: acute hypercapnic respiratory failure (pH &lt; 7.35, with a PaCO<SUB>2</SUB> &gt; 45 mmHg) requiring invasive or non-invasive mechanical ventilation</P>
<P>Exclusion criteria: asthma or atopy; use of systemic corticosteroids within the preceding month; use of systemic corticosteroids for the treatment of COPD exacerbation for &gt; </P>
<P>24 hours at the time of randomisation; clinical or radiological </P>
<P>evidence of pneumonia; uncontrolled LVF requiring the use of inotropes or vasoactive drugs; uncontrolled arterial hypertension; uncontrolled diabetes mellitus; neuromuscular disease; allergy or adverse reaction (or both) to corticosteroid therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:50 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: methylprednisolone 0.5 mg/kg every 6 hours for 72 hours, 0.5 mg/kg every 12 hours on days 4-6, and 0.5 mg/kg/day on days 7-10</P>
<P>Control: placebo normal saline 50 mL IV</P>
<P>Co-interventions: inhaled beta2- agonist (salbutamol 2.5 mg every 6 hours or 2 puffs from an MDI at least 4 times daily) and inhaled ipratropium bromide (0.5 mg every 6 hours or 2 puffs from an MDI at least 4 times daily). Any participant who was receiving inhaled corticosteroid therapy before randomisation was continued on this therapy. Systemic antibiotics were used at the judgement of the treating physicians</P>
<P>Treatment period: 10 days</P>
<P>Follow-up period: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:36:50 +0100" MODIFIED_BY="Emma J Welsh">
<P>Primary outcomes: duration of mechanical ventilation,</P>
<P>length of ICU stay,</P>
<P>need for intubation in people treated with NIV</P>
<P>Secondary outcomes:</P>
<P>length of hospital stay,</P>
<P>ICU mortality</P>
<P>Adverse events:</P>
<P>secondary infection,</P>
<P>gastrointestinal bleeding,</P>
<P>arterial hypertension,</P>
<P>hyperglycaemia,</P>
<P>hospital acquired pneumonia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:50 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: no age restrictions, no criterion for required pack history, diagnosis of asthma exclusion, required ventilator support although no specified threshold for fixed airflow obstruction at presentation</P>
<P>Trial registration: ClinicalTrials.gov/NCT01281748</P>
<P>Financial disclosure: none reported. Funding/Support: study funded in part by grant PI041233 from Fondo de Investigación Sanitaria</P>
<P>Study lasted 5 years because of a lower enrolment rate, mainly due to a reduction in ICU admissions of people with COPD exacerbations and a high rate of exclusion</P>
<P>Protocol: days 1-5: ABG analysis, plasma C-reactive protein level, white blood cell count, maximal blood glucose level, daily dose insulin, intrinsic positive end expiratory pressure (intubated participants)</P>
<P>Emailed data request to authors - 7 September 2013 (Esteban). Data provided for outcomes - length of hospital stay, ICU stay and mechanical ventilation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:36:54 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Bullard-1996">
<CHAR_METHODS MODIFIED="2014-08-28 14:36:54 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group</P>
<P>Duration: recruited March-August 1993, and November 1993-February 1994. Treatment for up to 8 days then follow-up for 2 weeks<BR/>Setting: single-centre tertiary hospital, Chang Gung Memorial Hospital, Linkou, Taiwan, ED with subsequent admission if required<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 138 (18 excluded on chest X-ray - 6 cardiac asthma, 2 pneumothoraces, 5 pneumonia, 3 severe bronchiectasis, 2 bronchogenic cancer. 1 participant in placebo group died, 2 incorrect diagnosis, 2 withdrew consent).</P>
<P>Number completed: 113</P>
<P>26 participants were discharged from the ED within 24 hours (16 in the corticosteroid group and 10 in the placebo group)</P>
<P>Baseline details:</P>
<P>Mean age (years): 66</P>
<P>Gender: M = 97, F = 16</P>
<P>Diagnosis COPD: no details of previous clinical COPD diagnosis</P>
<P>AE criteria: moderate-to-severe dyspnoea presenting to ED, FEV<SUB>1</SUB> &lt; 60% predicted or FEV<SUB>1</SUB>/FVC &lt; 60%</P>
<P>Inclusion criteria: &gt; 40 years of age; suspected chronic airflow limitation, presenting with dyspnoea and a FEV<SUB>1</SUB> &lt; 60% predicted or FEV<SUB>1</SUB>/FVC &lt; 60%</P>
<P>Exclusion criteria: pneumothorax, pneumonia, intubation within 2 hours, hospitalisation for a co-existent disease, known corticosteroid use</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: hydrocortisone 100 mg, IV, within 15 minutes of arrival. Hydrocortisone 100 mg IV 4 hourly for 4 days for those participants hospitalised. Participant received prednisolone 40 mg, orally, daily for 4 days either on discharge from the ED or if admitted having completed the IV therapy (5D-8D systemic steroid treatment)<BR/>Control: IV placebo administered within 15 minutes of arrival. Subsequent treatment not clearly reported</P>
<P>Co-interventions: inhaled fenoterol, inhaled ipratropium bromide, IV aminophylline</P>
<P>Confounders: IV hydrocortisone could be administered at the discretion of chest medicine physicians. 12 participants received cross-over treatment or had their treatment stopped after 24 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed: </P>
<P>FEV<SUB>1</SUB> (at 6 hours) published results for lower limit of 95% CI control group missing a minus sign as 95% CI in the paper does not include the point estimate as reported; </P>
<P>PEF (at 6 hours) published results for lower limit of 95% CI control group missing a minus sign as 95% CI in the paper does not include the point estimate as reported</P>
<P>Reported: admissions, discharges from the ED within 24 hours, serum aminophylline concentration, re-attendance to the ED, subjective assessment of dyspnoea.</P>
<P>Others: none reported </P>
<P>Mortality: 3 deaths in corticosteroid group, 2 in the placebo.</P>
<P>Morbidity: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: people &gt; 40 years of age, no requirement for past smoking, asthma not an exclusion, chronic airflow limitation suspected</P>
<P>Funding: no sources of funding declared<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:05 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Ceviker-2014">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Duration: 3 months (following discharge)<BR/>Setting: State Hospital, Gumushane, Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:37:00 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not available</P>
<P>Number randomised: 40</P>
<P>Number completed: 38</P>
<P>Number withdrawals: 2 (developed severe respiratory failure)<BR/>Baseline details:<BR/>Mean age (years): oral group: 69.0 (± 10.5), IV group: 67.1 (±8.4)<BR/>Smoking history: oral group: 56.3 (±38.8), IV group: 69.0 (±38.5)<BR/>Diagnosis COPD: previous documented diagnosis of COPD<BR/>AE criteria: presence of an exacerbation, which, in the opinion of the attending physician, necessitated admission to hospital<BR/>Inclusion criteria: aged &gt; 40 years, previous documented diagnosis of COPD, &#8805; 10 pack-years' smoking history, exacerbation requiring hospitalisation based on opinion of attending doctor<BR/>Exclusion criteria: the presence of pneumonia, uncontrolled hypertension or diabetes mellitus, previously diagnosed bronchiectasis, need for mechanical ventilation, use of systemic corticosteroids during the preceding month and a history of gastrointestinal bleeding during the preceding 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:37:01 +0100" MODIFIED_BY="Emma J Welsh">
<P>Group 1: oral methylprednisolone 32 mg/day</P>
<P>Group 2: IV methylprednisolone 1 mg/kg/day for 4 days, then 0.5 mg/kg/day for 3 days</P>
<P>Co-interventions: salbutamol 2.5 mg and Ipratropium 0.5 mg - every 6 hours, antibiotics (if meet Anthonisen criteria), nasal oxygen (according to attending physician's decision)<BR/>Treatment period: 7 days</P>
<P>Follow-up period: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:37:03 +0100" MODIFIED_BY="Emma J Welsh">
<P>Reported:<BR/>During treatment period:<BR/>Pre- and post-bronchodilator spirometry: days 7, 90<BR/>ABGs: days 2, 4, 7, 90<BR/>Symptom scores: days 2, 4, 7.<BR/>Adverse events: daily questioning of the participants and daily measurements of blood pressure and blood glucose levels during the treatment period</P>
<P>During 3 months' follow-up: visits to the ED or unplanned visits to family physicians and<BR/>admission to hospital</P>
<P>Treatment failure defined as severe respiratory failure requiring mechanical ventilation or need for systemic corticosteroids beyond 7 days intervention period<BR/>Relapse defined as re-admission for COPD during 12-week follow-up</P>
<P>No legend was provided for certain outcomes (ABG, symptom scores, lung function tests, length of hospital stay). Data for symptom score were obtained from a graph - confirmation is required<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:37:05 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 40 years for inclusion, &gt; 10 pack-years' smoking history, asthma not an exclusion, previously documented COPD diagnosis, no criteria specified for airflow obstruction</P>
<P>Funding: no sources of funding declared</P>
<P>Trial registration: not located, pre-study protocol not available</P>
<P>Emailed data request to authors - 7 September 2013, 30 September 2013 (Ceviker). No response received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Chen-2005">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Duration: 14 days<BR/>Setting: inpatients, unknown number of centres, China<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 130</P>
<P>Number completed: 121</P>
<P>Baseline details:</P>
<P>Mean age (years): 7-day corticosteroids 70.3, 14-day corticosteroids 71.7, placebo 73.0 (not significantly different)<BR/>Age range: not reported<BR/>Gender: M = 98, F = 32</P>
<P>Diagnosis COPD: criteria for COPD not reported</P>
<P>AE criteria: not reported</P>
<P>Diagnosis and severity: FEV<SUB>1</SUB> (L) baseline 7-day corticosteroids 0.79 (SD 0.25), 14-day corticosteroids 0.74 (SD 0.21), placebo 0.74 (SD 0.32), baseline PaO<SUB>2</SUB> (mmHg) 7-day corticosteroids 69.06 (SD 11.54), 14-day corticosteroids 68.07 (SD 13.53), placebo 67.48 (SD 11.61)<BR/>Current smokers: 7-day corticosteroids 18/44 (41%), 14-day corticosteroids 20/43 (47%), placebo 18/43 (42%) (not significantly different)<BR/>Inclusion criteria: not reported<BR/>Exclusion criteria: not reported, people with asthma excluded: not reported, bronchodilator reversibility tested: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Group 1 prednisolone 30 mg/day 7 days + placebo 7 days<BR/>Group 2 prednisolone 30 mg/day 10 days + 15 mg/day 5 days<BR/>Group 3 placebo 14 days<BR/>Delivery: oral<BR/>Co-interventions permitted/dose: not reported<BR/>Co-interventions not permitted: not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Outcomes measured: </P>
<P>lung function, </P>
<P>ABG measurement, </P>
<P>days hospitalisation, symptoms scores, </P>
<P>rate of treatment failure, </P>
<P>side effects corticosteroids, rate of relapse</P>
<P>Outcomes reported: FEV<SUB>1</SUB>, FEV<SUB>1</SUB>/FVC ratio, PEF, PaO<SUB>2</SUB>, number relapsed, number failed treatment, number side effect</P>
<P>Follow-up assessment points: not reported</P>
<P>Prednisolone 14-day treatment group data used in this review<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Full paper published in Chinese 2008. Abstract publication 2005. Study and outcome data also provided by authors<BR/>Likelihood of COPD: unknown if age threshold, unknown pack-years' smoking threshold, asthma an exclusion, fixed airflow obstruction, FEV<SUB>1</SUB>/FVC &lt; 70%, FEV<SUB>1</SUB> &lt; 80% predicted</P>
<P>Funding: no sources disclosed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:13 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Cordero-1996">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group randomised controlled study<BR/>Duration: conducted April-September 1995<BR/>Setting: outpatients, University Hospital La Fe, Valencia, Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 30</P>
<P>Number completed:</P>
<P>Baseline details: M = 30, F = 0</P>
<P>Median age (range) (years): not reported</P>
<P>Diagnosis COPD: airflow obstruction FEV<SUB>1</SUB> &gt; 70% predicted or FEV<SUB>1</SUB>/FVC &lt; 60% predicted</P>
<P>AE criteria: not described</P>
<P>Inclusion criteria: male, &gt; 50 years, airflow obstruction</P>
<P>Exclusion criteria: asthma or atopy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: oral prednisone 40 mg daily 10 days</P>
<P>Control: placebo 10 days</P>
<P>Co-interventions: standardised treatment, inhaled beta-agonists, anticholinergics, inhaled corticosteroids, antibiotics, physiotherapy</P>
<P>Treatment period: 10 days</P>
<P>Follow-up period: 14 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:37:13 +0100" MODIFIED_BY="Emma J Welsh">
<P>Reported: spirometry, PEF, ABG, PaO<SUB>2</SUB>, Borg dyspnoea scale<BR/>Measurements: days 1, 7, 14</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: &gt; 50 years for inclusion, unknown pack-years' smoking history, unknown if asthma an exclusion, fixed airflow obstruction, FEV<SUB>1</SUB>/FVC &lt; 60%, FEV<SUB>1</SUB> &lt; 70% predicted</P>
<P>Funding: no sources disclosed</P>
<P>Protocol: not available, no registration located</P>
<P>Published as conference abstract only. Emailed data request to authors 20 September 2012, 9 August 2013 (Cordero), 16 August 2013 (Sole). No response received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:16 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Davies-1999">
<CHAR_METHODS MODIFIED="2014-08-28 14:37:16 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Duration: follow-up for 6 weeks<BR/>Setting: single centre, people presenting to an ED of a university hospital, Liverpool UK<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 246</P>
<P>Number randomised: 60; prednisolone 29, placebo 29</P>
<P>Number completed: 27; prednisolone (1 withdrew, 1 died), 22 placebo (5 withdrew, 1 died, 1 lost to follow-up)</P>
<P>Baseline details:</P>
<P>Mean age (years): 67<BR/>Gender: M = 34, F = 16</P>
<P>Diagnosis COPD: not specified</P>
<P>AE criteria: increased breathlessness and 2 of following criteria: increased sputum - volume or purulence, cough frequency or severity, increased wheeze<BR/>Inclusion criteria: diagnosis of COPD, aged 40-80 years. FEV<SUB>1</SUB> &lt; 70% and FEV<SUB>1</SUB>/FVC &lt; 75%<BR/>Exclusion criteria: personal/family history of asthma, uncontrolled LVF, pneumonia, oral corticosteroids within last month, pH &lt; 7.26<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: prednisolone 30 mg orally for 14 days<BR/>Control: matched placebo</P>
<P>Treatment for 14 days</P>
<P>Co-interventions: nebulised salbutamol and ipratropium bromide, oxygen and antibiotics at physician's judgement</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>FEV<SUB>1</SUB>; FVC; visual analogue scale of symptoms; </P>
<P>length of hospitalisation data removed due to skewed data, was previously mentioned in text, but not data analysis; ABG, sputum culture</P>
<P>Treatment failure: defined arterial PH falling &lt; 7.26, physician or participant decision lack of progress requiring further treatment, QoL </P>
<P>(SGRQ)</P>
<P>Measurements: daily symptoms, lung function 5 days, 6 weeks SGRQ, AE<BR/>Mortality: 2 deaths, 1 in each treatment group<BR/>Adverse drug effects: heartburn and glycosuria</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 40 years, &gt; 20 pack-years' smoking history, history of asthma exclusion, evidence of fixed airflow obstruction</P>
<P>Funding: Glaxo Wellcome supplied oral corticosteroids and placebo. Fazakerley Foundation for funding research of L. Davies</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:22 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-de-Jong-2007">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group prospective, randomised, double-blind, double-dummy, placebo-controlled, parallel-group clinical study with treatment failure as the primary outcome<BR/>Duration: June 2001 to June 2003<BR/>Setting: inpatients, single centre, Isala Klinieken, Zwolle, the Netherlands</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 435</P>
<P>Number randomised: 210; 107 IV group, 103 oral group</P>
<P>Number completed: 193</P>
<P>Number withdrawals: 17 (6 withdrew consent before day 4 of the study, 2 in IV group and 4 in oral group</P>
<P>11 excluded from the per-protocol analysis because they did not fulfil inclusion or exclusion criteria, 6 IV group, 5 oral group)</P>
<P>Baseline details:<BR/>Smoking history (mean) (pack-years): IV group: 37.2 (SD 20.2) oral group: 40.5 (SD 23.1)<BR/>Baseline lung function (mean) (L): IV group: 1.0 (SD 0.43), 36% predicted (SD 14%); oral group: 1.0 (SD 0.40), 39% predicted (SD 17%)<BR/>
</P>
<P>Mean age (years): IV group: 69.8 (SD 8.6), oral group 71.6 (SD 8.1)</P>
<P>Gender: IV group: M = 76.6%, oral group: M = 72.8%</P>
<P>Diagnosis COPD: airflow limitation was defined as an FEV<SUB>1</SUB>/FVC ratio of &lt; 70% and FEV<SUB>1</SUB> of &lt; 80% predicted (at least GOLD severity stage II)</P>
<P>AE criteria: defined as a history of increased breathlessness and the presence of at least 2 of the following symptoms for at least 24 6 hours: increased cough frequency or severity, increased sputum volume or purulence and increased wheeze</P>
<P>Inclusion criteria: aged &gt; 40 years, &gt; 10 pack-years' smoking history, evidence of airflow limitation</P>
<P>Exclusion criteria: people who had signs of a very severe exacerbation on hospital admission (arterial pH &lt; 7.26 or PaCO2 &gt; 9.3 kPa), significant or unstable co-morbidity, history of asthma, participated in another study within the 4 weeks before hospital admission, previously randomised into this study, had clinically significant findings on chest radiography other than COPD, known hypersensitivity to prednisolone, known to be totally non-compliant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>IV group: IV prednisolone 60 mg + placebo medication 5-day course, up to 7 days tapering course oral prednisolone 30 mg </P>
<P>Oral group: oral prednisolone 60 mg + placebo medication 5-day course, up to 7 days tapering course oral prednisolone 30 mg </P>
<P>Co-interventions: nebulised ipratropium bromide and albuterol 4 times daily together with oral amoxicillin/clavulanate. In case of allergy to this regimen, doxycycline was prescribed</P>
<P>Treatment period: 12 days</P>
<P>Follow-up period: 90 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Reported: by early &lt; 2 weeks, late 2-12 weeks; </P>
<P>death from any cause, </P>
<P>admission to the ICU, </P>
<P>re-admission to the hospital because of COPD, </P>
<P>necessity to intensify pharmacological treatment</P>
<P>Spirometry days 1 and 7<BR/>Health status SGRQ days 1 and 7. Minimal clinically important difference &#10878;0.4, range 0-100<BR/>Health-related QoL 24-hour version CCQ daily on days 1-7. Minimal clinically important difference &#10878;0.4, range 0-6</P>
<P>Treatment failure defined as intensification of pharmacological treatment with open-label corticosteroids</P>
<P>Relapse defined as re-admission to the hospital for COPD between 2 and 12 weeks</P>
<P>Analysis: per-protocol IV group 99 (of 107 participants), oral group 94 (of 103 participants)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:37:22 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 40 years, &gt; 10 year-packs' smoking history, history of asthma exclusion, evidence of fixed airflow obstruction</P>
<P>Funding: sources not disclosed; authors reported on 23 January 2007 to the ACCP that no significant conflicts of interest existed with any companies/organisations whose products or services may be discussed in the article</P>
<P>Trial registration: ClinicalTrials.gov/NCT00311961</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 15:23:04 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Emerman-1989">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Duration:<BR/>Setting: single centre, ED of a urban county general hospital, Cleveland USA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 100</P>
<P>Number completed: 96 (4 lost to follow-up)</P>
<P>Baseline details:</P>
<P>Mean age (years): 64 (SD6.7)</P>
<P>Gender: M = 50, F = 46</P>
<P>Diagnosis COPD: clinical history of emphysema or chronic bronchitis</P>
<P>AE criteria: presenting to ED with respiratory distress, initial spirometry FEV<SUB>1</SUB> &lt; 70% predicted or FEV<SUB>1</SUB>/FVC &lt; 60%</P>
<P>Inclusion criteria: aged &gt; 50 years</P>
<P>Exclusion criteria: history of asthma, episodes of respiratory distress before 35 years of age, oral or IV corticosteroids within 1 month, pneumonia, acute congestive heart failure, other conditions requiring hospitalisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: methylprednisolone 100 mg IV (1D systemic corticosteroid treatment)<BR/>Control: matched placebo solution IV<BR/>Co-interventions: inhaled isoetharine, nasal oxygen and IV aminophylline</P>
<P>Exclusions: no antibiotics given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 15:23:04 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed: spirometry, outcomes reported as percentage of predicted lung function measurements,</P>
<P>hospitalisation rate</P>
<P>Reported: return to the ED. Active intervention was a single IV infusion of methylprednisolone given in the ED with participants observed over a minimum of 4 hours. Subsequently 30 of 96 participants required admission and for some participants allocation to treatment group was not maintained after re-admission</P>
<P>Follow-up measurements: 48 hours</P>
<P>Others: none reported</P>
<P>Mortality: none reported</P>
<P>Adverse drug effects: none reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 50 years; past smoking not required, but mean smoking history &gt; 50 pack-years so most participants will have a significant smoking history; asthma excluded; chronic airflow obstruction not known</P>
<P>Funding: no sources disclosed</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:44 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Gunen-2007">
<CHAR_METHODS MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Duration: treatment 15 days, follow-up 1 month<BR/>Setting: inpatients, single centre, Turgut Ozal Research Centre of Inonu University, Malatya, Turkey</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 159 (group 1 = 53, group 2 = 53, group 3 = 53)</P>
<P>Number completed: 121 (group 1 = 39, group 2 = 40, group 3 = 42)</P>
<P>Number withdrawals: 11 participants lost to follow-up post discharge group 1 = 4, group 2 = 3, group 3 = 4. Deaths group 1 = 1, group 2 = 1</P>
<P>Baseline details:</P>
<P>Age (years): 64.1 (SD 8.9)</P>
<P>Gender: group 1: M = 35, F = 4; group 2: M = 33, F = 7; group 3: M = 35, F = 7</P>
<P>FEV<SUB>1</SUB> at admission: 37.2% predicted (SD 12.2)</P>
<P>Diagnosis COPD: people with COPD hospitalised for an exacerbation prospectively enrolled, COPD according to the criteria set by the ATS</P>
<P>AE criteria: presence of worsening in at least 2 of the following symptoms: cough, purulent sputum and dyspnoea.</P>
<P>Inclusion criteria: level II exacerbation</P>
<P>Exclusion criteria: hospitalised for pneumonia, pulmonary emboli, congestive heart failure and pneumothorax. Risk of imminent respiratory failure requiring mechanical ventilation or direct admission to the ICU (level III exacerbation). Utilised systemic corticosteroids or had an exacerbation in the preceding month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:37:39 +0100" MODIFIED_BY="Emma J Welsh">
<P>Group 1: salbutamol nebulised 2.5 mg 4 times daily and ipratropium bromide nebulised 0.5 mg 4 times daily</P>
<P>Group 2 prednisolone IV 40 mg plus nebulised salbutamol 2.5 mg 4 times daily and nebulised ipratropium bromide 0.5 mg 4 times daily</P>
<P>Group 3 budesonide nebulised 1500 mg 4 times daily; combined nebulised solution of salbutamol and ipratropium bromide 4 times daily ipratropium</P>
<P>bromide 0.5 mg and salbutamol 2.5 mg/2.5 mL</P>
<P>Co-interventions: nebulised salbutamol as rescue medication. All participants were given supplemental oxygen and systemic methylxanthines, antibiotics were used where signs of bacterial infection existed: group 1 = 59, group 2 = 63, group 3 = 57%</P>
<P>Treatment period: 15 days; at least 10 days in hospital remainder continued after discharge: group 2 systemic corticosteroids methylprednisolone 32 mg tablets in the morning or group 3 or nebulised inhaled budesonide 1500 mg 4 times daily</P>
<P>Follow-up period: 1-month. Combivent aerosol, ipratropium bromide 20 µg plus salbutamol 100 µg x 2 puffs 4 times daily;</P>
<P>and methylxanthines</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:37:42 +0100" MODIFIED_BY="Emma J Welsh">
<P>Reported: complete blood counts, detailed biochemical analysis, spirometric measurements and ABG analysis at admission, 24 hours, 72 hours, 7 days and 10 days</P>
<P>Status after discharge was assessed by telephone calls and home visits every week during a 1-month period after discharge</P>
<P>Adverse effects:</P>
<P>COPD deterioration,</P>
<P>admission to the ICU,</P>
<P>respiratory failure,</P>
<P>participant withdrawal for any reason,</P>
<P>delayed discharge (beyond 15 days),</P>
<P>inhospital deaths,</P>
<P>deaths after discharge within 1 month,</P>
<P>exacerbation,</P>
<P>rehospitalisation rates within 1 month after discharge. Paper reports total number of exacerbations in 30 days and no response received to request for author clarification on whether data refer to number of participants or number of events. Data not used</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:37:44 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age inclusion not known; smoking history threshold not known, but mean smoking history &gt; 40 pack-years so most participants will have a significant smoking history; asthma not an exclusion; required COPD diagnosis according to 1087 ATS standards</P>
<P>Funding: no sources of funding disclosed</P>
<P>Trial registration: ClinicalTrials.gov/NCT00274222</P>
<P>Protocol: not available</P>
<P>Data on treatment failure and adverse effects were sought from author. Emailed data request to authors 30 September 2013 (Gunen). No response received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:48 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Maltais-2002">
<CHAR_METHODS MODIFIED="2014-08-28 14:37:48 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group</P>
<P>Duration: recruited over 20 months, treatment for 10 days</P>
<P>Setting: 34 centres (Belgium n = 3, Canada n = 11; France n = 20) participated; people in clinic or ED with deterioration in their respiratory status subsequently admitted to hospital<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 687 in 11 months, 75 enrolled</P>
<P>Number randomised: 199 (prednisone n = 62, placebo n = 66)</P>
<P>Number completed: 147 assessed at day 10 (prednisone n = 55, placebo n=55)</P>
<P>Baseline details:</P>
<P>Mean age (years): 70<BR/>Gender: M= 162; F = 37<BR/>
</P>
<P>Diagnosis COPD: based on clinical evaluation compatible with chronic bronchitis or emphysema as defined by the ATS and when available, baseline spirometry had to confirm the presence of irreversible airflow obstruction (post-bronchodilator FEV<SUB>1</SUB> 70% normal predicted value and FEV<SUB>1</SUB>/FVC &lt; 70%</P>
<P>AE criteria: recent (i.e. within 14 days) history of acute COPD exacerbation defined as increased breathlessness</P>
<P>Inclusion criteria: requiring admission to hospital; recent acute COPD exacerbation (within 14 days), defined as increased breathlessness; aged &gt; 50 years; &gt; 20 pack-years' smoking history<BR/>Exclusion criteria: history of asthma, allergic rhinitis or atopy; exposure to systemic corticosteroids within 1 month; if used, inhaled beclomethasone equivalent &gt; 1500 g/day; at risk of imminent acute respiratory failure requiring mechanical ventilation or admission to ICU; diagnosis of a specific underlying cause for the exacerbation (e.g. pneumonia, pneumothorax, heart failure)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:35:00 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: prednisone 30 mg orally every 12 hours and placebo Pulmicort Respules/Nebuamp for 72 hours followed by prednisone 40 mg/day orally and placebo turbuhaler for 7 days (10-day systemic corticosteroid course)<BR/>Control: placebo nebulisation and tablets for 72 hours and placebo turbuhaler for 7 days</P>
<P>Co-interventions: nebulised - agonists, ipratropium bromide, oral antibiotics (used in 83% budesonide, 84% prednisone, 80% placebo), and supplemental oxygen. Methylxanthines allowed, if prescribed before the study as a regular medication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed: post-bronchodilator FEV<SUB>1</SUB>; pre-bronchodilator FEV<SUB>1</SUB>; ABGs (0-72 hours); </P>
<P>dyspnoea score; </P>
<P>duration of hospitalisation; length of hospitalisation data removed due to skewed data, was previously given in text, but not in data analysis; </P>
<P>occurrence of adverse events<BR/>Reported: primary variable to assess treatment efficacy was the change in post-bronchodilator FEV<SUB>1</SUB> from 0 to 72 hours<BR/>Secondary endpoints included: <BR/>changes in pre-bronchodilator FEV<SUB>1</SUB>; <BR/>dyspnoea score; </P>
<P>ABGs from 0 to 72 hours; <BR/>duration of hospitalisation; </P>
<P>occurrence of adverse events, defined as any medical event reported by the participants from study entry to day 10<BR/>Measurements: participants were assessed every 12 hours during the acute phase (from 0 to 72 hours), at hospital discharge, and at day 10<BR/>Mortality: 1 death in prednisone group<BR/>Adverse drug effects: hyperglycaemia<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:35:00 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 50 years, &gt; 20 pack-years' smoking history, diagnosis of asthma exclusion, evidence of fixed airflow obstruction at presentation if spirometry available</P>
<P>Funding: financial support from AstraZeneca Canada</P>
<P>Dr. Robert Jenkins and Ms. Joanna Lee, AstraZeneca Canada assisted in reviewing and preparing the manuscript, and AstraZeneca R&amp;D Lund, Kurt Nikander advised</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:37:55 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Niewoehner-1999">
<CHAR_METHODS MODIFIED="2014-08-28 14:37:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group</P>
<P>Duration: November 1994 to October 1996. Treatment for 57 days, follow-up for 6 months</P>
<P>Setting: hospitalised people with exacerbations of COPD, 20 centres, Veterans Affairs USA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 1840</P>
<P>Number recruited: 271</P>
<P>Number withdrawals: oral prednisolone 2 weeks, n = 10, oral prednisolone 8 weeks n = 8, placebo n = 10. Follow-up data complete for 19 withdrawals</P>
<P>Mean age (years): oral prednisolone 2 weeks: 67.1 (SD10.6); oral prednisolone 8 weeks: 68.1 (SD 6.8); placebo group: 67.8 (SD 10.0)<BR/>Gender: M = 268, F = 3</P>
<P>Diagnosis COPD: clinical diagnosis. Likelihood of COPD: aged &gt; 50 years, &gt; 30 pack-years' smoking history, diagnosis of asthma exclusion, evidence of airflow obstruction</P>
<P>AE criteria: clinical diagnosis of exacerbations of COPD</P>
<P>Inclusion criteria: aged &gt; 50 years, &gt; 30 pack-years' smoking history, FEV<SUB>1</SUB> &lt; 1.5 L or inability to perform spirometry due to dyspnoea<BR/>Exclusion criteria: diagnosis of asthma, use of systemic corticosteroids within the preceding 30 days, co-morbidities making survival for 1 year unlikely, inability to give informed consent<BR/>Smoked in past 3 months: oral prednisolone 2 weeks 52%, oral prednisolone 8 weeks 50%, placebo 50%<BR/>FEV<SUB>1</SUB> (L): oral prednisolone 2 weeks 0.77 (SD 0.29); oral prednisolone 8 weeks 0.79 (SD 0.29); placebo 0.75 (SD 0.27)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Group 1: IV methyl prednisolone 125 mg 6 hourly for 72 hours followed by oral prednisolone 60 mg day 4- day 7, 40 mg day 8 to day 11, 20 mg day 12 to day 43, 10 mg day 44 to day50, 5 mg day 51 to day 56 (60-day SS course). Treatment 8 weeks<BR/>Group 2: IV methyl prednisolone 125 mg 6 hourly for 72 hours followed by oral prednisolone 60 mg day 4 to day 7, 40 mg day 8 to day 11, 20 mg day 12 to day 15 followed by oral placebo day 16 to day 57 (15-day systemic corticosteroid course). Placebo for weeks 3-8<BR/>Group 3: IV placebo (5% dextrose) 6 hourly for 72 hours followed by oral placebo day 3 to day 57. Treatment 8 weeks</P>
<P>Co-interventions: antibiotics for 7 days. Beta-agonists, ipratropium bromide and triamcinolone administered to all during the 6 months of the study</P>
<P>Exclusions: theophyllines, high dose inhaled corticosteroid &gt; 1600 &#956;g/day equivalent beclomethasone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed: time to treatment failure (death, need for intubation and mechanical ventilation, re-admission for COPD, intensification of pharmacological therapy), length of hospital stay, FEV<SUB>1</SUB>, death, complications<BR/>Reported: theophylline use, prior hospitalisation<BR/>Outcomes measured: 2, 8, 26 weeks<BR/>Mortality: 13 in experimental arm, 11 in placebo arm<BR/>Adverse events: 51 in placebo arm and 113 in experimental arm</P>
<P>Data from intervention groups 1 and 2 combined in analyses</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:37:55 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 50 years, &gt; 30 pack-years' smoking history, diagnosis of asthma exclusion, FEV<SUB>1</SUB> &lt; 1.50 L or an inability to undergo spirometry because of dyspnoea</P>
<P>Funding: conducted under the aegis of the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development and supported by a grant from Boehringer Ingelheim</P>
<P>Protocol: published (Erbland 1998)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:38:01 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Ridha-2006">
<CHAR_METHODS MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group, 3 groups<BR/>Duration: 10 days' treatment, 90 days' follow-up<BR/>Setting: inpatients, Mami Hospital, Ariana-Tunisia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:37:58 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 52; group 1 n = 18, group 2 n = 17, group 3 n = 17</P>
<P>Number completed: not reported</P>
<P>Baseline details: not reported</P>
<P>Age: not reported</P>
<P>Gender: not reported</P>
<P>Diagnosis COPD: not reported</P>
<P>AE criteria: not reported</P>
<P>Inclusion criteria: not reported</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:35:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Group 1 (n = 18): hydrocortisone 400 mg daily IV for 10 days</P>
<P>Group 2 (n = 17): prednisone 40 mg once daily for 10 days</P>
<P>Group 3 (n = 17): no corticosteroids (control group) no placebo use reported</P>
<P>Co-interventions: not known</P>
<P>Treatment period: 10 days</P>
<P>Follow-up period: 90 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:38:01 +0100" MODIFIED_BY="Emma J Welsh">
<P>Primary outcomes: PEF, spirometric measures (FEV<SUB>1</SUB> level)</P>
<P>Secondary outcomes: symptom scores (dyspnoea, cough, sputum),</P>
<P>treatment failure</P>
<P>Adverse events: hyperglycaemia, epigastric pain</P>
<P>Assessment: days 3, 10, 30 and 90<BR/>Reported: no results in abstract</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age limit for inclusion unknown, unknown pack-years' smoking, unknown if asthma an exclusion, fixed airflow obstruction criteria unknown</P>
<P>Funding: no sources disclosed</P>
<P>Protocol: not available. Abstract only</P>
<P>Emailed data request to authors - 4 September 2012, 9 August 2013, 30 September 2013 (Ridha). No response received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:47:42 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Rostom-1994">
<CHAR_METHODS MODIFIED="2014-08-28 14:47:42 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group</P>
<P>Duration: treatment for 19 days, follow-up over 1 month</P>
<P>Setting: hospitalised people, Canada</P>
<P>Publication: abstract only</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number recruited: 30 (6 withdrawn, data incomplete in a further 5)</P>
<P>Mean age: not reported</P>
<P>Gender: not reported</P>
<P>Diagnosis COPD: not reported</P>
<P>AE criteria: not reported</P>
<P>Inclusion criteria: not reported</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: methylprednisolone 40 mg IV, 6 hourly for 3 days followed by methylprednisolone 32 mg orally daily reducing by 4 mg every second day<BR/>Control: saline IV followed by oral placebo</P>
<P>Duration treatment: 19 days</P>
<P>Co-interventions: oxygen, inhaled (nebulised) beta-agonists, theophylline (route not detailed) and oral antibiotics (amoxicillin, trimethoprim/sulphamethoxazole or doxycycline)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:36:36 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed: spirometry</P>
<P>Reported: spirometry</P>
<P>Others: none reported</P>
<P>Mortality: not reported</P>
<P>Adverse events: hypertension (n = 1), hyperglycaemia (n = 1) and congestive heart failure (n = 1), but allocation not detailed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age limit for inclusion unknown, unknown pack-years' smoking, unknown if asthma an exclusion, fixed airflow obstruction criteria for COPD unknown</P>
<P>Funding: no sources disclosed</P>
<P>Published as abstract. No objective measurements included in the report. No response to letter of request<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 14:57:23 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Thompson-1996">
<CHAR_METHODS MODIFIED="2014-08-28 14:47:46 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group</P>
<P>Duration: May 1991 to April 1993<BR/>Setting: single centre, outpatients clinic and ED at a Veterans Affairs Medical Center, USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:55:09 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: 140 clinic, 199 ED</P>
<P>Number randomised 11 clinic, 16 ED</P>
<P>Baseline details:</P>
<P>Mean age (years): prednisolone 65 (SD 9), control 70 (SD 7)</P>
<P>Gender: M = 26, F = 1</P>
<P>Diagnosis COPD: clinical diagnosis of chronic bronchitis or emphysema according to ATS criteria. Airflow obstruction, FEV<SUB>1</SUB> &lt; 60% predicted or FEV<SUB>1</SUB>/FVC ratio &lt; 65% after bronchodilator</P>
<P>AE criteria: subjective worsening of dyspnoea or cough for &gt; 24 hours requiring a hospital visit, &gt; 25% increase in inhaled short-acting beta2 agonist use over 24 hours, or an increase in sputum production or purulence (or both).</P>
<P>Inclusion criteria: &gt; 20 pack-years' smoking history.</P>
<P>Exclusion criteria: family history of asthma; history of asthma, atopy, allergic rhinitis or nasal polyps; history of lung disease other than COPD; use of systemic corticosteroids within 1 month; uncompensated congestive heart failure; pneumonia; fever &gt; 38.5 ºC; arterial pH &lt; 7.35; hospitalisation for other reasons.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:55:47 +0100" MODIFIED_BY="Emma J Welsh">
<P>Experimental: prednisolone 60 mg orally daily for 3 days, then 40 mg for 3 days, then 20 mg for 3 days. (9-day systemic corticosteroid treatment)<BR/>Control: vitamin B6 orally daily<BR/>Treatment period: 9 days<BR/>Co-interventions: inhaled beta-agonist (MDI or nebulised 4 hourly) in all. Ipratropium bromide, inhaled corticosteroids and theophylline continued unchanged. Oral antibiotics if evidence of infection on gram stain of sputum.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:56:43 +0100" MODIFIED_BY="Emma J Welsh">
<P>Analysed:</P>
<P>spirometry FEV<SUB>1</SUB>,</P>
<P>dyspnoea using visual analogue scale (200 mm scale with improvement in dyspnoea represented by a higher score),</P>
<P>failure of study treatment (hospitalisation or requirement for oral prednisolone),</P>
<P>ABG.</P>
<P>Reported: complete blood count</P>
<P>Others: none reported</P>
<P>Mortality: none reported</P>
<P>Adverse events: none reported</P>
<P>Author supplied lung function, ABGs and mortality and adverse events data</P>
<P>Results: used result supplied by the trialist for day 3 and 10 PaCO<SUB>2</SUB> and PaO<SUB>2</SUB>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:57:23 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age limits not known, &gt; 20 pack-years' smoking pack history, diagnosis of asthma exclusion, FEV<SUB>1</SUB> post- bronchodilator &lt; 60% predicted or ratio FEV1/ FVC &lt; 65%</P>
<P>Funding: supported by the US Department of Veterans Affairs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 15:01:57 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Willaert-2002">
<CHAR_METHODS MODIFIED="2014-08-28 14:58:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel group<BR/>Duration: July 1999 to March 2000. Decision to discharge from hospital based on physician judgement (after a minimum of a 10-day inpatient therapeutic regimen)</P>
<P>Follow- up period: 4 weeks<BR/>Setting: single centre, casualty department of the University Hospital Gasthuisberg, Leuven, Belgium</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:36:31 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 48</P>
<P>Number completed: 37</P>
<P>Baseline details:</P>
<P>Age (years) IV group = 72 (SD 6), oral group 71 (SD 8)</P>
<P>Gender: IV group M = 91.3%, oral group 84.0%</P>
<P>Smoking history (pack-years): IV group: mean 27 (SD 16); oral group: mean 36 (SD 18)<BR/>Baseline lung function (mean):<BR/>
</P>
<P>FEV<SUB>1</SUB>: IV group 1.14 L (SD 0.43), oral group 1.10 (SD 0.51)</P>
<P>FVC: IV group 2.48 L (SD 0.64), oral group 2.55 L (SD 0.63)</P>
<P>FEV<SUB>1</SUB>/FVC: IV group 47% (SD 16%), oral group 42% (SD 12%)</P>
<P>Diagnosis COPD: clinical history of COPD</P>
<P>AE criteria: increased dyspnoea, increased cough frequency or severity, increased production or purulence of sputum, increased wheeze, lasting for at least 3 days</P>
<P>Inclusion criteria: ATS indications for hospitalisation of people with COPD exacerbations. People who had used inhaled or systemic corticosteroids prior to admission to casualty were not excluded. The cumulative dose over a period of 2 weeks prior to admission was recorded and used as a variable in the evaluation of the participants' characteristics</P>
<P>Exclusion criteria: personal or family history of asthma (defined as episodic wheezing or dyspnoea that rapidly improved with treatment) or atopy, invasive or non-invasive assisted ventilation, unable to use a MDI successfully as a device for administering bronchodilators</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 15:01:14 +0100" MODIFIED_BY="Emma J Welsh">
<P>IV group: methylprednisolone 40 mg/day IV with a decrease to 20 mg after 10 days and subsequent oral treatment with a further decrease of 4 mg. 4 days.<BR/>Co-intervention: aerosol therapy salbutamol 10 mg/day and ipratropium bromide 1 mg/day, aerosols<BR/>Oral group: oral methylprednisolone 32 mg for 1 week followed by 24 mg/day for a period of 4 days and a subsequent decrease of 4 mg/week.<BR/>Co-intervention: Duovent1 4 x 4 puffs/day (cumulative dose of fenoterol 1.6 mg/day and ipratropium bromide 640 mg/day), MDI with spacer<BR/>Treatment period: IV group: 14 days, oral group: 14 days plus tapering</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:47:52 +0100" MODIFIED_BY="Emma J Welsh">
<P>Treatment failure: required invasive or non-invasive assisted ventilation, clinical improvement was not satisfactory and a change of treatment was deemed necessary by the treating physician, participant was not satisfied with his or her own clinical progress and demanded another treatment regimen (non-compliance) Time point: while in hospital, minimum 10 days</P>
<P>Relapse defined as re-admission to hospital within 4 weeks</P>
<P>Analysed: late re-admission to hospital, followed up over 20 weeks; spirometry, FEV<SUB>1</SUB>, FVC daily for 10 days; Dyspnoea recorded on 10-cm visual analogue scale daily for 10 days; daily use and additional need of bronchodilators; cumulative corticosteroid dose; length of stay; QoL (Chronic Respiratory Disease Index Questionnaire daily for 10 days)<BR/>Follow-up after discharge: 28 days' follow-up, re-admissions followed up over 20 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 15:01:57 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age limits not known, mean 72 years; threshold pack- years' smoking history not known, mean 30 pack-years' smoking history; diagnosis of asthma exclusion; airflow obstruction criteria not known</P>
<P>Funding: the study was supported by the Research Foundation Katholieke Universiteit Leuven grant #OT98/27 and the "Fonds voor Wetenschappelijk Onderzoek Vlaanderen" grants #G.0/ 75.99 and #G.0237.01</P>
<P>Protocol: not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 15:07:01 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Wood_x002d_Baker-1998">
<CHAR_METHODS MODIFIED="2014-08-28 15:04:36 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel 3-group design</P>
<P>Duration: 2 weeks</P>
<P>Setting: hospitalised people, 2 centres, Australia/New Zealand</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 15:06:20 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number recruited: 47</P>
<P>Number commenced treatment: 38</P>
<P>Number analysed: 35</P>
<P>Number completed: study 28. 3 withdrawals, 5 treatment failure, 2 adverse events, 10 protocol violation, 1 death<BR/>Mean age (years): high-dose arm: 69.3 (SD 5.5), moderate-dose arm: 71.1 (SD 9.7), placebo 71.3 (SD 7.8). Range 61-86 years.<BR/>Gender: M = 24, F = 14<BR/>
</P>
<P>Diagnosis COPD: clinical diagnosis smoking-related COPD</P>
<P>AE criteria: increased breathlessness necessitating hospital admission</P>
<P>Inclusion criteria: aged &gt; 40 years, &gt; 10 pack- years' smoking history, FEV<SUB>1</SUB> FEV1 &lt; 50% predicted.<BR/>Exclusion criteria:</P>
<P>long-term corticosteroid therapy equivalent to &gt; 5 mg prednisolone 5 mg/day or taking oral prednisolone for the current exacerbation;</P>
<P>other co-existent lung disease, pneumonia;</P>
<P>inability to co-operate with investigations;</P>
<P>previous adverse drug reaction to corticosteroids, endoscopically or radiographically confirmed peptic ulcer disease within the past 2 years;</P>
<P>history of cardiac failure, current hepatic or renal failure; inadequately treated hypertension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 15:07:01 +0100" MODIFIED_BY="Emma J Welsh">
<P>High-dose arm: prednisolone 2.5 mg/kg orally daily for 3 days followed by 11 days placebo (3D systemic steroid treatment)<BR/>Moderate- dose arm: prednisolone 0.6 mg/kg orally daily for 7 days followed by prednisolone 0.3 mg/kg orally daily for 7 days (14D systemic steroid treatment)<BR/>Control: matched placebo for 14 days<BR/>Co-interventions: inhaled bronchodilators, oral antibiotics, oral/IV xanthines and oxygen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:47:56 +0100" MODIFIED_BY="Emma J Welsh">
<P>Measured: spirometry, 6-minute walking distance, duration of hospitalisation, PaO<SUB>2</SUB>, PaCO<SUB>2</SUB>, visual analogue scale of breathlessness (100-mm scale, more breathless represented by a higher number), treatment failure, mortality, adverse events<BR/>Reported or data available:</P>
<P>spirometry, 6-minute walking distance, duration of hospitalisation, visual analogue scale of breathlessness</P>
<P>Mortality: 1 death in the placebo arm.</P>
<P>Morbidity: no adverse biochemical effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 14:48:00 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: aged &gt; 40 years, &gt; 10 pack-years' smoking history, diagnosis of asthma not exclusion, FEV<SUB>1</SUB> &lt; 50% predicted</P>
<P>Funding: no funding source disclosed</P>
<P>Data analysed by review authors in 3 groups. Data from 14 day treatment group used in review</P>
<P>Study published as abstract. Protocol and study data available to review authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-08-28 15:08:25 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Zheng-2011">
<CHAR_METHODS MODIFIED="2014-08-28 14:36:17 +0100" MODIFIED_BY="Emma J Welsh">
<P>Design: parallel RCT</P>
<P>Duration: not reported<BR/>Setting: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-08-28 14:36:11 +0100" MODIFIED_BY="Emma J Welsh">
<P>Number screened: not reported</P>
<P>Number randomised: 153</P>
<P>Number completed: not reported</P>
<P>Number withdrawals: not reported</P>
<P>Baseline details: not reported</P>
<P>Gender: not reported</P>
<P>Age: not reported</P>
<P>Diagnosis COPD: not reported</P>
<P>AE criteria: not reported</P>
<P>Inclusion criteria: not reported</P>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-08-28 14:35:36 +0100" MODIFIED_BY="Emma J Welsh">
<P>Group 1 (n = 53): 2 mg/4 mL nebulised budesonide, every 6 hours and normal saline 10 mL IV 4 times daily</P>
<P>Group 2 (n = 54): methylprednisolone 40 mg, IV and nebulised normal saline 4 mL every 6 hours</P>
<P>Group 3 (n = 46): nebulised normal saline 4 mL every 6 hours and normal saline 10 mL IV 4 times daily</P>
<P>Treatment period: 7 days</P>
<P>Follow-up period: not reported<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-08-28 14:36:24 +0100" MODIFIED_BY="Emma J Welsh">
<P>Treatment failure,</P>
<P>FEV<SUB>1</SUB>,<BR/>dyspnoea score,</P>
<P>use of rescue medication and systemic glucocorticoids,</P>
<P>length of hospital stay,</P>
<P>adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-08-28 15:08:25 +0100" MODIFIED_BY="Emma J Welsh">
<P>Likelihood of COPD: age limit for inclusion unknown, unknown pack- years' smoking, unknown if asthma an exclusion, fixed airflow obstruction criteria for COPD unknown.</P>
<P>Funding: no sources disclosed</P>
<P>Protocol: not available (abstract only). No trial registration located</P>
<P>Emailed data request to authors - 9 August 2013, 30 September 2013 (Zheng). No response received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABG: arterial blood gas; ACCP: American College of Chest Physicians; AE: acute exacerbation; ATS: American Thoracic Society; CCQ: Clinical COPD Questionnaire; CI: confidence interval; COPD: chronic obstructive pulmonary disease; ED: emergency department; F: female; FEV<SUB>1</SUB> : forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICU: intensive care unit; IQR: interquartile range; IV: intravenous; LTOT: long-term oxygen therapy; LVF: left ventricular failure; M: male; MDI: metered-dose inhaler; NIV: non-invasive ventilation; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide dissolved in arterial blood; PaO<SUB>2</SUB> : partial pressure of oxygen dissolved in arterial blood; PEF: peak expiratory flow; QoL: quality of life; SD: standard deviation; SGRQ: St. George Respiratory Questionnaire.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-08-28 15:23:21 +0100" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:09:31 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Bafadhel-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:09:31 +0100" MODIFIED_BY="Emma J Welsh">
<P>Parallel group, double-blind trial, with randomisation to a biomarker-directed arm (peripheral blood eosinophil count at exacerbation was used to guide corticosteroid treatment) or standard treatment control group receiving prednisolone 30 mg capsule once daily (irrespective of the blood eosinophil biomarker results)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-16 21:48:34 +0000" MODIFIED_BY="Julia A.E. Walters" STUDY_ID="STD-Bingol-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-16 21:48:34 +0000" MODIFIED_BY="Julia A.E. Walters">
<P>Participants did not have an acute exacerbation of COPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:09:54 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Dahlen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:09:54 +0100" MODIFIED_BY="Emma J Welsh">
<P>Purpose of study was to analyse the changes seen in inflammatory markers after treatment with 1 of 2 corticosteroids, 1 given orally, the other inhaled. The study was not placebo-controlled. Comparison between the effects of oral and inhaled corticosteroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:10:39 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Gerogianni-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:10:39 +0100" MODIFIED_BY="Emma J Welsh">
<P>Not reported to be randomised. Study published as abstract only. Comparison of people with COPD divided into 2 groups. 1 group received prednisolone 12 mg daily plus SABA and the other SABA only during exacerbations and for 12 weeks after. Not clear how participants allocated to groups. Sent letter requesting details - no response within 4 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:11:08 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Ghanei-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:11:08 +0100" MODIFIED_BY="Emma J Welsh">
<P>Participants with exposure to mustard gas inducing "chronic bronchitis", all non-smokers. Lung function indicates restriction present low FVC. Comparison of IV methylprednisolone and oral prednisolone in "acute exacerbation" of symptoms. Excluded as COPD not confirmed in participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:23:18 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-GSK-FLIT98">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:23:18 +0100" MODIFIED_BY="Emma J Welsh">
<P>Mild or moderate stable COPD. group comparison. Group 1: placebo 14 days + inhaled fluticasone 500 mcg 12/52; group 2:prednisolone 20-40 mg/day 14 days + placebo diskus 14 days and fluticasone 500 mcg 10/52; group 3: placebo 14 days + placebo diskus 12/52 .</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:17:49 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Kunter-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:17:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Consecutive participants with exacerbations enrolled without randomisation to treatment. No placebo used in control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:18:14 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Li-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:18:14 +0100" MODIFIED_BY="Emma J Welsh">
<P>RCT comparison of 2 corticosteroids, methylprednisolone and dexamethasone in hospital for 7-14 days. Dose regimen was 3 steps. IV/oral/inhaled methylprednisolone and dexamethasone and matched co-interventions.<B> </B>No placebo control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:18:29 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Mirici-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:18:29 +0100" MODIFIED_BY="Emma J Welsh">
<P>Systemic (IV) corticosteroids versus nebulised budesonide in acute exacerbations of COPD, no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:18:49 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Murata-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:18:49 +0100" MODIFIED_BY="Emma J Welsh">
<P>Not an RCT. Retrospective study of 45 visits in which IV and oral corticosteroids were given (T visits) were compared with an equal number of matched visits in which they were withheld (N visits)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-20 00:02:50 +0100" MODIFIED_BY="Julia A.E. Walters" STUDY_ID="STD-Plant-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-20 00:02:50 +0100" MODIFIED_BY="Julia A.E. Walters">
<P>Abstract for conference paper not obtainable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:19:09 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Rahman-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:19:09 +0100" MODIFIED_BY="Emma J Welsh">
<P>Oral corticosteroids 7 days versus 14 days in acute exacerbations of COPD, no placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:19:36 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Rizzato-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:19:36 +0100" MODIFIED_BY="Emma J Welsh">
<P>The aim of study was to evaluate and compare clinical tolerability and relative potency of a new corticosteroid drug, deflazacort against that of methylprednisolone. No placebo control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:19:59 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Roede-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:19:59 +0100" MODIFIED_BY="Emma J Welsh">
<P>Cluster RCT of general practices, comparing high-dose oral corticosteroid course + antibiotics in accordance with the national guideline versus treatment 'as usual' (general practitioner could use oral corticosteroid and 75% of participants received oral corticosteroid)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:20:12 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Sayiner-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:20:12 +0100" MODIFIED_BY="Emma J Welsh">
<P>This study compared the likelihood of a link between duration of treatment with corticosteroids in COPD exacerbations and efficacy of treatment. Not a placebo-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:23:21 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Shortall-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:23:21 +0100" MODIFIED_BY="Emma J Welsh">
<P>Participants screened with acute exacerbation COPD (n = 117), 50 recruited but 1 participant was admitted and included twice and 1 patent was admitted and included 3 times. Data not reported for participants on 1 occasion only.</P>
<P>Comparison of oral corticosteroid methylprednisolone 40 mg + metered-dose inhaler bronchodilators with IV methylprednisolone 40 mg until wheeze-free then oral corticosteroid)/nebulised bronchodilators</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of inhaled corticosteroids, oral corticosteroids and placebo in stable COPD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-08-28 15:21:27 +0100" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Wang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-08-28 15:21:27 +0100" MODIFIED_BY="Emma J Welsh">
<P>Observational study of high-dose (60 mg) and, lower- dose (&lt; 60 mg) corticosteroid treatment in exacerbations (protocol clinicaltrials.gov/show/NCT01215825)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; IV: intravenous; RCT: randomised controlled trial; SABA: short-acting beta agonist.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-01-23 05:46:13 +0000" MODIFIED_BY="Julia AE Walters" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-05-02 04:14:05 +0100" MODIFIED_BY="Julia A.E. Walters" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-08-28 15:08:46 +0100" MODIFIED_BY="Emma J Welsh">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-08-28 15:08:36 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:33:22 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>Computer-generated random listing of the 2 treatment assignments blocked in groups of 4 and stratified according to the ED</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>Randomisation was performed at each centre by a random number table, and was stratified according to the type of mechanical ventilation (either conventional or NIV)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>Randomisation by table of random numbers using 20 subject blocks. Participants allocated to consecutive numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>Randomisation performed by hospital pharmacy at each centre by a random number table with permuted blocks of 4, with stratification according to the type of mechanical ventilation (conventional or NIV)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-17 03:06:08 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>A random numbers table was used to generate randomisation codes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>The participants were randomised to 1 of 2 treatment regimens according to a previously prepared randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-11 10:01:07 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>Stochastic function used to create 150 numbers 0-1. Randomisation code prepared by an assistant not involved in other parts of study. Sealed envelopes prepared before study initiation by assistant</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>Described as randomised controlled study, method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>Randomisation by hospital pharmacy according to random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>Randomly assigned to treatment arms, randomisation was by allocation of participants to receive corticosteroid or placebo that were prepared by the hospital pharmacy in a pre-determined random order, identical in appearance and labelling</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>Participants were randomly sorted into 1 of 3 groups - method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:00 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>Randomised; computerised single list using blocks of consecutive participant number, proportion 1 : 1 : 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>Random allocation, stratified randomisation with a permuted-block scheme, stratified according to hospital</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>Prospective controlled study randomised in 3 groups. Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-11 10:13:56 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>Described as randomised; no other details of randomisation procedure available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:57:29 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>Treatment assigned by computer-generated random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:02:16 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>Participants were randomly assigned to 1 of the 2 therapy groups, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:07:15 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>Computer-generated random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:08:36 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>Described as randomised, method for randomisation not known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Randomised using a computer minimisation programme for the following 10 parameters: use of oral prednisolone, use of inhaled corticosteroids, theophylline use 30 days before hospital admission, admission to the hospital because of an exacerbation of COPD in the last year, age, gender, smoking history, use of supplemental oxygen at home, pCO2 and time since the diagnosis of COPD (i.e. &lt; 5, 5-10, 10-15 or &gt; 15 years, or unknown)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-08-28 15:07:32 +0100" MODIFIED_BY="Emma J Welsh" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:04 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>Central allocation of a randomisation schedule prepared through a computer-generated random listing of the 2 treatment assignments blocked in groups of 4 and stratified according to the ED. Randomisation occurred at the time of discharge from the ED. Neither research staff nor participants were aware of the treatment assignment before randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>Participants were randomised (by means of sealed envelopes that were opened sequentially)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>Randomisation by table of random numbers using 20 subject blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>Allocation schedule was concealed with sealed envelopes that were opened sequentially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>Allocation was performed using consecutive allocation of participants to pre-packaged treatments based on random code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>This list was kept by 1 of the investigators (AS), who was also in contact with the nurses responsible for the treatment of the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>Sealed envelopes used and allocated by third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>Randomisation by random number table by hospital pharmacy and allocation to consecutive participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>Order of treatment prepared by the hospital pharmacy in a pre-determined random order</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>Participants were randomly sorted into 1 of 3 groups. No details on allocation method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>Allocated on site next available sequential participant number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>Blinded pharmacists responsible for drug administration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:51:31 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>Information not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:57:37 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>information not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-21 05:41:13 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>Allocation method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:07:32 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>Information not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:57 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>Allocation method not known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-20 02:19:57 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Allocation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-09-13 03:04:12 +0100" MODIFIED_BY="Julia AE Walters" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-08-28 15:08:46 +0100" MODIFIED_BY="Emma J Welsh" NO="8">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:04 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>Neither research staff nor participants were aware of the treatment assignment before or after randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-23 15:40:17 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>Open-label study, control group received usual care, no placebo used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>All participants, investigators, respiratory therapists and other hospital personnel were unaware of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>Pharmacists dispensed the IV medications in a blinded manner. Nurses who were administering the medications, the physicians who were caring for the participants, were unaware of the treatment assignments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-17 03:06:08 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>All participants were blinded to treatment allocation. Investigators did not break the code during the course of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="NO" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>No use of placebo, participants and hospital staff not blind to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-12 04:27:32 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>Use of identical boxes and medications. Allocated by third party. Researchers blinded to medications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-20 03:25:07 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>All participants, investigators, respiratory physicians, technicians and other hospital staff were masked to treatment status until the end of the study. Use of identical placebo tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>Identical in appearance and labelling. Participants, treating physicians and investigators blinded to allocation until termination of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>Participants received apparently identical treatment, given same number of scheduled nebulised solutions every day (8 times a day) and were infused with a single physiological saline solution (50 mL) IV in the morning</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>Study described as placebo-controlled, double-blind, double dummy; identical nebuliser ampoules and placebo tablets used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-06 08:20:09 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>Medication dispensed in blinded fashion, identical appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="NO" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>Control group "no corticosteroids"  and placebo use not specified in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:51:53 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>Described as double-blind; no other details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:57:42 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>Double blind, use of similar appearing placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-21 05:41:04 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>Participants not blinded, no placebo used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 15:07:37 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>Participants blinded to allocation until completion. Use of identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 15:08:46 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>Described as double-blind, double-dummy and parallel controlled trial. Each group used nebulised medication (active or placebo) and had IV medication (active or saline) over same period and frequency</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Blinding: double blind. Active and placebo medication had a similar appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2014-08-28 15:02:45 +0100" MODIFIED_BY="Emma J Welsh" NO="9">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-12 05:27:31 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>Open-label study, control group received usual care. Outcomes of mortality and duration of ICU stay were objective endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-12 05:15:45 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>Investigators, respiratory therapists and other hospital personnel were unaware of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2013-11-14 02:07:26 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>The local investigators and research personnel who collected the data were unaware of the treatment assignments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-12 04:33:44 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>All participant interviews and measurements were performed by another investigator (YC), who remained blinded to the treatment regimens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-12 04:27:36 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-20 03:25:14 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>All participants, investigators, respiratory physicians, technicians and other hospital staff were masked to treatment status until the end of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>Investigators blinded to allocation until termination of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-04-09 15:49:22 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>No details on investigator or assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-12 03:11:47 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>No details on assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-06 08:20:20 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-02-28 06:17:54 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>No details on assessor blinding and as placebo use was not specified in abstract assessors were unlikely to be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:52:07 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>No details reported on assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:57:53 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>No details on assessor/investigator blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 15:02:45 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>Physicians in charge received no information on the objectives or specific target variables of the trial, thereby minimising bias, although they could not be completely blinded. No information on outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2012-09-06 06:18:51 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>No information on assessor blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-02-28 06:17:57 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>Assessor blinding not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Assessor blinding not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-08-28 15:08:00 +0100" MODIFIED_BY="Emma J Welsh" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-12 05:37:09 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>Withdrawals accounted for with reasons, 4 in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-23 15:40:17 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>All participants randomised were included in outcome measures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>1 participant was not randomised. Data from 2 participants in the placebo group were not analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>All participants' data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>16/60 corticosteroid group and 10/53 of placebo group were discharged from ED within 24 hours. 12 participants had a physician-directed change to their study intervention following admission to hospital (either given corticosteroids or corticosteroids stopped). Treatment failure defined as a return to the ED within 14 days. The author of this study noted that results of treatment administered in the ED and measured in the first 24 hours were reliable, later measurement of outcomes was affected by breaks in protocol after admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>Withdrawals (2 participants) accounted for (reasons supplied), otherwise, all data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>Description of withdrawals/drop-outs given. Intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-28 06:17:52 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>Results data incomplete in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>All withdrawals accounted for, intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>30 of 96 participants required admission and for some participants allocation to treatment group was not maintained after re-admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>Data from 38 enrolled participants were not evaluated due to exclusion during hospitalisation period of the study; group 1 = 39, group 2 = 40, group 3 = 42. The main reasons for exclusion were: the inability to perform 2 consecutive spirometric examinations (n = 10), non-compliance with the treatment (n = 8), adverse effects (n = 6), treatment failure or admission to the ICU (n = 5), withdrawal of consent (n = 5) and request for early discharge (n = 4). Not clear which group these drop-outs occurred in. Rates of drop-outs similar: group 1 = 26%, group 2 = 24%, group 3 = 21%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>28 participants were withdrawn from the study during the acute phase for the following reasons: adverse events (n = 12), treatment failure according to the evaluation of the attending physician (n = 9), inclusion or exclusion criteria not fulfilled (n = 4), need for a prohibited medication (n = 2) and withdrawal of participant's consent (n = 1). The proportion of drop-outs during the acute phase was similar in the 3 groups: 10 (14%) participants in the budesonide group, 7 (11%) in the prednisone group, and 11 (17%) in the placebo group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>Withdrawals: 10 oral prednisolone 2 week, 5 oral prednisolone 8 week, 10 placebo. Follow-up data complete for 19 withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-17 04:04:40 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>No results or details in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:52:25 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>6 withdrawals, no details given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:58:01 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>No participant withdrew from follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 15:03:23 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>All participants accounted for. IV group: 4 withdrew; 3 ICU, 1 femur fracture.</P>
<P>In oral group:,7 withdrew, ICU, 2 progress unsatisfactory, 3 non-compliance 1 lung tumour</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 15:08:00 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>3 participants withdrew from follow-up (6%), no details on group allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-28 06:17:57 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="NO" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>Results data incomplete in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>All withdrawals accounted for, per-protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-08-28 15:07:56 +0100" MODIFIED_BY="Emma J Welsh" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 05:37:44 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>Outcomes in methods all reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-23 15:40:18 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>All outcomes listed in methods and trial registration were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-13 02:11:56 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>Outcomes listed in methods are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>All outcomes reported. ClinicalTrials.gov/NCT01281748</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 04:35:28 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>All outcomes supplied by author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>All outcomes listed in methods are reported but protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 04:30:45 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>Not fully published, no protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-09 15:48:19 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>No details, protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>All outcomes in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 04:07:32 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>Results reported for outcomes in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 06:56:13 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>Protocol: not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-12 03:11:20 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>Protocol published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-20 00:58:36 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>No results or details in abstract. No protocol or registration found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-06 07:28:34 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>Not full publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-06 06:24:22 +0100" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>Protocol not available. All outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:03:43 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>Outcomes in methods fully reported, protocol not available. Inclusion criteria for the study were established before the trial and strictly applied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:07:56 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>Study outcome data supplied to review authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:58 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Registration protocol available, all outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-07-11 10:08:53 +0100" MODIFIED_BY="Toby J Lasserson" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2014-08-28 15:04:04 +0100" MODIFIED_BY="Emma J Welsh" NO="7">
<NAME>Free of other potential confounders?</NAME>
<DESCRIPTION>
<P>Potential for bias from study conduct e.g. deviation from protocol</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:05 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Aaron-2003">
<DESCRIPTION>
<P>Inhaled corticosteroids and all other medications used by the participants at the time of enrolment were continued throughout the study in both groups. Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Abroug-2014">
<DESCRIPTION>
<P>Study halted early because of the slow inclusion rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:49 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Albert-1980">
<DESCRIPTION>
<P>None identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Alia-2011">
<DESCRIPTION>
<P>Study lasted 5 years because of a lower enrolment rate, mainly due to a reduction in ICU admissions of people with COPD exacerbations and a high rate of exclusion. Authors do not believe that this limitation affected the study findings, main change in practice over time was higher use of NIV</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:52 +0100" MODIFIED_BY="Emma J Welsh" RESULT="NO" STUDY_ID="STD-Bullard-1996">
<DESCRIPTION>
<P>IV hydrocortisone could be administered at the discretion of chest medicine physicians. 12 participants received cross-over treatment or had their treatment stopped after 24 hours</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ceviker-2014">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:55 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Chen-2005">
<DESCRIPTION>
<P>Information not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:52 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Cordero-1996">
<DESCRIPTION>
<P>No information on group characteristics at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-17 03:17:07 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Davies-1999">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:34:59 +0100" MODIFIED_BY="Emma J Welsh" RESULT="NO" STUDY_ID="STD-Emerman-1989">
<DESCRIPTION>
<P>Allocation to treatment group was not maintained for an unknown number of participants after re-admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-10 09:40:43 +0100" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-Gunen-2007">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:54 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Maltais-2002">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" RESULT="UNKNOWN" STUDY_ID="STD-Niewoehner-1999">
<DESCRIPTION>
<P>There were differences between groups at baseline in pack-years' smoking, previous use of systemic corticosteroids and proportion with diabetes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:54 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Ridha-2006">
<DESCRIPTION>
<P>No results or details in abstract</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:55 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Rostom-1994">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:56 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Thompson-1996">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-08-28 15:04:04 +0100" MODIFIED_BY="Emma J Welsh" RESULT="YES" STUDY_ID="STD-Willaert-2002">
<DESCRIPTION>
<P>Bronchodilators administered via different devices in IV group (aerosol) and oral group (MDI + spacer). Total dose recorded, data available, doses equivalent. Extra bronchodilator did not differ between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:56 +0000" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Wood_x002d_Baker-1998">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:58 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2011">
<DESCRIPTION>
<P>No data on baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-28 06:17:53 +0000" MODIFIED_BY="Julia A.E. Walters" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Characteristics of both groups were similar at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-08-19 17:49:23 +0100" MODIFIED_BY="Emma J Welsh">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-08-19 17:48:27 +0100" MODIFIED_BY="Emma J Welsh" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-08-19 17:47:27 +0100" MODIFIED_BY="Emma J Welsh">Systemic corticosteroid compared with placebo for acute exacerbations of COPD</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Systemic corticosteroid compared with placebo for acute exacerbations of COPD</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>acute exacerbations COPD<BR/>
<B>Settings: </B>outpatient, inpatient and people in ICU</P>
<P>
<B>Intervention:</B> systemic corticosteroid<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Systemic corticosteroid</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment failure</B>
<BR/>Need to intensify therapy/ED or hospital admission<BR/>Follow-up: 3-30 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>276 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
<BR/>(118 to 203)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.48 </B>
<BR/>(0.35 to 0.67)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>917<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Relapse</B>
<BR/>Treatment for AE of COPD or hospital re-admission<BR/>Follow-up: 1-4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>215 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>174 per 1000</B>
<BR/>(122 to 242)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.77 </B>
<BR/>(0.51 to 1.17)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>596<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>In 2 studies (n = 415) relapse to 1 month was lower with systemic corticosteroid compared with placebo (HR 0.78; 95% CI 0.63 to 0.97</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Improvement in lung function - early effect </B>
<BR/>FEV<SUB>1</SUB> (L) as absolute or change<BR/>Follow-up: 3 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean FEV<SUB>1</SUB> in control groups ranged from 0.77 to 0.91 L</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean early improvement in lung function in the intervention group was<BR/>
<B>0.14 L higher</B>
<BR/>(0.09 to 0.20 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>649<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Decreased breathlessness - early effect</B>
<BR/>Borg scale or VAS<BR/>Follow-up: 3 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean change in breathlessness in control group was 1.8 units using the Borg scale and 1.5 units on the VAS scale</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean early decrease in breathlessness in the intervention group was<BR/>
<B>0.35 standard deviations higher</B>
<BR/>(0.05 to 0.64 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>178<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Effect size on Borg scale 0.93 units; 95% CI 0.18 to 1.7 (MCID = 2); effect size on VAS scale 5.24; 95% CI 0.75 to 9.59 (MCID = 10).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse drug effect</B>
<BR/>Follow-up: 2-26 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>285 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>481 per 1000</B>
<BR/>(388 to 577)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 2.33 </B>
<BR/>(1.59 to 3.43)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>736<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hyperglycaemia</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>282 per 1000</B>
<BR/>(208 to 371)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 2.79 </B>
<BR/>(1.86 to 4.19)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>804<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>AE:</B> acute exacerbation; <B>CI:</B> confidence interval; <B>COPD:</B> chronic obstructive pulmonary disease; <B>ED:</B> emergency department; <B>FEV<SUB>1</SUB>:</B> forced expiratory volume in 1 second; <B>HR:</B> hazard ratio; <B>MCID:</B> minimum clinically important difference; <B>OR:</B> odds ratio; <B>VAS:</B> visual analogue scale.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Wide CIs include significant benefit and harm (-1 for imprecision).<BR/>
<SUP>2 </SUP>Upper or lower CI of effect size crosses 0.5 (-1 for imprecision).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-08-19 17:49:23 +0100" MODIFIED_BY="Emma J Welsh" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-08-19 17:48:33 +0100" MODIFIED_BY="Emma J Welsh">Treatment route: intravenous corticosteroid compared with oral corticosteroid for acute exacerbations of COPD</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Intravenous corticosteroid compared with oral corticosteroid for acute exacerbations of COPD</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> acute exacerbations of COPD<BR/>
<B>Settings: </B>inpatient<BR/>
<B>Intervention:</B> intravenous corticosteroid<BR/>
<B>Comparison: </B>oral corticosteroid</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Oral corticosteroid</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Intravenous corticosteroid</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment failure</B>
<BR/>Need to intensify therapy<BR/>Follow-up: 7-14 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>162 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<BR/>(62 to 201)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.67 </B>
<BR/>(0.34 to 1.3)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>298<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Relapse</B>
<BR/>Hospital readmission for COPD<BR/>Follow-up: 4-12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>155 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>149 per 1000</B>
<BR/>(84 to 249)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 0.95 </B>
<BR/>(0.5 to 1.8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>298<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Breathlessness - early effect</B>
<BR/>VAS 0-10. Scale from: 0 to 10.<BR/>Follow-up: 3 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The early breathlessness VAS in control groups ranged from mean 4.4 to 7.5 units</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The early mean breathlessness in the intravenous corticosteroid group was<BR/>
<B>0.62 higher</B>
<BR/>(0.55 lower to 1.78 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>75<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Mortality after discharge (1-3 months)</B>
<BR/>Follow-up: 1-3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>37 per 1000</B>
<BR/>(12 to 111)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.4 </B>
<BR/>(0.44 to 4.51)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>298<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Duration of hospitalisation</B>
<BR/>Days<BR/>Follow-up: mean 14 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean duration in the control group ranged from 10.6 to 11.2 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean duration of hospitalisation in the intravenous corticosteroid group was<BR/>
<B>1.54 longer</B>
<BR/>(0.09 lower to 3.17 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>298<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Adverse drug effect - hyperglycaemia</B>
<BR/>Follow-up: mean 12 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>550 per 1000</B>
<BR/>(231 to 833)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 4.89 </B>
<BR/>(1.2 to 19.94)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>PaO<SUB>2</SUB>
</B>
<BR/>mmHg<BR/>Follow-up: 7 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean PaO<SUB>2</SUB> in the control group was 66.5 mmHg</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean PaO<SUB>2</SUB> in the intravenous corticosteroid group was<BR/>
<B>1.2 mmHg lower</B>
<BR/>(8.61 lower to 6.21 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>38<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>COPD:</B> chronic obstructive pulmonary disease; <B>OR:</B> odds ratio; <B>PaO<SUB>2</SUB>:</B> partial pressure of oxygen dissolved in arterial blood; <B>VAS:</B> visual analogue scale.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Wide CIs include significant benefit and harm (-1 for imprecision).<BR/>
<SUP>2</SUP> Participants and physicians not blinded to treatment in 2 studies (-1 for risk of bias).<BR/>
<SUP>3</SUP> Participants and physicians not blinded to treatment in 2 studies; however, the risk of bias for the event mortality was considered to be low.<BR/>
<SUP>4</SUP> Single inpatient study (-1 indirectness).<BR/>
<SUP>5</SUP> Participants and physicians not blinded to treatment; however, the risk of bias for the outcome measurement was considered to be low.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-08-19 17:51:08 +0100" MODIFIED_BY="Emma J Welsh">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-08-19 17:50:46 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<TITLE MODIFIED="2014-02-27 06:50:15 +0000" MODIFIED_BY="Julia A.E. Walters">Summary of study characteristics</TITLE>
<TABLE COLS="10" ROWS="23">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Setting/exacerbation definition</P>
</TH>
<TH>
<P>n (% male)</P>
</TH>
<TH>
<P>Systemic corticosteroid (treatment duration)</P>
</TH>
<TH>
<P>Age mean (SD)</P>
</TH>
<TH>
<P/>
<P>FEV<SUB>1</SUB> mean (SD)</P>
</TH>
<TH>
<P>PYH smoking mean (SD)</P>
</TH>
<TH>
<P>Withdrawals (n/n)</P>
</TH>
<TH>
<P>History asthma excluded</P>
</TH>
<TH>
<P>Previous ICS use</P>
</TH>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>Systemic corticosteroid vs. placebo</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>
</P>
</TD>
<TD>
<P>Outpatient/AO criteria used</P>
</TD>
<TD>
<P>147 (57%)</P>
</TD>
<TD>
<P>Oral prednisone 40 mg (10 days)</P>
</TD>
<TD>
<P>69.4 (10.5)</P>
</TD>
<TD>
<P>1.0 (0.5)</P>
</TD>
<TD>
<P>50 (38)</P>
</TD>
<TD>
<P>3/147</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>52%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Abroug-2014" TYPE="STUDY">Abroug 2014</LINK>
</P>
</TD>
<TD>
<P>ICU/AO criteria used</P>
</TD>
<TD>
<P>217 (88%)</P>
</TD>
<TD>
<P>Prednisone 1 mg/kg daily until discharge or maximum 10 days</P>
</TD>
<TD>
<P>69 (9)</P>
</TD>
<TD>
<P>0.8 (0.4)</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>0/217</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Albert-1980" TYPE="STUDY">Albert 1980</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>45 (100%)</P>
</TD>
<TD>
<P>IV methylprednisolone 0.5 mg/kg 4 hourly x 72 hours (3 days)</P>
</TD>
<TD>
<P>61.5 (9)</P>
</TD>
<TD>
<P>0.8 (0.3)</P>
</TD>
<TD>
<P>80 (30)</P>
</TD>
<TD>
<P>3/45</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Alia-2011" TYPE="STUDY">Alia 2011</LINK>
</P>
</TD>
<TD>
<P>ICU/AO criteria not used</P>
</TD>
<TD>
<P>83 (80%)</P>
</TD>
<TD>
<P>IV methylprednisolone 0.5 mg/kg every 6 hours for first 72 hours, 0.5 mg/kg 12 hourly days 4-6, and 0.5 mg/kg days 7-10</P>
</TD>
<TD>
<P>68.4 (10.2)</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>0/83</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>
</P>
</TD>
<TD>
<P>ED-inpatient 76%/AO criteria used</P>
</TD>
<TD>
<P>138 (86%)</P>
</TD>
<TD>
<P>IV hydrocortisone x 96 hours + 4 days oral prednisone 40 mg (5-8 days)</P>
</TD>
<TD>
<P>66 (10.8)</P>
</TD>
<TD>
<P>0.53 (0.53)</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>27/138</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>130 (75%)</P>
</TD>
<TD>
<P>1. Prednisolone 30 mg/day 7 days + placebo 7 days (7 days) vs. 2. prednisolone 30 mg/day 10 days + 15 mg/day 5 days vs. 3. placebo 14 days (14 days) (data from group 2 used)</P>
</TD>
<TD>
<P>72 (6.7)</P>
</TD>
<TD>
<P>0.73 (0.25)</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>9/130</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cordero-1996" TYPE="STUDY">Cordero 1996</LINK> [abstract only]</P>
</TD>
<TD>
<P>Outpatient/AO criteria used</P>
</TD>
<TD>
<P>30 (100%)</P>
</TD>
<TD>
<P>Oral prednisolone 40 mg/day for 10 days</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria used</P>
</TD>
<TD>
<P>60 (68%)</P>
</TD>
<TD>
<P>Oral prednisone 30 mg/day (14 days)</P>
</TD>
<TD>
<P>67 (8.5)</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>55 (35)</P>
</TD>
<TD>
<P>10/60</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>80%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>
</P>
</TD>
<TD>
<P>ED-inpatient 63%/AO criteria used</P>
</TD>
<TD>
<P>100 (52%)</P>
</TD>
<TD>
<P>IV methylprednisolone 100 mg single dose (1 day)</P>
</TD>
<TD>
<P>64 (7.8)</P>
</TD>
<TD>
<P>64% (35)</P>
</TD>
<TD>
<P>59 (50)</P>
</TD>
<TD>
<P>4/100</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gunen-2007" TYPE="STUDY">Gunen 2007</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>159 (85%)</P>
</TD>
<TD>
<P>IV prednisolone 40 mg/day for days 1-15 if not discharged, oral methylprednisolone 32 mg/day for days 11-15 if discharged</P>
</TD>
<TD>
<P>64.1 (9)</P>
</TD>
<TD>
<P>37.2% (12.2)</P>
</TD>
<TD>
<P>45 (20.8)</P>
</TD>
<TD>
<P>38/159</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria used</P>
</TD>
<TD>
<P>199 (82%)</P>
</TD>
<TD>
<P>Oral prednisone 40 mg x 3 days then 30 mg/day x 7 days (10 days)</P>
</TD>
<TD>
<P>70 (8)</P>
</TD>
<TD>
<P>0.91 (0.4)</P>
</TD>
<TD>
<P>56 (27)</P>
</TD>
<TD>
<P>28/199</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>59%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>271 (99%)</P>
</TD>
<TD>
<P>IV methylprednisolone 72 hours + oral prednisolone 60 mg/day tapering over 57 days (group 1) or 12 days (group 2) or IV placebo + oral placebo 57 days (group 3) (15 or 60 days)</P>
</TD>
<TD>
<P>67.4 (10)</P>
</TD>
<TD>
<P>0.76 (0.27)</P>
</TD>
<TD>
<P>70 (33)</P>
</TD>
<TD>
<P>20/191</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>45%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rostom-1994" TYPE="STUDY">Rostom 1994</LINK> [abstract only]</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>30 (not known)</P>
</TD>
<TD>
<P>IV methyl prednisolone 72 hours + oral prednisolone 15 days (19 days)</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>
</P>
</TD>
<TD>
<P>Outpatient/AO criteria specified</P>
</TD>
<TD>
<P>27 (96%)</P>
</TD>
<TD>
<P>Oral prednisone 60 mg tapering 9 days (9 days)</P>
</TD>
<TD>
<P>67.5 (8)</P>
</TD>
<TD>
<P>1.35 (0.5)</P>
</TD>
<TD>
<P>65 (30)</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>30%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK> [abstract and data supplied]</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>47 (64%)</P>
</TD>
<TD>
<P>Oral prednisone high dose 2.5 mg/kg/day x 3 days OR medium dose 0.6-0.3 mg/kg/day x 14 days (14 days or 3 day high dose)</P>
</TD>
<TD>
<P>72 (6.3)</P>
</TD>
<TD>
<P>0.6</P>
</TD>
<TD>
<P>&gt; 10</P>
</TD>
<TD>
<P>3/38</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zheng-2011" TYPE="STUDY">Zheng 2011</LINK> [abstract only]</P>
</TD>
<TD>
<P>Inpatient/not known</P>
</TD>
<TD>
<P>107 (not known)</P>
</TD>
<TD>
<P>Group 2 methylprednisolone 40 mg, IV and nebulised normal saline 4 mL 6 hourly x 7 days</P>
<P>Group 3 (placebo): nebulised normal saline 4 mL and normal saline 10 mL IV 6 hourly x 7 days</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known/107</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10">
<P>
<B>IV corticosteroids vs. oral corticosteroids</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ceviker-2014" TYPE="STUDY">Ceviker 2014</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>40 (not known)</P>
</TD>
<TD>
<P>1. Oral methylprednisolone 32 mg/day</P>
<P>2. IV methylprednisolone 1 mg/kg/day for 4 days, then 0.5 mg/kg/day for 3 days</P>
</TD>
<TD>
<P>68 (9.4)</P>
</TD>
<TD>
<P>1.03 (0.37)</P>
</TD>
<TD>
<P>63 (38.7)</P>
</TD>
<TD>
<P>2/40</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria used</P>
</TD>
<TD>
<P>157 (75%)</P>
</TD>
<TD>
<P>1. IV prednisolone 60 mg + placebo 5 days then tapering oral prednisolone 30 mg up to day 12 vs. </P>
<P>2. oral prednisolone 60 mg + placebo 5 days then tapering oral prednisolone 30 mg up to day 12</P>
</TD>
<TD>
<P>71 (8.4)</P>
</TD>
<TD>
<P>1.0 (0.4)</P>
</TD>
<TD>
<P>38 (21)</P>
</TD>
<TD>
<P>17/210</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>85%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ridha-2006" TYPE="STUDY">Ridha 2006</LINK> [abstract only]</P>
</TD>
<TD>
<P>Not known/not known</P>
</TD>
<TD>
<P>52 (not known)</P>
</TD>
<TD>
<P>1. Oral prednisone 40 mg/day for 10 days vs. </P>
<P>2. IV hydrocortisone 400 mg/day for 10 days</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Willaert-2002" TYPE="STUDY">Willaert 2002</LINK>
</P>
</TD>
<TD>
<P>Inpatient/AO criteria not used</P>
</TD>
<TD>
<P>42 (87.5%)</P>
</TD>
<TD>
<P>1. IV methylprednisolone 40 mg/day days 1-10, decreased to 20 mg/day then to oral treatment 4 mg for 4 days vs. </P>
<P>2. oral methylprednisolone 32 mg/day days 1-7, decreased to 24 mg/day for days 8-11, then decrease in dosage by 4 mg/week, 14 days total</P>
</TD>
<TD>
<P>71.5 (7)</P>
</TD>
<TD>
<P>1.12 (0.47)</P>
</TD>
<TD>
<P>31.7 (17.5)</P>
</TD>
<TD>
<P>11/48</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Not known</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>AO: airflow obstruction; ED: emergency department; FEV<SUB>1</SUB>: forced expiratory volume in 1 second; ICU: intensive care unit; IV: intravenous; PYH: pack-years' history; SD: standard deviation.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-08-19 17:51:08 +0100" MODIFIED_BY="Emma J Welsh" NO="2">
<TITLE MODIFIED="2014-06-11 07:36:18 +0100" MODIFIED_BY="Julia A.E. Walters">Definition of treatment failure by study</TITLE>
<TABLE COLS="4" ROWS="13">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Treatment failure definition used in study</P>
</TH>
<TH>
<P>Time period</P>
</TH>
<TH>
<P>Data</P>
</TH>
</TR>
<TR>
<TD COLSPAN="4">
<P>Inpatient (treatment &gt; 3 days)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bullard-1996" TYPE="STUDY">Bullard 1996</LINK>
</P>
</TD>
<TD>
<P>Returned to ED</P>
</TD>
<TD>
<P>&lt; 14 days</P>
</TD>
<TD>
<P>5/60, 14/53</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>
</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>Not known</P>
</TD>
<TD>
<P>5/43, 6/43</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Davies-1999" TYPE="STUDY">Davies 1999</LINK>
</P>
</TD>
<TD>
<P>Withdrawal due to unsatisfactory clinical improvement (specialist), or participant not satisfied with progress, or pH &lt; 7.26</P>
</TD>
<TD>
<P>&lt; 14 days</P>
</TD>
<TD>
<P>1/29, 5/27</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maltais-2002" TYPE="STUDY">Maltais 2002</LINK>
</P>
</TD>
<TD>
<P>Deterioration of COPD while participant hospitalised defined as need for treatment intensification according to the treating physician, the development of confusion, lethargy, acute respiratory acidosis (PaCO<SUB>2</SUB> &gt; 70 mmHg with a pH &lt; 7.30 or an increase in PaCO<SUB>2</SUB> &gt; 10 mmHg) or need for ventilatory assistance</P>
</TD>
<TD>
<P>&lt; 11 days</P>
</TD>
<TD>
<P>3/62, 8/66</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Niewoehner-1999" TYPE="STUDY">Niewoehner 1999</LINK>
</P>
</TD>
<TD>
<P>Intubation and mechanical ventilation, re-admission because of COPD or intensification of pharmacological therapy</P>
</TD>
<TD>
<P>&lt; 30 days</P>
</TD>
<TD>
<P>35/160, 37/111</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wood_x002d_Baker-1998" TYPE="STUDY">Wood-Baker 1998</LINK>
</P>
</TD>
<TD>
<P>Lack of progress according to attending physician during treatment</P>
</TD>
<TD>
<P>&lt; 7 days</P>
</TD>
<TD>
<P>1/13, 4/13</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>Inpatient (treatment 1 day)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Emerman-1989" TYPE="STUDY">Emerman 1989</LINK>
</P>
</TD>
<TD>
<P>Required unscheduled visit to ED</P>
</TD>
<TD>
<P>&lt; 2 days</P>
</TD>
<TD>
<P>8/38, 4/32</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>Outpatient</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aaron-2003" TYPE="STUDY">Aaron 2003</LINK>
</P>
</TD>
<TD>
<P>Unscheduled visit to doctor's surgery or return to ED because of worsening dyspnoea</P>
</TD>
<TD>
<P>&lt; 30 days</P>
</TD>
<TD>
<P>19/70, 30/70</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Thompson-1996" TYPE="STUDY">Thompson 1996</LINK>
</P>
</TD>
<TD>
<P>Failure of outpatient therapy defined as hospitalisation for deteriorating respiratory status or lack of improvement of subjective dyspnoea requiring treatment with open-label prednisone</P>
</TD>
<TD>
<P>&lt; 14 days</P>
</TD>
<TD>
<P>0/13, 8/14</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>COPD: chronic obstructive pulmonary disease; ED: emergency department; PaCO<SUB>2</SUB>: partial pressure of carbon dioxide dissolved in arterial blood.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<COMPARISON ID="CMP-001" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<NAME>Systemic corticosteroid (SCS) versus placebo</NAME>
<DICH_OUTCOME CHI2="11.749644475099466" CI_END="0.6715312760361124" CI_START="0.3451556313889888" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="0.48143826351641156" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="114" I2="31.91283347377814" I2_Q="58.106406427955314" ID="CMP-001.01" LOG_CI_END="-0.17293375560347796" LOG_CI_START="-0.4619850364833766" LOG_EFFECT_SIZE="-0.31745939604342727" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.16272860060020966" P_Q="0.09190524680949985" P_Z="1.6684956499197417E-5" Q="4.77399962493212" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="488" TOTAL_2="429" WEIGHT="100.0" Z="4.305180595670731">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.197035698531019" CI_END="0.6934710185896014" CI_START="0.3041555349827464" DF="5" EFFECT_SIZE="0.45926359386974086" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="72" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.1589716841647639" LOG_CI_START="-0.5169042758948211" LOG_EFFECT_SIZE="-0.3379379800297925" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.5214106746677316" P_Z="2.1478927354914046E-4" STUDIES="6" TAU2="0.0" TOTAL_1="367" TOTAL_2="313" WEIGHT="67.04553695867916" Z="3.700955348408912">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="0.7611498748113116" CI_START="0.08425925057915913" EFFECT_SIZE="0.2532467532467532" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.11852981971454028" LOG_CI_START="-1.0743824079053876" LOG_EFFECT_SIZE="-0.5964561138099639" MODIFIED="2014-02-28 04:26:52 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="5" O_E="0.0" SE="0.5614725418499246" STUDY_ID="STD-Bullard-1996" TOTAL_1="60" TOTAL_2="53" VAR="0.3152514152514153" WEIGHT="13.527728463848021"/>
<DICH_DATA CI_END="2.889912925742923" CI_START="0.22781850905703244" EFFECT_SIZE="0.8114035087719298" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4608847574835159" LOG_CI_START="-0.6424109946783958" LOG_EFFECT_SIZE="-0.09076311859744" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.6480813862219604" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" VAR="0.4200094831673779" WEIGHT="5.263189310519184"/>
<DICH_DATA CI_END="1.4446373893267501" CI_START="0.017093478082087155" EFFECT_SIZE="0.15714285714285714" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1597588508455774" LOG_CI_START="-1.767169560557641" LOG_EFFECT_SIZE="-0.8037053548560318" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="1.131887287307721" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="27" VAR="1.2811688311688312" WEIGHT="4.96309518316502"/>
<DICH_DATA CI_END="1.4587500092773733" CI_START="0.09316088970511968" EFFECT_SIZE="0.3686440677966102" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.16398087181545712" LOG_CI_START="-1.0307663725184333" LOG_EFFECT_SIZE="-0.43339275035148805" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.701800445415968" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" VAR="0.492523865186051" WEIGHT="7.320565395168405"/>
<DICH_DATA CI_END="1.016759136970072" CI_START="0.3376678836576365" EFFECT_SIZE="0.5859410430839003" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="35" LOG_CI_END="0.007218083823469469" LOG_CI_START="-0.4715102441130534" LOG_EFFECT_SIZE="-0.23214608014479202" MODIFIED="2014-06-11 07:26:06 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="15" O_E="0.0" SE="0.28120738957335556" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="160" TOTAL_2="111" VAR="0.07907759595066097" WEIGHT="32.30590370148744"/>
<DICH_DATA CI_END="1.977052530274167" CI_START="0.01778215270543405" EFFECT_SIZE="0.1875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.29601820866881756" LOG_CI_START="-1.750015664541342" LOG_EFFECT_SIZE="-0.7269987279362623" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="1.2018504251546631" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="13" TOTAL_2="13" VAR="1.4444444444444444" WEIGHT="3.6650549044910923"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.8909813955614405" CI_START="0.505652859067188" DF="0" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.8382810773975049" LOG_CI_START="-0.296147532824429" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="2" P_CHI2="1.0" P_Z="0.3489387869429731" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="32" WEIGHT="3.403265268456014" Z="0.936649704176973">
<NAME>Inpatient (treatment 1 day)</NAME>
<DICH_DATA CI_END="6.8909813955614405" CI_START="0.505652859067188" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.8382810773975049" LOG_CI_START="-0.296147532824429" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2014-06-11 09:00:23 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="1" O_E="0.0" SE="0.6663689811565504" STUDY_ID="STD-Emerman-1989" TOTAL_1="38" TOTAL_2="32" VAR="0.444047619047619" WEIGHT="3.403265268456014"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.466439959146518" CI_END="0.7172639016118747" CI_START="0.19315945344038524" DF="1" EFFECT_SIZE="0.37221808554645486" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" I2="71.15195959585543" ID="CMP-001.01.03" LOG_CI_END="-0.1443210257451642" LOG_CI_START="-0.7140840321397827" LOG_EFFECT_SIZE="-0.4292025289424734" MODIFIED="2014-06-11 08:46:54 +0100" MODIFIED_BY="Julia A.E. Walters" NO="3" P_CHI2="0.06262607243007956" P_Z="0.0031482215199811446" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="84" WEIGHT="29.551197772864832" Z="2.9528821259347513">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="1.0085619564386716" CI_START="0.2446480399361758" EFFECT_SIZE="0.49673202614379086" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="0.0037025822839862658" LOG_CI_START="-0.6114582593576011" LOG_EFFECT_SIZE="-0.30387783853680744" MODIFIED="2014-06-11 08:46:54 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.3613485234755452" STUDY_ID="STD-Aaron-2003" TOTAL_1="70" TOTAL_2="70" VAR="0.13057275541795665" WEIGHT="21.695816086407092"/>
<DICH_DATA CI_END="0.5698580433840209" CI_START="0.001407649890710423" EFFECT_SIZE="0.02832244008714597" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.2442333174033858" LOG_CI_START="-2.8515053490574633" LOG_EFFECT_SIZE="-1.5478693332304245" MODIFIED="2014-06-11 08:46:52 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="9" O_E="0.0" SE="1.5315244975983104" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="14" VAR="2.345567286743757" WEIGHT="7.855381686457739"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.02027310739525989" CI_END="0.97440815752087" CI_START="0.6304771385976243" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.7837997620438152" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.011259088882515362" LOG_CI_START="-0.2003306565308769" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.10579487270669612" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="2" P_CHI2="0.8867769751534317" P_Q="0.8867769751534317" P_Z="0.02827906575081659" Q="0.02027310739525989" RANDOM="NO" SCALE="3.3429679501817318" SHOW_PARTICIPANTS="NO" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="2.193393145602565">
<NAME>Rate of relapse to 30 days</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.2967216990255523" CI_START="0.5035665959815486" DF="0" EFFECT_SIZE="0.8080753256434128" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.1128467782841618" LOG_CI_START="-0.29794308647132767" LOG_EFFECT_SIZE="-0.09254815409358294" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="1.0" P_Z="0.37716440982091703" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="21.184245969919743" Z="0.8831330294239537">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<IV_DATA CI_END="1.2967216990255523" CI_START="0.5035665959815486" EFFECT_SIZE="0.8080753256434128" ESTIMABLE="YES" ESTIMATE="-0.2131" LOG_CI_END="0.1128467782841618" LOG_CI_START="-0.29794308647132767" LOG_EFFECT_SIZE="-0.09254815409358294" MODIFIED="2012-09-21 06:16:22 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="15" SE="0.2413" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="1" TOTAL_2="1" WEIGHT="21.184245969919743"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.9934132826165329" CI_START="0.6083581582001933" DF="0" EFFECT_SIZE="0.7774002025624911" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.0028700374870603354" LOG_CI_START="-0.2158406635994173" LOG_EFFECT_SIZE="-0.1093553505432388" MODIFIED="2014-08-10 16:39:04 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.0441367507797197" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="78.81575403008026" Z="2.012789768185452">
<NAME>Outpatient</NAME>
<IV_DATA CI_END="0.9934132826165329" CI_START="0.6083581582001933" EFFECT_SIZE="0.7774002025624911" ESTIMABLE="YES" ESTIMATE="-0.2518" LOG_CI_END="-0.0028700374870603354" LOG_CI_START="-0.2158406635994173" LOG_EFFECT_SIZE="-0.1093553505432388" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SE="0.1251" STUDY_ID="STD-Aaron-2003" TOTAL_1="1" TOTAL_2="1" WEIGHT="78.81575403008026"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="2.3869212670401048" CI_END="1.072518363803716" CI_START="0.42259816748319223" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6732342052625684" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.03040473696896989" LOG_CI_START="-0.37407239051527935" LOG_EFFECT_SIZE="-0.17183382677315473" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="3" P_CHI2="0.6649921450963263" P_Q="0.36844275053652786" P_Z="0.09585269018244001" Q="0.808910038912072" RANDOM="NO" SCALE="23.502270613739245" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="277" TOTAL_2="305" WEIGHT="100.0" Z="1.6653011451886985">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5751686786023233" CI_END="1.31203679662257" CI_START="0.4453918030966651" DF="3" EFFECT_SIZE="0.7644412564591859" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="38" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.11794601518144161" LOG_CI_START="-0.35125777989884727" LOG_EFFECT_SIZE="-0.11665588235870285" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.6650332135998531" P_Z="0.32976228249945116" STUDIES="4" TAU2="0.0" TOTAL_1="205" TOTAL_2="234" WEIGHT="69.3704384715405" Z="0.9745928332428538">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="3.481880691882049" CI_START="0.15357406235851412" EFFECT_SIZE="0.73125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5418138857517342" LOG_CI_START="-0.8136821275712605" LOG_EFFECT_SIZE="-0.13593412090976317" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.7962250680394075" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" VAR="0.633974358974359" WEIGHT="8.488424997228119"/>
<DICH_DATA CI_END="2.1267242073238113" CI_START="0.32989007789052976" EFFECT_SIZE="0.8376068376068376" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.32771117443339054" LOG_CI_START="-0.4816307465407241" LOG_EFFECT_SIZE="-0.07695978605366678" MODIFIED="2014-03-26 03:08:51 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="15" O_E="0.0" SE="0.4754114506873166" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="80" TOTAL_2="111" VAR="0.2260160474446189" WEIGHT="22.35877809479302"/>
<DICH_DATA CI_END="4.126375971452288" CI_START="0.4006084845215878" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.6155687958349482" LOG_CI_START="-0.3972798569848121" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-09-11 08:01:20 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="201" O_E="0.0" SE="0.5949523123480183" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="27" VAR="0.35396825396825393" WEIGHT="11.406321090025283"/>
<DICH_DATA CI_END="1.3047519294045378" CI_START="0.18797502072826117" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.11552794774181077" LOG_CI_START="-0.7258998586120885" LOG_EFFECT_SIZE="-0.3051859554351389" MODIFIED="2014-02-17 02:00:19 +0000" MODIFIED_BY="Julia A.E. Walters" NOTES="&lt;p&gt;DT - Gunen relapse outcome defined as 'exacerbations', but does not clarify if no. people or no. events (letter sent)&lt;/p&gt;" NOTES_MODIFIED="2014-02-17 02:00:19 +0000" NOTES_MODIFIED_BY="Julia A.E. Walters" ORDER="436" O_E="0.0" SE="0.49425885858709634" STUDY_ID="STD-Gunen-2007" TOTAL_1="53" TOTAL_2="53" VAR="0.24429181929181928" WEIGHT="27.116914289494073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1827708734468803" CI_START="0.18412507668803235" DF="0" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.07290062118292104" LOG_CI_START="-0.7348870592657697" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2014-02-17 02:05:03 +0000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.10822970021191784" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="71" WEIGHT="30.629561528459504" Z="1.6062012435936763">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="1.1827708734468803" CI_START="0.18412507668803235" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.07290062118292104" LOG_CI_START="-0.7348870592657697" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2012-09-21 06:17:37 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.474498482109068" STUDY_ID="STD-Aaron-2003" TOTAL_1="72" TOTAL_2="71" VAR="0.2251488095238095" WEIGHT="30.629561528459504"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.016942031272202" CI_END="1.6576503990996174" CI_START="0.5984700515573832" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9960191362686085" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.21949294252828566" LOG_CI_START="-0.22295757753626183" LOG_EFFECT_SIZE="-0.0017323175039880765" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="4" P_CHI2="0.991196849320049" P_Q="0.8623282138885284" P_Z="0.9877548563966775" Q="0.2962386744005958" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="693" TOTAL_2="626" WEIGHT="100.0" Z="0.015347614088507013">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.6980431969162344" CI_END="1.9175867254097463" CI_START="0.35930929320592603" DF="6" EFFECT_SIZE="0.8300642932737452" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.2827550146106771" LOG_CI_START="-0.4445315500209034" LOG_EFFECT_SIZE="-0.08088826770511315" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.9452722618768218" P_Z="0.6628574403226788" STUDIES="7" TAU2="0.0" TOTAL_1="400" TOTAL_2="349" WEIGHT="40.5016212208958" Z="0.4359714565995491">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="4.218224201685183" CI_START="0.09509004072160672" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6251296590846035" LOG_CI_START="-1.0218649666182704" LOG_EFFECT_SIZE="-0.1983676537668335" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="3" O_E="0.0" SE="0.9674527958927513" STUDY_ID="STD-Albert-1980" TOTAL_1="22" TOTAL_2="22" VAR="0.9359649122807017" WEIGHT="9.19302607428814"/>
<DICH_DATA CI_END="8.355180010722716" CI_START="0.2155844081257939" EFFECT_SIZE="1.3421052631578947" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9219558111200614" LOG_CI_START="-0.6663826521578092" LOG_EFFECT_SIZE="0.1277865794811262" MODIFIED="2014-02-28 04:27:47 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="5" O_E="0.0" SE="0.9329978757316176" STUDY_ID="STD-Bullard-1996" TOTAL_1="60" TOTAL_2="53" VAR="0.8704850361197111" WEIGHT="6.801212210712288"/>
<DICH_DATA CI_END="81.13482501762184" CI_START="0.12969650247748613" EFFECT_SIZE="3.2439024390243905" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.909207303861729" LOG_CI_START="-0.8870717353670281" LOG_EFFECT_SIZE="0.5110677842473503" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="1.6425481494474539" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" VAR="2.697964423253255" WEIGHT="1.5946364459630582"/>
<DICH_DATA CI_END="15.621247574110008" CI_START="0.055196929302127704" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.193715715387341" LOG_CI_START="-1.2580850821301433" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="1.4401999250714548" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="27" VAR="2.074175824175824" WEIGHT="3.3707762272389847"/>
<DICH_DATA CI_END="10.054724908353617" CI_START="0.014309326113306955" EFFECT_SIZE="0.3793103448275862" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0023701930413282" LOG_CI_START="-1.8443808185227906" LOG_EFFECT_SIZE="-0.42100531274073105" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="1.6721956358375376" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="14" TOTAL_2="17" VAR="2.7962382445141065" WEIGHT="4.443295935905934"/>
<DICH_DATA CI_END="2.7729786581799445" CI_START="0.07488663080373663" EFFECT_SIZE="0.45569620253164556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4429465271074862" LOG_CI_START="-1.1255957081537946" LOG_EFFECT_SIZE="-0.34132459052315417" MODIFIED="2014-02-27 05:10:16 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="15" O_E="0.0" SE="0.9213694734017637" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="160" TOTAL_2="111" VAR="0.8489217065166432" WEIGHT="11.791497651005749"/>
<DICH_DATA CI_END="16.41725191852324" CI_START="0.06091153409613706" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.215300462375167" LOG_CI_START="-1.215300462375167" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-09-16 23:24:44 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.427747014866968" STUDY_ID="STD-Gunen-2007" TOTAL_1="53" TOTAL_2="53" VAR="2.0384615384615383" WEIGHT="3.3071766757816454"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-11 07:06:39 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>In patient (treatment 1 day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-28 04:27:48 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Emerman-1989" TOTAL_1="52" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.071791879866044" CI_START="0.06052781167558056" DF="0" EFFECT_SIZE="0.9863013698630136" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="1.2060642999216906" LOG_CI_START="-1.2180450273000658" LOG_EFFECT_SIZE="-0.005990363689187465" MODIFIED="2012-09-21 06:20:06 +0100" MODIFIED_BY="Julia A.E. Walters" NO="3" P_CHI2="1.0" P_Z="0.9922711951078729" STUDIES="2" TAU2="0.0" TOTAL_1="87" TOTAL_2="87" WEIGHT="3.3478457767135494" Z="0.00968677192340993">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-21 06:19:57 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.071791879866044" CI_START="0.06052781167558056" EFFECT_SIZE="0.9863013698630136" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2060642999216906" LOG_CI_START="-1.2180450273000658" LOG_EFFECT_SIZE="-0.005990363689187465" MODIFIED="2012-09-21 06:20:06 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="1.4239338183447554" STUDY_ID="STD-Aaron-2003" TOTAL_1="74" TOTAL_2="73" VAR="2.027587519025875" WEIGHT="3.3478457767135494"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.008951168123891132" CI_END="2.1626579959146954" CI_START="0.5762035540131003" DF="1" EFFECT_SIZE="1.1163024784353461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.33498784526860187" LOG_CI_START="-0.23942406732683466" LOG_EFFECT_SIZE="0.04778188897088359" MODIFIED="2014-05-02 00:46:12 +0100" MODIFIED_BY="Julia A.E. Walters" NO="4" P_CHI2="0.9246241200793096" P_Z="0.7443673502778512" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="146" WEIGHT="56.15053300239065" Z="0.3260753457325407">
<NAME>ICU</NAME>
<DICH_DATA CI_END="4.761876818808216" CI_START="0.2944961879522316" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6777781567967497" LOG_CI_START="-0.5309203224796826" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2013-09-27 16:07:00 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.7099954698809438" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="0.504093567251462" WEIGHT="12.345975579284955"/>
<DICH_DATA CI_END="2.3267901254419807" CI_START="0.5173508774902864" EFFECT_SIZE="1.097163120567376" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.3667572120477851" LOG_CI_START="-0.2862148099598098" LOG_EFFECT_SIZE="0.04027120104398766" MODIFIED="2014-05-02 00:46:12 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="311" O_E="0.0" SE="0.38355899799089943" STUDY_ID="STD-Abroug-2014" TOTAL_1="111" TOTAL_2="106" VAR="0.1471175049397828" WEIGHT="43.8045574231057"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.793555991663322" CI_END="0.20001839808788022" CI_START="0.08522824999931658" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1426233240435984" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="5" P_CHI2="0.5705508182850968" P_Q="1.0" P_Z="1.113763875453811E-6" Q="0.0" RANDOM="NO" SCALE="0.81" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="354" TOTAL_2="295" UNITS="" WEIGHT="100.0" Z="4.87039320247533">
<NAME>Early FEV<SUB>1</SUB> (L) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.793555991663322" CI_END="0.20001839808788022" CI_START="0.08522824999931658" DF="6" EFFECT_SIZE="0.1426233240435984" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.5705508182850968" P_Z="1.113763875453811E-6" STUDIES="7" TAU2="0.0" TOTAL_1="354" TOTAL_2="295" WEIGHT="100.0" Z="4.87039320247533">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="0.2638225509979801" CI_START="-0.06382255099798012" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.96" MEAN_2="0.86" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="3" SD_1="0.24" SD_2="0.31" SE="0.08358447006689483" STUDY_ID="STD-Albert-1980" TOTAL_1="22" TOTAL_2="22" WEIGHT="12.27444522745622"/>
<CONT_DATA CI_END="0.24522370561569756" CI_START="-0.0052237056156975575" EFFECT_SIZE="0.12000000000000001" ESTIMABLE="YES" MEAN_1="0.14" MEAN_2="0.02" MODIFIED="2014-06-11 06:03:37 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="5" SD_1="0.3097" SD_2="0.3628" SE="0.06389081973110025" STUDY_ID="STD-Bullard-1996" TOTAL_1="60" TOTAL_2="53" WEIGHT="21.0075854360593"/>
<CONT_DATA CI_END="0.6859926600022543" CI_START="0.03400733999774569" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="1.27" MEAN_2="0.91" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="9" SD_1="0.52" SD_2="0.31" SE="0.16632584199181352" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="14" WEIGHT="3.099799455489084"/>
<CONT_DATA CI_END="0.4152722306745561" CI_START="0.08472776932544365" EFFECT_SIZE="0.2499999999999999" ESTIMABLE="YES" MEAN_1="1.15" MEAN_2="0.9" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" NOTES="&lt;p&gt;Where does the data entered for Maltais FEV1 come from in the paper. The effect size does not match Figure 2 in the paper?&lt;/p&gt;&lt;p&gt;Data supplied by astrazeneca in 2004. Using absolute group values of post BD feV1 72 hours the effect size is 0.25 [0.08, 0.42]. Paper gives mean diference for change in FEV1 PRED-PLAc of 0.16 (0.09, 0.24) page 700. The stats section says anaylsis was by Ancova with ajustment for baseline values as covariates which may explains the difference. which to use? &lt;/p&gt;" NOTES_MODIFIED="2012-09-21 05:48:50 +0100" NOTES_MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="0.49" SD_2="0.41" SE="0.08432411614611417" STUDY_ID="STD-Maltais-2002" TOTAL_1="57" TOTAL_2="58" WEIGHT="12.060059859439114"/>
<CONT_DATA CI_END="0.42738091144882684" CI_START="-0.04738091144882697" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" MEAN_1="0.96" MEAN_2="0.77" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.48" SD_2="0.41" SE="0.12111493543823114" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="25" WEIGHT="5.845984438065902"/>
<CONT_DATA CI_END="0.3738805290634757" CI_START="-0.013880529063475644" EFFECT_SIZE="0.18000000000000002" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.16" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.33" SD_2="0.13" SE="0.09892045496385675" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="13" TOTAL_2="12" WEIGHT="8.763565735871222"/>
<CONT_DATA CI_END="0.19442257996839" CI_START="0.005577420031609964" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.97" MEAN_2="0.87" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="15" SD_1="0.39" SD_2="0.39" SE="0.04817567093741685" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="160" TOTAL_2="111" WEIGHT="36.94855984761916"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2012-09-21 06:22:09 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6235030863000888" CI_END="7.523620093536652" CI_START="0.18054775443962612" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.8520839239881393" ESTIMABLE="YES" I2="23.766051183854774" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="6" P_CHI2="0.26934801829459354" P_Q="0.687651459218444" P_Z="0.03974925498681938" Q="0.16163981767306318" RANDOM="NO" SCALE="22.32" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="2.0563451938894812">
<NAME>Early FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.4618632686270265" CI_END="9.417906385389898" CI_START="-0.382378810045374" DF="1" EFFECT_SIZE="4.517763787672262" ESTIMABLE="YES" I2="59.38035987848761" ID="CMP-001.06.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.1166405886246501" P_Z="0.07075920421994855" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="66" WEIGHT="56.140746729433346" Z="1.8070197219609834">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="17.026390108374784" CI_START="1.5736098916252157" EFFECT_SIZE="9.3" ESTIMABLE="YES" MEAN_1="37.1" MEAN_2="27.8" MODIFIED="2012-09-21 06:33:37 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="15.3" SD_2="14.2" SE="3.9421082067423505" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="27" WEIGHT="22.580957729856333"/>
<CONT_DATA CI_END="7.637795183631245" CI_START="-5.037795183631251" EFFECT_SIZE="1.2999999999999972" ESTIMABLE="YES" MEAN_1="38.4" MEAN_2="37.1" MODIFIED="2013-09-10 03:25:13 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="197" SD_1="15.3" SD_2="13.4" SE="3.2336283899209204" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="33.559788999577016"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4649166347286635E-32" CI_END="8.543923058844076" CI_START="-2.543923058844077" DF="0" EFFECT_SIZE="2.9999999999999996" ESTIMABLE="YES" I2="100.0" ID="CMP-001.06.02" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="2" P_CHI2="0.0" P_Z="0.2888711513140404" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="44" WEIGHT="43.85925327056666" Z="1.0606012910370612">
<NAME>Inpatient (treatment 1 day)</NAME>
<CONT_DATA CI_END="8.543923058844076" CI_START="-2.5439230588440767" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="38.0" MEAN_2="35.0" MODIFIED="2014-02-28 04:30:11 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="1" SD_1="14.42" SD_2="13.27" SE="2.828584148777138" STUDY_ID="STD-Emerman-1989" TOTAL_1="52" TOTAL_2="44" WEIGHT="43.85925327056666"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8016141220887063" CI_END="0.4452564805480423" CI_START="-0.05236571044209298" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.19644538505297465" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="7" P_CHI2="0.6697795074881503" P_Q="1.0" P_Z="0.1217517218046846" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="1.5474626598417356">
<NAME>Early FVC (L) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8016141220887063" CI_END="0.4452564805480423" CI_START="-0.05236571044209298" DF="2" EFFECT_SIZE="0.19644538505297465" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.6697795074881503" P_Z="0.1217517218046846" STUDIES="3" TAU2="0.0" TOTAL_1="64" TOTAL_2="59" WEIGHT="100.0" Z="1.5474626598417356">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="0.5437081720710637" CI_START="-0.28370817207106397" EFFECT_SIZE="0.1299999999999999" ESTIMABLE="YES" MEAN_1="2.38" MEAN_2="2.25" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="3" SD_1="0.69" SD_2="0.71" SE="0.21107947663035703" STUDY_ID="STD-Albert-1980" TOTAL_1="22" TOTAL_2="22" WEIGHT="36.17023141896075"/>
<CONT_DATA CI_END="0.5679690666324727" CI_START="-0.4079690666324727" EFFECT_SIZE="0.08000000000000002" ESTIMABLE="YES" MEAN_1="0.44" MEAN_2="0.36" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.59" SD_2="0.65" SE="0.2489683843588507" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="13" TOTAL_2="12" WEIGHT="25.99889575661833"/>
<CONT_DATA CI_END="0.7445261141806152" CI_START="-0.06452611418061543" EFFECT_SIZE="0.33999999999999986" ESTIMABLE="YES" MEAN_1="2.05" MEAN_2="1.71" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.74" SD_2="0.77" SE="0.206394667132389" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="25" WEIGHT="37.83087282442092"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="22.32" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Early FVC (% predicted)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="7.750211558524658" CI_START="-10.950211558524646" EFFECT_SIZE="-1.5999999999999943" ESTIMABLE="YES" MEAN_1="64.5" MEAN_2="66.1" MODIFIED="2013-09-27 16:51:34 +0100" MODIFIED_BY="[Empty name]" ORDER="449" SD_1="19.3" SD_2="22.9" SE="4.770603762251719" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="17.91" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Early FEV<SUB>1</SUB>/FVC (%)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="8.54668872924675" CI_START="-3.9466887292467563" EFFECT_SIZE="2.299999999999997" ESTIMABLE="YES" MEAN_1="48.4" MEAN_2="46.1" MODIFIED="2013-09-27 16:58:29 +0100" MODIFIED_BY="[Empty name]" ORDER="456" SD_1="13.7" SD_2="14.6" SE="3.1871446508812595" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.481496096159957" CI_END="40.02883475947329" CI_START="5.019320686241379" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="22.524077722857335" ESTIMABLE="YES" I2="77.68602318192653" I2_Q="77.68602318192653" ID="CMP-001.10" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="10" P_CHI2="0.034263759398768356" P_Q="0.034263759398768356" P_Z="0.011670138467199142" Q="4.481496096159957" RANDOM="NO" SCALE="126.94" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="2.5219648024498245">
<NAME>Early PEF (L/minute) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="34.65096241802388" CI_START="-2.270962418023881" DF="0" EFFECT_SIZE="16.19" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="1.0" P_Z="0.08563979761060572" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="53" WEIGHT="89.90906846764803" Z="1.7188603817709387">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="34.65096241802388" CI_START="-2.270962418023881" EFFECT_SIZE="16.19" ESTIMABLE="YES" MEAN_1="21.71" MEAN_2="5.52" MODIFIED="2014-06-11 06:12:08 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="5" SD_1="54.52" SD_2="45.5677" SE="9.419031453456082" STUDY_ID="STD-Bullard-1996" TOTAL_1="60" TOTAL_2="53" WEIGHT="89.90906846764803"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="134.06493030794525" CI_START="23.855069692054776" DF="0" EFFECT_SIZE="78.96000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" MODIFIED="2013-11-14 06:41:24 +0000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.004978253469749329" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.090931532351977" Z="2.808437563652431">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="134.06493030794525" CI_START="23.855069692054776" EFFECT_SIZE="78.96000000000001" ESTIMABLE="YES" MEAN_1="273.48" MEAN_2="194.52" MODIFIED="2013-11-14 06:41:24 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="557" SD_1="81.84" SD_2="52.8" SE="28.11527698600887" STUDY_ID="STD-Thompson-1996" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.090931532351977"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8930943688865005" CI_END="0.6435220834975123" CI_START="0.04798928222300525" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.34575568286025876" ESTIMABLE="YES" I2="30.86986648244856" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="11" P_CHI2="0.23538166227511004" P_Q="1.0" P_Z="0.022855587561666887" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="92" UNITS="" WEIGHT="99.99999999999999" Z="2.275840002115326">
<NAME>Early dyspnoea score</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.8930943688865005" CI_END="0.6435220834975123" CI_START="0.04798928222300525" DF="2" EFFECT_SIZE="0.34575568286025876" ESTIMABLE="YES" I2="30.86986648244856" ID="CMP-001.11.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.23538166227511004" P_Z="0.022855587561666887" STUDIES="3" TAU2="0.0" TOTAL_1="86" TOTAL_2="92" WEIGHT="99.99999999999999" Z="2.275840002115326">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="1.6798805050184362" CI_START="0.08633709891291175" EFFECT_SIZE="0.883108801965674" ESTIMABLE="YES" MEAN_1="18.4" MEAN_2="5.0" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="9" SD_1="14.42" SD_2="14.98" SE="0.4065236449942936" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="14" WEIGHT="13.966371137497156"/>
<CONT_DATA CI_END="0.6723232968150439" CI_START="-0.025621387689598207" EFFECT_SIZE="0.32335095456272284" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="1.8" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="2.3" SD_2="2.6" SE="0.1780503851116502" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" WEIGHT="72.80636787825604"/>
<CONT_DATA CI_END="0.7204280986022349" CI_START="-0.9170319987210314" EFFECT_SIZE="-0.09830195005939824" ESTIMABLE="YES" MEAN_1="1.28" MEAN_2="1.54" MODIFIED="2014-02-20 06:52:46 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="2.91" SD_2="2.17" SE="0.41772708841574197" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="11" TOTAL_2="12" WEIGHT="13.227260984246799"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.34535114204496165" CI_END="6.881446656839591" CI_START="0.5485422872698069" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.7149944720546992" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="12" P_CHI2="0.8414105802918918" P_Q="1.0" P_Z="0.021476589005392992" Q="0.0" RANDOM="NO" SCALE="16.25" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="114" TOTAL_2="119" UNITS="" WEIGHT="100.00000000000001" Z="2.299499548099838">
<NAME>Early PaO<SUB>2</SUB> (mmHg) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.34535114204496165" CI_END="6.881446656839591" CI_START="0.5485422872698069" DF="2" EFFECT_SIZE="3.7149944720546992" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.8414105802918918" P_Z="0.021476589005392992" STUDIES="3" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="100.00000000000001" Z="2.299499548099838">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="9.11733235850514" CI_START="-1.5173323585051453" EFFECT_SIZE="3.799999999999997" ESTIMABLE="YES" MEAN_1="59.5" MEAN_2="55.7" MODIFIED="2013-11-14 03:54:30 +0000" MODIFIED_BY="[Empty name]" ORDER="440" SD_1="11.8" SD_2="12.3" SE="2.7129745242502317" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="35.46159417374285"/>
<CONT_DATA CI_END="7.530489078912858" CI_START="-1.5304890789128578" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="4.0" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="41" SD_1="14.0" SD_2="12.0" SE="2.3115164945115203" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" WEIGHT="48.84900172786655"/>
<CONT_DATA CI_END="13.743102452326058" CI_START="-2.245102452326053" EFFECT_SIZE="5.749000000000002" ESTIMABLE="YES" MEAN_1="66.492" MEAN_2="60.743" MODIFIED="2013-11-14 03:53:50 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="42" SD_1="6.919" SD_2="13.306" SE="4.07869864721113" STUDY_ID="STD-Thompson-1996" TOTAL_1="12" TOTAL_2="14" WEIGHT="15.689404098390607"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.227916690538805" CI_END="-0.5808658045943869" CI_START="-3.8420667822230836" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.2114662934087352" ESTIMABLE="YES" I2="58.49426427497513" I2_Q="75.88880583615246" ID="CMP-001.13" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="13" NOTES="&lt;p&gt;RevMan suggested a possible data entry error as I-square was over 90%. It seems SE has been entered instead of SD? I have entered the SDs given in the paper. CJC Oct 13&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" P_CHI2="0.06497752603487739" P_Q="0.04169736457301321" P_Z="0.007856896968155759" Q="4.147451151546054" RANDOM="NO" SCALE="14.73" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="159" UNITS="" WEIGHT="100.0" Z="2.6581583397273842">
<NAME>Early PaCO<SUB>2</SUB> (mmHg) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.080465538992751" CI_END="-0.005438029784399445" CI_START="-3.408218678511651" DF="2" EFFECT_SIZE="-1.7068283541480254" ESTIMABLE="YES" I2="35.07474845331466" ID="CMP-001.13.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.21433129622081004" P_Z="0.049272224695142426" STUDIES="3" TAU2="0.0" TOTAL_1="114" TOTAL_2="119" WEIGHT="91.85170429437873" Z="1.9662284744526">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="6.6942159930339225" CI_START="-2.8942159930339253" EFFECT_SIZE="1.8999999999999986" ESTIMABLE="YES" MEAN_1="48.1" MEAN_2="46.2" MODIFIED="2013-11-14 03:45:09 +0000" MODIFIED_BY="[Empty name]" ORDER="441" SD_1="9.7" SD_2="11.9" SE="2.4460735150493007" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="11.568044315789294"/>
<CONT_DATA CI_END="-0.09099070042885349" CI_START="-3.9090092995711467" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="1.0" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" NOTES="&lt;p&gt;Maltais PaCO2 results altered by CJC: SD of 5 and 6 reported in the paper on page 701. Could you check this and discuss as previous SD was much lower? Where did the previous SD entries come from? Does this mean other data will need to be checked&lt;/p&gt;&lt;p&gt;The lower SD entered were an error. the correct SD are 5 and 6. other dat has been checked. Astra supplied absolutevalues for Paco2 for each group. Using these figures with change results in other study, gives similar effect size as in current version, -0.65 [-0.90, -0.41]&lt;/p&gt;" NOTES_MODIFIED="2012-09-21 05:48:50 +0100" NOTES_MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="5.0" SD_2="6.0" SE="0.9740022340355069" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" WEIGHT="72.95902948753576"/>
<CONT_DATA CI_END="1.5419674908627305" CI_START="-10.50796749086274" EFFECT_SIZE="-4.483000000000004" ESTIMABLE="YES" MEAN_1="37.367" MEAN_2="41.85" MODIFIED="2013-11-14 03:44:38 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="9" SD_1="5.83" SD_2="9.625" SE="3.074019491371734" STUDY_ID="STD-Thompson-1996" TOTAL_1="12" TOTAL_2="14" WEIGHT="7.324630491053687"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.187658308084944" CI_START="-13.612341691915052" DF="0" EFFECT_SIZE="-7.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" MODIFIED="2013-11-14 03:45:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.006716719198878068" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="8.14829570562126" Z="2.710572355953646">
<NAME>ICU</NAME>
<CONT_DATA CI_END="-2.187658308084944" CI_START="-13.612341691915052" EFFECT_SIZE="-7.899999999999999" ESTIMABLE="YES" MEAN_1="52.2" MEAN_2="60.1" MODIFIED="2013-11-14 03:45:07 +0000" MODIFIED_BY="[Empty name]" ORDER="434" SD_1="11.8" SD_2="14.5" SE="2.914513601766806" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" WEIGHT="8.14829570562126"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.27704239827145" CI_END="0.18958842115249105" CI_START="-0.005656624965255652" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0919658980936177" ESTIMABLE="YES" I2="46.79456023930811" I2_Q="31.33671580115359" ID="CMP-001.14" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="14" P_CHI2="0.08018245120806111" P_Q="0.227506889317017" P_Z="0.064834709790474" Q="1.4563824199029511" RANDOM="YES" SCALE="1.0" SORT_BY="WEIGHT" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0073675002152856104" TOTALS="YES" TOTAL_1="361" TOTAL_2="308" UNITS="" WEIGHT="100.00000000000001" Z="1.8463961227540493">
<NAME>FEV<SUB>1</SUB> (L) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.20801742859136" CI_END="0.15173531166884638" CI_START="-0.047948642684546156" DF="4" EFFECT_SIZE="0.05189333449215011" ESTIMABLE="YES" I2="35.56719120056294" ID="CMP-001.14.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.1841428566422112" P_Z="0.3083452150607222" STUDIES="5" TAU2="0.004500486004950848" TOTAL_1="291" TOTAL_2="231" WEIGHT="75.79568991065561" Z="1.0187004456282331">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="0.4610482630442471" CI_START="-0.1010482630442468" EFFECT_SIZE="0.18000000000000016" ESTIMABLE="YES" MEAN_1="1.12" MEAN_2="0.94" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.61" SD_2="0.4" SE="0.1433946058504747" STUDY_ID="STD-Davies-1999" TOTAL_1="28" TOTAL_2="22" WEIGHT="8.882608220586045"/>
<CONT_DATA CI_END="0.34554011842808197" CI_START="-0.165540118428082" EFFECT_SIZE="0.09" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="0.06" MODIFIED="2014-02-18 04:53:52 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.459" SD_2="0.7213" SE="0.13038000720612716" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" WEIGHT="10.181497889943644"/>
<CONT_DATA CI_END="0.28042652025246184" CI_START="-0.12042652025246212" EFFECT_SIZE="0.07999999999999985" ESTIMABLE="YES" MEAN_1="1.15" MEAN_2="1.07" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="0.46" SD_2="0.51" SE="0.10226030775738777" STUDY_ID="STD-Maltais-2002" TOTAL_1="48" TOTAL_2="43" WEIGHT="13.918177055666197"/>
<CONT_DATA CI_END="0.2885230050141222" CI_START="-0.028523005014122194" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="0.18" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.23" SD_2="0.16" SE="0.08088057039033952" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="12" TOTAL_2="12" WEIGHT="17.836217343082364"/>
<CONT_DATA CI_END="0.039264763556512525" CI_START="-0.15926476355651265" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="1.02" MEAN_2="1.08" MODIFIED="2014-02-18 04:53:42 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="15" SD_1="0.41" SD_2="0.41" SE="0.050646218164976685" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="160" TOTAL_2="111" WEIGHT="24.977189401377355"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.593787587638352" CI_END="0.45109207234415816" CI_START="-0.027819674316121118" DF="1" EFFECT_SIZE="0.21163619901401853" ESTIMABLE="YES" I2="37.25638173140855" ID="CMP-001.14.02" MODIFIED="2013-08-16 00:54:59 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="0.20678587658852476" P_Z="0.08322765445883312" STUDIES="2" TAU2="0.014604501638712148" TOTAL_1="70" TOTAL_2="77" WEIGHT="24.204310089344403" Z="1.7322578983917452">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.829896666852994" CI_START="0.010103333147005844" EFFECT_SIZE="0.41999999999999993" ESTIMABLE="YES" MEAN_1="1.42" MEAN_2="1.0" MODIFIED="2012-09-21 06:37:37 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="9" SD_1="0.61" SD_2="0.46" SE="0.2091347953769593" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="14" WEIGHT="4.854468043149209"/>
<CONT_DATA CI_END="0.28474083999162003" CI_START="-0.004740839991620033" EFFECT_SIZE="0.13999999999999999" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.16" MODIFIED="2012-09-21 06:37:18 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="0.44" SD_2="0.36" SE="0.07384872433030264" STUDY_ID="STD-Aaron-2003" TOTAL_1="57" TOTAL_2="63" WEIGHT="19.349842046195196"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3809046112146888" CI_END="10.960084325686577" CI_START="1.3246046555394644" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="6.142344490613021" ESTIMABLE="YES" I2="27.583701880728217" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="15" P_CHI2="0.23994731363746535" P_Q="1.0" P_Z="0.012459960650387025" Q="0.0" RANDOM="NO" SCALE="22.32" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="2.498842692707532">
<NAME>FEV<SUB>1</SUB> (% predicted)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3809046112146888" CI_END="10.960084325686577" CI_START="1.3246046555394644" DF="1" EFFECT_SIZE="6.142344490613021" ESTIMABLE="YES" I2="27.583701880728217" ID="CMP-001.15.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.23994731363746535" P_Z="0.012459960650387025" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="61" WEIGHT="100.0" Z="2.498842692707532">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="16.43777118841718" CI_START="2.1622288115828123" EFFECT_SIZE="9.299999999999997" ESTIMABLE="YES" MEAN_1="41.5" MEAN_2="32.2" MODIFIED="2013-09-11 07:55:45 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="14.61316131" SD_2="11.13519245" SE="3.641786912779527" STUDY_ID="STD-Davies-1999" TOTAL_1="28" TOTAL_2="22" WEIGHT="45.557663631259"/>
<CONT_DATA CI_END="10.02942543280498" CI_START="-3.0294254328049792" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="44.2" MEAN_2="40.7" MODIFIED="2013-09-10 03:31:53 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="197" SD_1="14.6" SD_2="15.0" SE="3.331400721803183" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="54.44233636874101"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20373624445109428" CI_END="0.32020153760942816" CI_START="-0.283227612122823" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.01848696274330257" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="16" P_CHI2="0.6517218209657418" P_Q="1.0" P_Z="0.904409549090764" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="0.12009290958676494">
<NAME>FVC (L) - absolute or change</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.20373624445109428" CI_END="0.32020153760942816" CI_START="-0.283227612122823" DF="1" EFFECT_SIZE="0.01848696274330257" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.6517218209657418" P_Z="0.904409549090764" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="34" WEIGHT="100.0" Z="0.12009290958676494">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="0.39517324071475246" CI_START="-0.5151732407147523" EFFECT_SIZE="-0.05999999999999994" ESTIMABLE="YES" MEAN_1="0.68" MEAN_2="0.74" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.46" SD_2="0.66" SE="0.23223551264467143" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="12" TOTAL_2="12" WEIGHT="43.93788375478392"/>
<CONT_DATA CI_END="0.4829596366731003" CI_START="-0.3229596366731002" EFFECT_SIZE="0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.14" MEAN_2="2.06" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="0.76" SD_2="0.69" SE="0.20559542922808502" STUDY_ID="STD-Davies-1999" TOTAL_1="28" TOTAL_2="22" WEIGHT="56.062116245216075"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="22.32" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="39" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FVC (% predicted)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="13.601218490825172" CI_START="-6.201218490825166" EFFECT_SIZE="3.700000000000003" ESTIMABLE="YES" MEAN_1="73.8" MEAN_2="70.1" MODIFIED="2013-09-27 16:53:57 +0100" MODIFIED_BY="[Empty name]" ORDER="452" SD_1="22.6" SD_2="22.3" SE="5.051734913970214" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2515400782787744" CI_END="4.256751865860114" CI_START="-2.1082386251427336" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0742566203586903" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="18" P_CHI2="0.5348497499584024" P_Q="1.0" P_Z="0.5082345748687904" Q="0.0" RANDOM="NO" SCALE="58.43" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="94" UNITS="" WEIGHT="100.0" Z="0.6615891379674361">
<NAME>FEV<SUB>1</SUB>/FVC (%)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2515400782787744" CI_END="4.256751865860114" CI_START="-2.1082386251427336" DF="2" EFFECT_SIZE="1.0742566203586903" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.5348497499584024" P_Z="0.5082345748687904" STUDIES="3" TAU2="0.0" TOTAL_1="95" TOTAL_2="94" WEIGHT="100.0" Z="0.6615891379674361">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="3.9896805986319075" CI_START="-4.4896805986319075" EFFECT_SIZE="-0.25" ESTIMABLE="YES" MEAN_1="53.6" MEAN_2="53.85" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="8.4" SD_2="11.43" SE="2.1631420944843716" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" WEIGHT="56.3467987745816"/>
<CONT_DATA CI_END="15.152106363065446" CI_START="-4.212106363065448" EFFECT_SIZE="5.469999999999999" ESTIMABLE="YES" MEAN_1="45.04" MEAN_2="39.57" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="11.59" SD_2="12.59" SE="4.93994095781181" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.804279944319198"/>
<CONT_DATA CI_END="7.452738320448091" CI_START="-3.652738320448094" EFFECT_SIZE="1.8999999999999986" ESTIMABLE="YES" MEAN_1="47.5" MEAN_2="45.6" MODIFIED="2013-09-27 16:59:14 +0100" MODIFIED_BY="[Empty name]" ORDER="457" SD_1="11.7" SD_2="13.4" SE="2.833081813873818" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="32.8489212810992"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.266229911382182" CI_END="173.73069708951218" CI_START="64.38505960340515" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="119.05787834645866" ESTIMABLE="YES" I2="55.873850443086944" I2_Q="55.873850443086944" ID="CMP-001.19" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="19" P_CHI2="0.13222131637537027" P_Q="0.13222131637537027" P_Z="1.971434016983378E-5" Q="2.266229911382182" RANDOM="NO" SCALE="550.99" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="56" UNITS="" WEIGHT="99.99999999999999" Z="4.268101755124131">
<NAME>PEF (L/minute) - absolute</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="314.41591362808924" CI_START="81.58408637191079" DF="0" EFFECT_SIZE="198.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="1.0" P_Z="8.5759557135611E-4" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="22.05556708773563" Z="3.333503615138878">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="314.41591362808924" CI_START="81.58408637191079" EFFECT_SIZE="198.0" ESTIMABLE="YES" MEAN_1="240.0" MEAN_2="42.0" MODIFIED="2014-02-18 05:43:57 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="275.4124" SD_2="275.4124" SE="59.39696573322932" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" WEIGHT="22.05556708773563"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="158.6468392802706" CI_START="34.79316071972946" DF="0" EFFECT_SIZE="96.72000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.02" MODIFIED="2013-11-14 06:37:30 +0000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.0022048417455746224" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="13" WEIGHT="77.94443291226436" Z="3.0611560155163446">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="158.6468392802706" CI_START="34.79316071972946" EFFECT_SIZE="96.72000000000003" ESTIMABLE="YES" MEAN_1="308.04" MEAN_2="211.32" MODIFIED="2013-11-14 06:37:30 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="81.36" SD_2="79.74" SE="31.595906745604292" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="13" WEIGHT="77.94443291226436"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.20" MODIFIED="2014-07-28 12:06:50 +0100" MODIFIED_BY="Emma J Welsh" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="74" TOTAL_2="73" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Transitional dyspnoea index (change)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.01" MODIFIED="2012-09-21 06:50:30 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="3.5284150944592687" CI_START="0.23158490554073174" EFFECT_SIZE="1.8800000000000003" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="2.07" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="4.62" SD_2="5.53" SE="0.8410435637908433" STUDY_ID="STD-Aaron-2003" TOTAL_1="74" TOTAL_2="73" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Dyspnoea score walking (change, VAS)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="3.740121911058172" CI_START="-3.320121911058172" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="2.19" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="3.92" SD_2="3.92" SE="1.8011157036064556" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="10" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9688661871971336" CI_END="0.40942446704169405" CI_START="-0.04531309139975537" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18205568782096934" ESTIMABLE="YES" I2="0.0" I2_Q="58.53300811516975" ID="CMP-001.22" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="22" P_CHI2="0.39645052509350376" P_Q="0.1204427466887622" P_Z="0.11656497620796394" Q="2.411556649147311" RANDOM="NO" SCALE="2.27" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="146" UNITS="" WEIGHT="100.00000000000001" Z="1.5693561470168762">
<NAME>Overall dyspnoea score</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5573095380498228" CI_END="0.32401602646331823" CI_START="-0.31033509487637884" DF="2" EFFECT_SIZE="0.006840465793469677" ESTIMABLE="YES" I2="0.0" ID="CMP-001.22.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.7568011496058565" P_Z="0.9662833205816751" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="73" WEIGHT="51.38806058981074" Z="0.04227017543332833">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="1.1381805493146118" CI_START="-0.7273931643331086" EFFECT_SIZE="0.2053936924907516" ESTIMABLE="YES" MEAN_1="-1.68" MEAN_2="-2.36" MODIFIED="2014-02-18 05:56:25 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="2.43" SD_2="3.89" SE="0.4759204067939839" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="10" TOTAL_2="8" WEIGHT="5.941509880672812"/>
<CONT_DATA CI_END="0.40350499950365165" CI_START="-0.7150993288458196" EFFECT_SIZE="-0.155797164671084" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-2.6" MODIFIED="2014-02-18 05:56:38 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="1.61" SD_2="7.42" SE="0.2853634906490322" STUDY_ID="STD-Davies-1999" TOTAL_1="28" TOTAL_2="22" WEIGHT="16.52603470287702"/>
<CONT_DATA CI_END="0.48177810296903356" CI_START="-0.36380794179413933" EFFECT_SIZE="0.058985080587447114" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="-6.0" MODIFIED="2014-02-18 05:57:12 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="1380" SD_1="18.3608" SD_2="15.0821" SE="0.2157146895129318" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" WEIGHT="28.92051600626091"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6933834921171982" CI_START="0.04117064121150843" DF="0" EFFECT_SIZE="0.3672770666643533" ESTIMABLE="YES" I2="0.0" ID="CMP-001.22.02" MODIFIED="2014-02-18 05:56:10 +0000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.027285591389482784" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="73" WEIGHT="48.61193941018927" Z="2.2074076645685095">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="0.6933834921171982" CI_START="0.04117064121150843" EFFECT_SIZE="0.3672770666643533" ESTIMABLE="YES" MEAN_1="3.95" MEAN_2="2.07" MODIFIED="2014-02-18 05:56:10 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="4.62" SD_2="5.53" SE="0.1663838866556379" STUDY_ID="STD-Aaron-2003" TOTAL_1="74" TOTAL_2="73" WEIGHT="48.61193941018927"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.764027320126573" CI_END="10.963152289154554" CI_START="2.7497968250432425" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="6.856474557098898" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="23" P_CHI2="0.6227942227131165" P_Q="1.0" P_Z="0.0010666146451814035" Q="0.0" RANDOM="NO" SCALE="30.27" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="100" TOTAL_2="100" UNITS="" WEIGHT="100.00000000000001" Z="3.272339362772997">
<NAME>PaO<SUB>2</SUB> (mmHg) - change or absolute</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.764027320126573" CI_END="10.963152289154554" CI_START="2.7497968250432425" DF="3" EFFECT_SIZE="6.856474557098898" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.6227942227131165" P_Z="0.0010666146451814035" STUDIES="4" TAU2="0.0" TOTAL_1="100" TOTAL_2="100" WEIGHT="100.00000000000001" Z="3.272339362772997">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="25.83384809146922" CI_START="1.0861519085307787" EFFECT_SIZE="13.459999999999999" ESTIMABLE="YES" MEAN_1="12.68" MEAN_2="-0.78" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="6.89" SD_2="11.83" SE="6.3133038102090415" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="4" TOTAL_2="5" WEIGHT="11.014674978361528"/>
<CONT_DATA CI_END="22.801749498683304" CI_START="-8.801749498683304" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="5.0" MODIFIED="2014-02-18 05:51:11 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="45.9021" SD_2="26.2298" SE="8.062265237180625" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" WEIGHT="6.754153105084783"/>
<CONT_DATA CI_END="17.91187666984535" CI_START="-0.21787666984535825" EFFECT_SIZE="8.846999999999994" ESTIMABLE="YES" MEAN_1="68.585" MEAN_2="59.738" MODIFIED="2013-11-14 03:55:56 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="247" SD_1="7.573" SD_2="14.857" SE="4.625022062317441" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="13" WEIGHT="20.523784554921193"/>
<CONT_DATA CI_END="10.227837067320733" CI_START="-0.22783706732073306" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="62.5" MEAN_2="57.5" MODIFIED="2013-09-27 16:54:21 +0100" MODIFIED_BY="[Empty name]" ORDER="445" SD_1="12.3" SD_2="11.4" SE="2.6673128223565556" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="61.707387361632506"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.894813692931072" CI_END="1.4369264514339148" CI_START="-5.059864225864068" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8114688872150766" ESTIMABLE="YES" I2="59.14042647040205" I2_Q="60.86801084876713" ID="CMP-001.24" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="24" P_CHI2="0.08651770219074206" P_Q="0.1099145776998639" P_Z="0.27440494448063424" Q="2.5554540458838253" RANDOM="NO" SCALE="16.99" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="96" TOTAL_2="92" UNITS="" WEIGHT="100.0" Z="1.0929746560752724">
<NAME>PaCO<SUB>2</SUB> (mmHg) - absolute</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.339359647047246" CI_END="2.9736859316434527" CI_START="-4.171291272887106" DF="1" EFFECT_SIZE="-0.5988026706218263" ESTIMABLE="YES" I2="57.25325940104139" ID="CMP-001.24.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.12614154811811717" P_Z="0.7425190094083822" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="82.67915958453702" Z="0.3285193597317546">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="5.622404564800271" CI_START="-3.0224045648002624" EFFECT_SIZE="1.3000000000000043" ESTIMABLE="YES" MEAN_1="45.2" MEAN_2="43.9" MODIFIED="2013-09-27 16:42:50 +0100" MODIFIED_BY="[Empty name]" ORDER="441" SD_1="9.8" SD_2="9.8" SE="2.2053489752336484" STUDY_ID="STD-Gunen-2007" TOTAL_1="40" TOTAL_2="39" WEIGHT="56.47899118936223"/>
<CONT_DATA CI_END="1.6542450445313603" CI_START="-11.038245044531362" EFFECT_SIZE="-4.692" ESTIMABLE="YES" MEAN_1="38.2" MEAN_2="42.892" MODIFIED="2013-11-14 03:51:45 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="246" SD_1="4.875" SD_2="10.608" SE="3.2379396226612998" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="13" WEIGHT="26.200168395174785"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2052065159180705" CI_START="-15.405206515918074" DF="0" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.24.02" MODIFIED="2013-10-07 05:42:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05633506666835094" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="17.32084041546299" Z="1.908434613757601">
<NAME>ICU</NAME>
<CONT_DATA CI_END="0.20520651591807137" CI_START="-15.405206515918074" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" MEAN_1="51.9" MEAN_2="59.5" MODIFIED="2013-10-07 05:42:49 +0100" MODIFIED_BY="[Empty name]" ORDER="435" SD_1="16.4" SD_2="19.6" SE="3.9823213984973935" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" WEIGHT="17.32084041546299"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.25" MODIFIED="2014-07-28 12:07:02 +0100" MODIFIED_BY="Emma J Welsh" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="74" TOTAL_2="73" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Overall quality of life score (CRQ) (change)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.25.01" MODIFIED="2012-09-21 06:52:25 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="74" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<CONT_DATA CI_END="1.4441769184555517" CI_START="-0.684176918455552" EFFECT_SIZE="0.3799999999999999" ESTIMABLE="YES" MEAN_1="1.42" MEAN_2="1.04" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" SD_1="4.43" SD_2="1.47" SE="0.5429573843446326" STUDY_ID="STD-Aaron-2003" TOTAL_1="74" TOTAL_2="73" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.26" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="521.01" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physical capacity (m) (6-minute walk distance)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.26.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="63.75016303151234" CI_START="-148.19016303151227" EFFECT_SIZE="-42.21999999999997" ESTIMABLE="YES" MEAN_1="250.56" MEAN_2="292.78" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="118.2" SD_2="146.53" SE="54.06740321117706" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="18" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.929244035551446" CI_END="0.23884110094948863" CI_START="-1.4642403127497179" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6126996059001146" ESTIMABLE="YES" I2="49.40333064363429" I2_Q="75.37075433992217" ID="CMP-001.27" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="27" P_CHI2="0.11510390652850788" P_Q="0.04390503713521343" P_Z="0.15847146480334767" Q="4.060213673620243" RANDOM="NO" SCALE="11.35" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="326" TOTAL_2="270" UNITS="" WEIGHT="200.0" Z="1.41023106851685">
<NAME>Length of stay (days)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.01681149239480107" CI_END="-0.1834232178609294" CI_START="-2.2556527071555807" DF="1" EFFECT_SIZE="-1.219537962508255" ESTIMABLE="YES" I2="0.0" ID="CMP-001.27.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.8968361163866354" P_Z="0.021058383944536782" STUDIES="2" TAU2="0.0" TOTAL_1="172" TOTAL_2="124" WEIGHT="100.0" Z="2.30693607695848">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<CONT_DATA CI_END="2.319678777170906" CI_START="-5.239678777170904" EFFECT_SIZE="-1.459999999999999" ESTIMABLE="YES" MEAN_1="8.08" MEAN_2="9.54" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" SD_1="4.38" SD_2="5.25" SE="1.9284429749651162" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="12" TOTAL_2="13" WEIGHT="7.514600964713706"/>
<CONT_DATA CI_END="-0.12261415164272838" CI_START="-2.2773858483572704" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="8.5" MEAN_2="9.7" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="15" SD_1="4.45" SD_2="4.45" SE="0.5496967581320641" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="160" TOTAL_2="111" WEIGHT="92.48539903528629"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8522188695364028" CI_END="2.145006295584458" CI_START="-0.8444801838734266" DF="1" EFFECT_SIZE="0.6502630558555158" ESTIMABLE="YES" I2="46.010700115030524" ID="CMP-001.27.02" MODIFIED="2014-05-02 02:29:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.17352573180329578" P_Z="0.3938536772664316" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="146" WEIGHT="100.0" Z="0.8526495628673229">
<NAME>ICU</NAME>
<CONT_DATA CI_END="2.251045930120269" CI_START="-7.111045930120272" EFFECT_SIZE="-2.4300000000000015" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="18.03" MODIFIED="2013-10-07 05:45:02 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="10.52" SD_2="11.19" SE="2.388332626029745" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" WEIGHT="10.196412365728394"/>
<CONT_DATA CI_END="2.577319797806569" CI_START="-0.577319797806569" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="8.0" MODIFIED="2014-05-02 02:29:13 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="520" SD_1="5.925925926" SD_2="5.925925926" SE="0.8047697867145857" STUDY_ID="STD-Abroug-2014" TOTAL_1="111" TOTAL_2="106" WEIGHT="89.80358763427161"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.5600674932943273" CI_END="1.3833292345648247" CI_START="-3.4383328258043773" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0275017956197763" ESTIMABLE="YES" I2="60.93852983879002" I2_Q="0.0" ID="CMP-001.28" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="28" P_CHI2="0.10959425534281297" P_Q="1.0" P_Z="0.40352562803440406" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.9043290574621885" TOTALS="YES" TOTAL_1="154" TOTAL_2="146" UNITS="" WEIGHT="100.0" Z="0.8353412114953541">
<NAME>Duration of mechanical ventilation (days)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.5600674932943273" CI_END="1.3833292345648247" CI_START="-3.4383328258043773" DF="1" EFFECT_SIZE="-1.0275017956197763" ESTIMABLE="YES" I2="60.93852983879002" ID="CMP-001.28.01" MODIFIED="2014-05-02 07:57:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10959425534281297" P_Z="0.40352562803440406" STUDIES="2" TAU2="1.9043290574621885" TOTAL_1="154" TOTAL_2="146" WEIGHT="100.0" Z="0.8353412114953541">
<NAME>ICU</NAME>
<CONT_DATA CI_END="0.11265217430285368" CI_START="-5.112652174302854" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="4.37" MEAN_2="6.87" MODIFIED="2013-10-20 23:26:59 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="3.08" SD_2="7.89" SE="1.3330102975927725" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" WEIGHT="41.10007182479105"/>
<CONT_DATA CI_END="1.5976116345546416" CI_START="-1.5976116345546416" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="6.0" MODIFIED="2014-05-02 07:57:22 +0100" MODIFIED_BY="[Empty name]" ORDER="521" SD_1="5.92592593" SD_2="6.07407" SE="0.8151229548891705" STUDY_ID="STD-Abroug-2014" TOTAL_1="111" TOTAL_2="106" WEIGHT="58.89992817520895"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.273674545667946" CI_END="3.4264576749241886" CI_START="1.5872618525069324" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="2.332098959443352" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="96" I2="24.151557602548767" I2_Q="100.0" ID="CMP-001.29" LOG_CI_END="0.5348453715947096" LOG_CI_START="0.2006485787510447" LOG_EFFECT_SIZE="0.3677469751728772" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="29" P_CHI2="0.26035158026239913" P_Q="0.0" P_Z="1.6072541983394726E-5" Q="3.1984583514029076E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="399" TOTAL_2="337" WEIGHT="99.99999999999999" Z="4.313451488444156">
<NAME>Adverse drug effects</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.273674545667946" CI_END="3.4264576749241886" CI_START="1.5872618525069324" DF="4" EFFECT_SIZE="2.332098959443352" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="96" I2="24.151557602548767" ID="CMP-001.29.01" LOG_CI_END="0.5348453715947096" LOG_CI_START="0.2006485787510447" LOG_EFFECT_SIZE="0.3677469751728772" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.26035158026239913" P_Z="1.6072541983394726E-5" STUDIES="6" TAU2="0.0" TOTAL_1="334" TOTAL_2="279" WEIGHT="99.99999999999999" Z="4.313451488444156">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="4.218224201685183" CI_START="0.09509004072160672" EFFECT_SIZE="0.6333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6251296590846035" LOG_CI_START="-1.0218649666182704" LOG_EFFECT_SIZE="-0.1983676537668335" MODIFIED="2012-09-21 06:45:48 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="3" O_E="0.0" SE="0.9674527958927513" STUDY_ID="STD-Albert-1980" TOTAL_1="22" TOTAL_2="22" VAR="0.9359649122807017" WEIGHT="7.9762373718991615"/>
<DICH_DATA CI_END="112.44999780428616" CI_START="0.24426591969919614" EFFECT_SIZE="5.240963855421687" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0509594512915585" LOG_CI_START="-0.6121371221344316" LOG_EFFECT_SIZE="0.7194111645785635" MODIFIED="2012-09-21 06:46:03 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="1.5643161097710703" STUDY_ID="STD-Chen-2005" TOTAL_1="43" TOTAL_2="43" VAR="2.4470848912892955" WEIGHT="1.3792243788908969"/>
<DICH_DATA CI_END="29.030453468536813" CI_START="1.089911497052297" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.462853819756755" LOG_CI_START="0.037391233810045214" LOG_EFFECT_SIZE="0.7501225267834001" MODIFIED="2012-09-21 06:46:25 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.837323779138698" STUDY_ID="STD-Davies-1999" TOTAL_1="29" TOTAL_2="27" VAR="0.7011111111111111" WEIGHT="4.178029099566228"/>
<DICH_DATA CI_END="3.0575758118047496" CI_START="0.7077488762569839" EFFECT_SIZE="1.4710526315789474" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="40" LOG_CI_END="0.4853772340616455" LOG_CI_START="-0.15012081152241913" LOG_EFFECT_SIZE="0.16762821126961314" MODIFIED="2012-09-21 06:45:59 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.37329469774213947" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" VAR="0.13934893136239526" WEIGHT="34.729866890144265"/>
<DICH_DATA CI_END="4.687076580622658" CI_START="1.7069518486644908" EFFECT_SIZE="2.8285356695869837" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="51" LOG_CI_END="0.670902049374731" LOG_CI_START="0.232221270292088" LOG_EFFECT_SIZE="0.4515616598334095" MODIFIED="2012-09-21 06:46:34 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="15" O_E="0.0" SE="0.25768326113802253" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="160" TOTAL_2="111" VAR="0.06640066307072631" WEIGHT="51.73664225949944"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-21 06:46:16 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.0" STUDY_ID="STD-Wood_x002d_Baker-1998" TOTAL_1="18" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.29.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient (treatment 1 day)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Emerman-1989" TOTAL_1="52" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.29.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-21 06:45:53 +0100" MODIFIED_BY="Julia A.E. Walters" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-21 06:45:53 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="9" O_E="0.0" SE="0.0" STUDY_ID="STD-Thompson-1996" TOTAL_1="13" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.56869145518515" CI_END="4.186105723546641" CI_START="1.861389555185225" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="2.7914106596326533" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="51" I2="23.881338709353855" I2_Q="68.8356975167245" ID="CMP-001.30" LOG_CI_END="0.6218101926058918" LOG_CI_START="0.26983727262715207" LOG_EFFECT_SIZE="0.44582373261652186" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="30" P_CHI2="0.25474319151257374" P_Q="0.04040514408195406" P_Z="6.864942279138762E-7" Q="6.417599113836452" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="391" TOTAL_2="413" WEIGHT="100.0" Z="4.965145951764575">
<NAME>Adverse effect - hyperglycaemia (30 days)</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7484025127452578" CI_END="21.628583875540215" CI_START="2.95738059835693" DF="2" EFFECT_SIZE="7.997746827917108" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="4" I2="0.0" ID="CMP-001.30.01" LOG_CI_END="1.3350280850806964" LOG_CI_START="0.47090721939582225" LOG_EFFECT_SIZE="0.9029676522382593" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.6878386130794718" P_Z="4.200789113811478E-5" STUDIES="3" TAU2="0.0" TOTAL_1="170" TOTAL_2="199" WEIGHT="12.42946813007135" Z="4.096149388058124">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="321.7172628584358" CI_START="1.0040734358397096" EFFECT_SIZE="17.972972972972972" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.5074743651077944" LOG_CI_START="0.0017654773644244838" LOG_EFFECT_SIZE="1.2546199212361095" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="1.4718658041194903" STUDY_ID="STD-Maltais-2002" TOTAL_1="62" TOTAL_2="66" VAR="2.166388945336314" WEIGHT="1.4642404299954863"/>
<DICH_DATA CI_END="244.7274507028014" CI_START="0.6905641337523459" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.388682686230037" LOG_CI_START="-0.1607959816163635" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="1.4975763896159162" STUDY_ID="STD-Davies-1999" TOTAL_1="28" TOTAL_2="22" VAR="2.2427350427350428" WEIGHT="1.4840274628332633"/>
<DICH_DATA CI_END="17.969915048351506" CI_START="1.7917183805510637" EFFECT_SIZE="5.674242424242424" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="1.25454602401385" LOG_CI_START="0.2532697489733834" LOG_EFFECT_SIZE="0.7539078864936166" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.5881546403562672" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="80" TOTAL_2="111" VAR="0.34592588097260996" WEIGHT="9.4812002372426"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.425583668409328" CI_START="0.13884510136839115" DF="0" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.30.02" LOG_CI_END="0.8707305959026442" LOG_CI_START="-0.8574694381046182" LOG_EFFECT_SIZE="0.006630578899013076" MODIFIED="2012-09-21 06:53:40 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.9880006087460568" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="6.605448986833158" Z="0.015039573640770177">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="7.425583668409326" CI_START="0.1388451013683912" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.870730595902644" LOG_CI_START="-0.857469438104618" LOG_EFFECT_SIZE="0.006630578899013076" MODIFIED="2012-09-21 06:53:40 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="1.015153254704003" STUDY_ID="STD-Aaron-2003" TOTAL_1="67" TOTAL_2="68" VAR="1.0305361305361305" WEIGHT="6.605448986833158"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23781049371070476" CI_END="3.430252645082126" CI_START="1.3313810779658395" DF="1" EFFECT_SIZE="2.1370478385624905" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="45" I2="0.0" ID="CMP-001.30.03" LOG_CI_END="0.5353261078924236" LOG_CI_START="0.1243023803207604" LOG_EFFECT_SIZE="0.329814244106592" MODIFIED="2014-05-02 00:48:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6257920089197222" P_Z="0.0016584050913866254" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="146" WEIGHT="80.96508288309549" Z="3.145434176544059">
<NAME>ICU</NAME>
<DICH_DATA CI_END="6.634465553067244" CI_START="1.0257484873856728" EFFECT_SIZE="2.608695652173913" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.821805943522632" LOG_CI_START="0.01104088520946948" LOG_EFFECT_SIZE="0.41642341436605074" MODIFIED="2013-09-27 16:15:05 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.47624740860491677" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="0.22681159420289854" WEIGHT="19.008266083518958"/>
<DICH_DATA CI_END="3.452623498119079" CI_START="1.1496898884603612" EFFECT_SIZE="1.9923469387755102" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="35" LOG_CI_END="0.538149221962441" LOG_CI_START="0.06058071175124508" LOG_EFFECT_SIZE="0.29936496685684305" MODIFIED="2014-05-02 00:48:15 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="312" O_E="0.0" SE="0.28052610690030816" STUDY_ID="STD-Abroug-2014" TOTAL_1="111" TOTAL_2="106" VAR="0.07869489665264312" WEIGHT="61.95681679957653"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.057636268457549" CI_END="3.2467961163244476" CI_START="0.4430857466670916" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1994203105990122" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="51.40054560033476" I2_Q="51.34008270984617" ID="CMP-001.31" LOG_CI_END="0.5114550178113083" LOG_CI_START="-0.3535122202762037" LOG_EFFECT_SIZE="0.0789713987675523" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="31" P_CHI2="0.15144497943588975" P_Q="0.15169978616553847" P_Z="0.7204264399865736" Q="2.055079530935304" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="151" WEIGHT="100.0" Z="0.3578889247536877">
<NAME>Adverse effect - hypertension</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.953573890024378" CI_START="0.5914585495640617" DF="0" EFFECT_SIZE="2.168918918918919" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.31.01" LOG_CI_END="0.9005623200962533" LOG_CI_START="-0.22807568607642392" LOG_EFFECT_SIZE="0.33624331700991467" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="1.0" P_Z="0.24287813154794935" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="111" WEIGHT="43.95620124525872" Z="1.1678231421898242">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="7.953573890024378" CI_START="0.5914585495640617" EFFECT_SIZE="2.168918918918919" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.9005623200962533" LOG_CI_START="-0.22807568607642392" LOG_EFFECT_SIZE="0.33624331700991467" MODIFIED="2014-01-19 16:58:13 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.6629675516740646" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="80" TOTAL_2="111" VAR="0.43952597457270354" WEIGHT="43.95620124525872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5401383930819494" CI_START="0.07587870635472581" DF="0" EFFECT_SIZE="0.43902439024390244" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.31.02" LOG_CI_END="0.4048573787122625" LOG_CI_START="-1.1198800819451213" LOG_EFFECT_SIZE="-0.35751135161642944" MODIFIED="2014-04-09 15:23:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3580321161731449" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="56.04379875474129" Z="0.919121345559818">
<NAME>ICU</NAME>
<DICH_DATA CI_END="2.5401383930819494" CI_START="0.07587870635472581" EFFECT_SIZE="0.43902439024390244" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4048573787122625" LOG_CI_START="-1.1198800819451213" LOG_EFFECT_SIZE="-0.35751135161642944" MODIFIED="2014-01-19 16:58:27 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.8956383319623032" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="0.8021680216802168" WEIGHT="56.04379875474129"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="32" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="154" TOTAL_2="146" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - gastrointestinal bleeding</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.32.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-03 04:51:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="146" WEIGHT="0.0" Z="0.0">
<NAME>ICU</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-05-03 04:51:02 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.0" STUDY_ID="STD-Abroug-2014" TOTAL_1="111" TOTAL_2="106" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.910587459907125" CI_START="0.12430383054228718" EFFECT_SIZE="0.926829268292683" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8395149677434516" LOG_CI_START="-0.9055154879493021" LOG_EFFECT_SIZE="-0.03300026010292532" MODIFIED="2013-09-27 16:11:59 +0100" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="1.0250395277139919" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="1.0507060333761233" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6856922176146317E-5" CI_END="3.206472611622438" CI_START="0.45212090360823054" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.204040404040404" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.33" LOG_CI_END="0.5060275347032679" LOG_CI_START="-0.3447454130899325" LOG_EFFECT_SIZE="0.0806410608066677" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="33" P_CHI2="0.9967241200176612" P_Q="0.9967241469365227" P_Z="0.71022576891696" Q="1.685664513923415E-5" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="90" WEIGHT="100.0" Z="0.3715528926164016">
<NAME>Adverse effect - dyspepsia</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.890468899549419" CI_START="0.1824986598809394" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.33.01" LOG_CI_END="0.8971028123901532" LOG_CI_START="-0.7387403202949037" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="1.0" P_Z="0.8495129202670765" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="22" WEIGHT="27.272727272727273" Z="0.18973994193394064">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="7.890468899549419" CI_START="0.1824986598809394" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8971028123901532" LOG_CI_START="-0.7387403202949037" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.960902353693305" STUDY_ID="STD-Davies-1999" TOTAL_1="28" TOTAL_2="22" VAR="0.9233333333333333" WEIGHT="27.272727272727273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7949746903414514" CI_START="0.382970722105158" DF="0" EFFECT_SIZE="1.2055555555555555" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-001.33.02" LOG_CI_END="0.5792088838199839" LOG_CI_START="-0.41683442632953716" LOG_EFFECT_SIZE="0.08118722874522341" MODIFIED="2012-09-21 06:56:38 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.7493380664411607" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="72.72727272727272" Z="0.3195122997640855">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="3.7949746903414505" CI_START="0.38297072210515803" EFFECT_SIZE="1.2055555555555555" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5792088838199839" LOG_CI_START="-0.4168344263295371" LOG_EFFECT_SIZE="0.08118722874522341" MODIFIED="2012-09-21 06:56:38 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.5850807708757318" STUDY_ID="STD-Aaron-2003" TOTAL_1="67" TOTAL_2="68" VAR="0.34231950844854064" WEIGHT="72.72727272727272"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.34" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="34" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - weight gain</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.34.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-21 06:54:11 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="82.67840984378185" CI_START="1.253520425866399" EFFECT_SIZE="10.180327868852459" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.9173921152373987" LOG_CI_START="0.09813141509422774" LOG_EFFECT_SIZE="1.007761765165813" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="1.068642740749803" STUDY_ID="STD-Aaron-2003" TOTAL_1="70" TOTAL_2="70" VAR="1.1419973073572505" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.35" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="35" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - depression</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-001.35.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-21 06:54:23 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="5.503316686265755" CI_START="0.7655922126754576" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.7406245048410373" LOG_CI_START="-0.11600249269369675" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.5031869387239284" STUDY_ID="STD-Aaron-2003" TOTAL_1="70" TOTAL_2="70" VAR="0.25319709530235845" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.36" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="36" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - anxiety</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="19" EVENTS_2="13" I2="0.0" ID="CMP-001.36.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-21 06:54:42 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="3.6362847090610946" CI_START="0.7337903172936007" EFFECT_SIZE="1.6334841628959276" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.5606578797021458" LOG_CI_START="-0.13442802326105133" LOG_EFFECT_SIZE="0.21311492822054723" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.408296900131293" STUDY_ID="STD-Aaron-2003" TOTAL_1="70" TOTAL_2="70" VAR="0.16670635865682304" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.030212801043731335" CI_END="4.879803955991137" CI_START="0.9509948701097547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.1542210957301617" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.37" LOG_CI_END="0.6884023747606032" LOG_CI_START="-0.021821825742959523" LOG_EFFECT_SIZE="0.3332902745088218" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="37" P_CHI2="0.8620082988389655" P_Q="0.8620132699710781" P_Z="0.06583827397417998" Q="0.03021060220175737" RANDOM="NO" SCALE="33.54" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="181" WEIGHT="100.0" Z="1.8395231645770482">
<NAME>Adverse effect - psychiatric disorder</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.348344074915712" CI_START="0.5566107928284086" DF="0" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.37.01" LOG_CI_END="1.0148708602602974" LOG_CI_START="-0.2544483768370853" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="1.0" P_Z="0.24032566310578896" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="111" WEIGHT="29.245466952622344" Z="1.174173239469826">
<NAME>Inpatient (treatment &gt; 3 days)</NAME>
<DICH_DATA CI_END="10.348344074915712" CI_START="0.5566107928284086" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="1.0148708602602974" LOG_CI_START="-0.2544483768370853" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="14" O_E="0.0" SE="0.7456044031025608" STUDY_ID="STD-Niewoehner-1999" TOTAL_1="80" TOTAL_2="111" VAR="0.5559259259259259" WEIGHT="29.245466952622344"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.503316686265755" CI_START="0.7655922126754576" DF="0" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" ID="CMP-001.37.02" LOG_CI_END="0.7406245048410373" LOG_CI_START="-0.11600249269369675" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2012-09-21 06:55:31 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.15296509213414627" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="70.75453304737765" Z="1.429136194963419">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="5.503316686265755" CI_START="0.7655922126754576" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.7406245048410373" LOG_CI_START="-0.11600249269369675" LOG_EFFECT_SIZE="0.3123110060736703" MODIFIED="2012-09-21 06:55:31 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.5031869387239284" STUDY_ID="STD-Aaron-2003" TOTAL_1="70" TOTAL_2="70" VAR="0.25319709530235845" WEIGHT="70.75453304737765"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.38" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="38" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="67" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - insomnia</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="14" I2="0.0" ID="CMP-001.38.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-09-21 06:56:24 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Outpatient</NAME>
<DICH_DATA CI_END="7.5294304465468205" CI_START="1.651707688568133" EFFECT_SIZE="3.526530612244898" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" LOG_CI_END="0.8767621258319086" LOG_CI_START="0.21793319039681297" LOG_EFFECT_SIZE="0.5473476581143608" MODIFIED="2012-09-21 05:48:50 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="10" O_E="0.0" SE="0.3869993779304025" STUDY_ID="STD-Aaron-2003" TOTAL_1="67" TOTAL_2="68" VAR="0.1497685185185185" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.39" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="39" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="72.02" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - delirium</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.39.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-09-27 16:13:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>ICU</NAME>
<DICH_DATA CI_END="2.946294626643179" CI_START="0.02926753754765757" EFFECT_SIZE="0.29365079365079366" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46927617371077573" LOG_CI_START="-1.5336138158119117" LOG_EFFECT_SIZE="-0.5321688210505678" MODIFIED="2013-09-27 16:13:39 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="1.176507494310973" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="1.384169884169884" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.40" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="40" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - secondary infection</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="6" I2="0.0" ID="CMP-001.40.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-09-27 16:11:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>ICU</NAME>
<DICH_DATA CI_END="2.665175498586345" CI_START="0.20859425190373804" EFFECT_SIZE="0.7456140350877193" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.42572581207108734" LOG_CI_START="-0.6806976633154471" LOG_EFFECT_SIZE="-0.12748592562217986" MODIFIED="2013-09-27 16:11:48 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="0.6499186263265835" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="0.42239422084623324" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0022947447613546066" CI_END="3.402409639846315" CI_START="0.4438367507646032" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2288671365609678" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.41" LOG_CI_END="0.5317866001686198" LOG_CI_START="-0.35277673997362713" LOG_EFFECT_SIZE="0.08950493009749633" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="41" P_CHI2="0.9617931679879663" P_Q="1.0" P_Z="0.6916332226575308" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="154" TOTAL_2="146" WEIGHT="100.0" Z="0.39663963329445134">
<NAME>Adverse effect - ventilator-associated pneumonia</NAME>
<GROUP_LABEL_1>SCS</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0022947447613546066" CI_END="3.402409639846315" CI_START="0.4438367507646032" DF="1" EFFECT_SIZE="1.2288671365609678" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-001.41.01" LOG_CI_END="0.5317866001686198" LOG_CI_START="-0.35277673997362713" LOG_EFFECT_SIZE="0.08950493009749633" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.9617931679879663" P_Z="0.6916332226575308" STUDIES="2" TAU2="0.0" TOTAL_1="154" TOTAL_2="146" WEIGHT="100.0" Z="0.39663963329445134">
<NAME>ICU</NAME>
<DICH_DATA CI_END="6.038186023828594" CI_START="0.2649996001868104" EFFECT_SIZE="1.264957264957265" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7809064885939647" LOG_CI_START="-0.5767547812963734" LOG_EFFECT_SIZE="0.10207585364879572" MODIFIED="2013-09-27 16:13:21 +0100" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="0.7974969504652579" STUDY_ID="STD-Alia-2011" TOTAL_1="43" TOTAL_2="40" VAR="0.636001386001386" WEIGHT="41.909179445700794"/>
<DICH_DATA CI_END="4.6055911452652385" CI_START="0.31414001311982" EFFECT_SIZE="1.2028301886792452" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6632853814709306" LOG_CI_START="-0.5028767424605232" LOG_EFFECT_SIZE="0.0802043195052037" MODIFIED="2014-05-02 07:54:59 +0100" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.6850094041929486" STUDY_ID="STD-Abroug-2014" TOTAL_1="111" TOTAL_2="106" VAR="0.4692378838327784" WEIGHT="58.0908205542992"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="2">
<NAME>Intravenous corticosteroid (IVCS) versus oral corticosteroid (OCS)</NAME>
<DICH_OUTCOME CHI2="0.5763522553877063" CI_END="1.2981931861930323" CI_START="0.3408438394534572" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6651925660546351" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.11333932532619972" LOG_CI_START="-0.4674445512050522" LOG_EFFECT_SIZE="-0.17705261293942617" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.7496295755491169" P_Q="1.0" P_Z="0.23208923333596188" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="1.1949944161761274">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5763522553877063" CI_END="1.2981931861930323" CI_START="0.3408438394534572" DF="2" EFFECT_SIZE="0.6651925660546351" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="24" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.11333932532619972" LOG_CI_START="-0.4674445512050522" LOG_EFFECT_SIZE="-0.17705261293942617" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.7496295755491169" P_Z="0.23208923333596188" STUDIES="3" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="1.1949944161761274">
<NAME>Inpatient treatment</NAME>
<DICH_DATA CI_END="2.175082951107662" CI_START="0.10373167601957448" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.3374758242889873" LOG_CI_START="-0.9840886050392542" LOG_EFFECT_SIZE="-0.3233063903751334" MODIFIED="2013-09-12 00:33:40 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="202" O_E="0.0" SE="0.7762934876368398" STUDY_ID="STD-Willaert-2002" TOTAL_1="23" TOTAL_2="25" VAR="0.6026315789473684" WEIGHT="23.510971786833856"/>
<DICH_DATA CI_END="2.7598005427135255" CI_START="0.07157432616609029" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.44087769571411367" LOG_CI_START="-1.1452427319368386" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2014-01-23 04:10:24 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.9316949906249123" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.8680555555555556" WEIGHT="16.927899686520377"/>
<DICH_DATA CI_END="1.8295743763993115" CI_START="0.3524432149697792" EFFECT_SIZE="0.8030075187969925" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.26235006924937443" LOG_CI_START="-0.4529108457984708" LOG_EFFECT_SIZE="-0.09528038827454817" MODIFIED="2014-01-23 04:29:58 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="616" O_E="0.0" SE="0.42014780209773583" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" VAR="0.1765241756075582" WEIGHT="59.56112852664577"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5688593282511982" CI_END="1.803600966372182" CI_START="0.5004924625442152" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9500993048659385" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.25614045933024915" LOG_CI_START="-0.3006024586444112" LOG_EFFECT_SIZE="-0.022230999657081044" METHOD="MH" MODIFIED="2014-05-23 15:57:12 +0100" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="0.45638007078588083" P_Q="1.0" P_Z="0.8756195942640643" Q="0.0" RANDOM="NO" SCALE="36.38" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="0.15652451880917967">
<NAME>Relapse</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5688593282511982" CI_END="1.803600966372182" CI_START="0.5004924625442152" DF="2" EFFECT_SIZE="0.9500993048659385" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.25614045933024915" LOG_CI_START="-0.3006024586444112" LOG_EFFECT_SIZE="-0.022230999657081044" MODIFIED="2014-02-19 22:29:59 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.45638007078588083" P_Z="0.8756195942640643" STUDIES="3" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="0.15652451880917967">
<NAME>Inpatient treatment</NAME>
<DICH_DATA CI_END="5.925549770768965" CI_START="0.30001904406366553" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7727286502660702" LOG_CI_START="-0.5228511770494704" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-01-23 06:42:52 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.7610300037887249" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.5791666666666666" WEIGHT="15.64051638530288"/>
<DICH_DATA CI_END="2.7139124947049913" CI_START="0.4929756193459406" EFFECT_SIZE="1.1566731141199227" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.43359584049415906" LOG_CI_START="-0.3071745587052223" LOG_EFFECT_SIZE="0.06321064089446836" MODIFIED="2013-09-28 07:20:42 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="617" O_E="0.0" SE="0.4351321993623312" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" VAR="0.18934003092189955" WEIGHT="51.34061569016882"/>
<DICH_DATA CI_END="1.7552831940946305" CI_START="0.1140206348630572" EFFECT_SIZE="0.4473684210526316" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.24434719471102453" LOG_CI_START="-0.9430165451880971" LOG_EFFECT_SIZE="-0.34933467523853623" MODIFIED="2014-02-19 22:29:59 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="203" O_E="0.0" SE="0.6974633383620483" STUDY_ID="STD-Willaert-2002" TOTAL_1="23" TOTAL_2="25" VAR="0.48645510835913314" WEIGHT="33.0188679245283"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.413228796278304" CI_END="4.509147110765731" CI_START="0.43638668235532196" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.402758620689655" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="17.12348190588426" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.6540944043798861" LOG_CI_START="-0.36012851167638454" LOG_EFFECT_SIZE="0.14698294635175083" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="3" P_CHI2="0.29920863335674197" P_Q="1.0" P_Z="0.5699787701814143" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="0.5680827688476946">
<NAME>Mortality after discharge (1-3 months)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.413228796278304" CI_END="4.509147110765731" CI_START="0.43638668235532196" DF="2" EFFECT_SIZE="1.402758620689655" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="17.12348190588426" ID="CMP-002.03.01" LOG_CI_END="0.6540944043798861" LOG_CI_START="-0.36012851167638454" LOG_EFFECT_SIZE="0.14698294635175083" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.29920863335674197" P_Z="0.5699787701814143" STUDIES="3" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="0.5680827688476946">
<NAME>Inpatient treatment</NAME>
<DICH_DATA CI_END="4.009391292006816" CI_START="0.008124886132875167" EFFECT_SIZE="0.18048780487804877" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6030784427974784" LOG_CI_START="-2.0901827167749967" LOG_EFFECT_SIZE="-0.7435521369887593" MODIFIED="2013-09-28 07:12:53 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="1.5820349369906253" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="20" VAR="2.502834541858932" WEIGHT="50.49261083743842"/>
<DICH_DATA CI_END="13.055143399515389" CI_START="0.4693975028346226" EFFECT_SIZE="2.4754901960784315" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1157816465363057" LOG_CI_START="-0.32845922515078063" LOG_EFFECT_SIZE="0.39366121069276266" MODIFIED="2013-09-28 07:21:22 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.8483542371366087" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" VAR="0.7197049116676374" WEIGHT="40.19704433497537"/>
<DICH_DATA CI_END="87.72449079690927" CI_START="0.1317761994967007" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9431208560013304" LOG_CI_START="-0.8801630219168202" LOG_EFFECT_SIZE="0.5314789170422551" MODIFIED="2013-10-20 23:54:48 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.658410925369711" STUDY_ID="STD-Willaert-2002" TOTAL_1="23" TOTAL_2="25" VAR="2.750326797385621" WEIGHT="9.310344827586206"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Early FEV<SUB>1</SUB> (L)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="0.3044985441917691" CI_START="-0.224498544191769" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.86" MODIFIED="2013-10-20 23:56:58 +0100" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="0.44" SD_2="0.38" SE="0.13495071658362082" STUDY_ID="STD-Willaert-2002" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2014-07-28 12:08:12 +0100" MODIFIED_BY="Emma J Welsh" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.41" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Early FVC (L)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" MODIFIED="2014-01-23 03:34:50 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="0.48950362820384624" CI_START="-0.48950362820384624" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.9" MODIFIED="2013-10-20 23:58:09 +0100" MODIFIED_BY="[Empty name]" ORDER="243" SD_1="0.65" SD_2="0.85" SE="0.2497513383230449" STUDY_ID="STD-Willaert-2002" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.027372029638543682" CI_END="1.7849113765230724" CI_START="-0.5518839240947466" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6165137262141629" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2014-02-28 00:38:20 +0000" MODIFIED_BY="Julia A.E. Walters" NO="6" P_CHI2="0.8685938060275629" P_Q="1.0" P_Z="0.3010475494944911" Q="0.0" RANDOM="NO" SCALE="9.373062586236202" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="36" UNITS="" WEIGHT="99.99999999999997" Z="1.034189600633719">
<NAME>Early dyspnoea score (VAS)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.027372029638543682" CI_END="1.7849113765230724" CI_START="-0.5518839240947466" DF="1" EFFECT_SIZE="0.6165137262141629" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" MODIFIED="2014-01-23 01:14:19 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.8685938060275629" P_Z="0.3010475494944911" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="99.99999999999997" Z="1.034189600633719">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="2.308415138286833" CI_START="-1.3084151382868332" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="4.4" MODIFIED="2013-10-20 23:55:41 +0100" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="2.62" SD_2="2.97" SE="0.9226777392602012" STUDY_ID="STD-Willaert-2002" TOTAL_1="19" TOTAL_2="18" WEIGHT="41.74313689291831"/>
<CONT_DATA CI_END="2.230795323991556" CI_START="-0.8307953239915571" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="7.5" MODIFIED="2014-01-23 01:14:19 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="248" SD_1="2.2361" SD_2="2.5456" SE="0.7810323740978276" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="58.25686310708167"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="33.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Early cough score (VAS)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.01" MODIFIED="2014-01-23 01:23:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="4.821509567746773" CI_START="-3.2215095677467733" EFFECT_SIZE="0.7999999999999998" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="4.3" MODIFIED="2014-01-23 01:22:56 +0000" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="6.7082" SD_2="5.9397" SE="2.0518282986156517" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="21.75" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Early sputum volume score (VAS)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.01" MODIFIED="2014-01-23 01:25:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="4.444498698235343" CI_START="-3.0444986982353424" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="4.8" MODIFIED="2014-01-23 01:25:29 +0000" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="6.261" SD_2="5.5154" SE="1.9104936252765206" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.38433037677829573" CI_END="0.03397101274032391" CI_START="-0.07588331742665667" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.020956152343166386" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2014-08-10 18:37:34 +0100" MODIFIED_BY="Anne Lawson" NO="9" NOTES="&lt;p&gt;Ceviker - no legend provided in article, assumed this data was provided as mean(SD)&lt;/p&gt;" NOTES_MODIFIED="2014-08-10 18:37:34 +0100" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="0.8251706079733638" P_Q="0.9013506567406699" P_Z="0.4545943195627782" Q="0.0153649208168031" RANDOM="YES" SCALE="0.54" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="146" TOTAL_2="139" UNITS="" WEIGHT="100.0" Z="0.7477776030259092">
<NAME>FEV<SUB>1</SUB> (L) - absolute or change</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.36896545596149266" CI_END="0.1734002812627266" CI_START="-0.24055386834955417" DF="1" EFFECT_SIZE="-0.03357679354341378" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.01" MODIFIED="2014-01-23 03:39:51 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.5435689967824963" P_Z="0.750519401120991" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="7.042549038614757" Z="0.317954566335748">
<NAME>Inpatient treatment (absolute)</NAME>
<CONT_DATA CI_END="0.24032750614714465" CI_START="-0.49632750614714444" EFFECT_SIZE="-0.1279999999999999" ESTIMABLE="YES" MEAN_1="1.239" MEAN_2="1.367" MODIFIED="2013-10-20 23:43:47 +0100" MODIFIED_BY="[Empty name]" ORDER="201" SD_1="0.531" SD_2="0.618" SE="0.18792565019177132" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="2.2238529382252374"/>
<CONT_DATA CI_END="0.26022022821795954" CI_START="-0.24022022821795952" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="0.91" MEAN_2="0.9" MODIFIED="2013-10-20 23:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="0.47" SD_2="0.29" SE="0.12766572763156095" STUDY_ID="STD-Willaert-2002" TOTAL_1="19" TOTAL_2="18" WEIGHT="4.81869610038952"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.03696985073564758" CI_START="-0.07696985073564756" DF="0" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.02" MODIFIED="2014-01-23 03:39:51 +0000" MODIFIED_BY="Julia A.E. Walters" NO="2" P_CHI2="1.0" P_Z="0.49140832470885876" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="103" WEIGHT="92.95745096138525" Z="0.6880706054978833">
<NAME>Inpatient treatment (change)</NAME>
<CONT_DATA CI_END="0.03696985073564758" CI_START="-0.07696985073564756" EFFECT_SIZE="-0.01999999999999999" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.12" MODIFIED="2014-01-23 03:39:51 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="620" SD_1="0.23" SD_2="0.19" SE="0.029066784484316287" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" WEIGHT="92.95745096138525"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0268507240997886" CI_END="0.2241749275466948" CI_START="-0.331765374109947" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.053795223281626094" ESTIMABLE="YES" I2="2.614861485668026" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2014-02-19 22:43:37 +0000" MODIFIED_BY="Julia A.E. Walters" NO="10" P_CHI2="0.31089979714350446" P_Q="1.0" P_Z="0.7044580967932337" Q="0.0" RANDOM="NO" SCALE="1.72" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="36" UNITS="" WEIGHT="100.00000000000001" Z="0.37930943253470867">
<NAME>FVC (L) - absolute</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0268507240997886" CI_END="0.2241749275466948" CI_START="-0.331765374109947" DF="1" EFFECT_SIZE="-0.053795223281626094" ESTIMABLE="YES" I2="2.614861485668026" ID="CMP-002.10.01" MODIFIED="2014-01-23 03:42:24 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.31089979714350446" P_Z="0.7044580967932337" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="100.00000000000001" Z="0.37930943253470867">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="0.2345956319913851" CI_START="-0.7825956319913852" EFFECT_SIZE="-0.274" ESTIMABLE="YES" MEAN_1="2.186" MEAN_2="2.46" MODIFIED="2013-10-20 23:44:47 +0100" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="0.911" SD_2="0.682" SE="0.2594923355751037" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="29.87109021707833"/>
<CONT_DATA CI_END="0.3719323793166362" CI_START="-0.29193237931663657" EFFECT_SIZE="0.039999999999999813" ESTIMABLE="YES" MEAN_1="1.88" MEAN_2="1.84" MODIFIED="2013-10-20 23:58:39 +0100" MODIFIED_BY="[Empty name]" ORDER="244" SD_1="0.52" SD_2="0.51" SE="0.16935636671636653" STUDY_ID="STD-Willaert-2002" TOTAL_1="19" TOTAL_2="18" WEIGHT="70.12890978292168"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.11" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="35.97" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>FEV<SUB>1</SUB>/FVC ratio</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.11.01" MODIFIED="2014-01-23 03:43:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="10.266391935626944" CI_START="-7.666391935626949" EFFECT_SIZE="1.2999999999999972" ESTIMABLE="YES" MEAN_1="53.9" MEAN_2="52.6" MODIFIED="2013-10-20 23:45:17 +0100" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="13.6" SD_2="14.5" SE="4.574773825617563" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.11918260019151337" CI_END="2.7952424934679403" CI_START="-0.24428135695918063" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2754805682543797" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="12" P_CHI2="0.729922777872047" P_Q="1.0" P_Z="0.09998506261059234" Q="0.0" RANDOM="NO" SCALE="13.96" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="1.6449260474846912">
<NAME>Dyspnoea score (VAS) at 7-10 days</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.11918260019151337" CI_END="2.7952424934679403" CI_START="-0.24428135695918063" DF="1" EFFECT_SIZE="1.2754805682543797" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" MODIFIED="2014-01-23 01:27:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.729922777872047" P_Z="0.09998506261059234" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="36" WEIGHT="100.0" Z="1.6449260474846912">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="3.0761359770447925" CI_START="-0.27613597704479353" EFFECT_SIZE="1.3999999999999995" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="2.7" MODIFIED="2013-10-20 23:56:10 +0100" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="2.6" SD_2="2.6" SE="0.8551871311238062" STUDY_ID="STD-Willaert-2002" TOTAL_1="19" TOTAL_2="18" WEIGHT="82.21150975062574"/>
<CONT_DATA CI_END="4.3033464061728885" CI_START="-2.9033464061728878" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="3.5" MODIFIED="2014-01-23 01:27:55 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="251" SD_1="5.8138" SD_2="5.5154" SE="1.8384758263904972" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="17.78849024937426"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.29" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cough score (VAS) at 7 days</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.01" MODIFIED="2014-01-23 02:23:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="4.191760821932887" CI_START="-1.7917608219328875" EFFECT_SIZE="1.1999999999999997" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="1.1" MODIFIED="2014-01-23 02:23:50 +0000" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="5.8138" SD_2="3.3941" SE="1.5264366312501223" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.14" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.31" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Sputum volume score (VAS) at 7 days</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.14.01" MODIFIED="2014-01-23 02:24:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="4.4675475193916565" CI_START="-2.467547519391657" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="2.4" MODIFIED="2014-01-23 02:24:54 +0000" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="5.8138" SD_2="5.0912" SE="1.7691894069193257" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.15" MODIFIED="2014-08-10 18:26:27 +0100" MODIFIED_BY="Anne Lawson" NO="15" NOTES="&lt;p&gt;Ceviker - no legend provided in article, assumed this data was provided as mean(SD)&lt;/p&gt;" NOTES_MODIFIED="2014-08-10 18:26:27 +0100" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="22.72" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>PaO<SUB>2</SUB> (mmHg) at 7 days</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.15.01" MODIFIED="2014-01-23 04:45:16 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="6.211296267325565" CI_START="-8.61129626732557" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="65.3" MEAN_2="66.5" MODIFIED="2013-09-28 07:17:22 +0100" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="10.6" SD_2="12.5" SE="3.7813430888449617" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.785922255397526" CI_START="-0.7859222553975256" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.16" MODIFIED="2014-08-10 18:24:20 +0100" MODIFIED_BY="Anne Lawson" NO="16" NOTES="&lt;p&gt;Ceviker - no legend provided in article, assumed this data was provided as mean(SD)&lt;/p&gt;" NOTES_MODIFIED="2014-08-10 18:24:20 +0100" NOTES_MODIFIED_BY="Anne Lawson" P_CHI2="1.0" P_Q="1.0" P_Z="0.0863614086493814" Q="0.0" RANDOM="NO" SCALE="14.86" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.7149117467550634">
<NAME>PaCO<SUB>2</SUB> (mmHg) at 7 days</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.785922255397526" CI_START="-0.7859222553975256" DF="0" EFFECT_SIZE="5.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.01" MODIFIED="2014-01-23 04:43:17 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="1.0" P_Z="0.0863614086493814" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0" Z="1.7149117467550634">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="11.785922255397526" CI_START="-0.7859222553975256" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="40.8" MEAN_2="35.3" MODIFIED="2013-09-28 07:16:22 +0100" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="11.2" SD_2="8.5" SE="3.207162123885989" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.17" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.62" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="107" TOTAL_2="103" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Health status: Clinical COPD Questionnaire (change at 1 week)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.17.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treament</NAME>
<CONT_DATA CI_END="0.37054981244000307" CI_START="-0.1705498124400029" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-1.1" MODIFIED="2013-09-28 07:33:04 +0100" MODIFIED_BY="[Empty name]" ORDER="621" SD_1="1.0" SD_2="1.0" SE="0.13803815507533065" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.18" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.75" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="107" TOTAL_2="103" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life: SGRQ (change at 7 days)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.18.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="103" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treament</NAME>
<CONT_DATA CI_END="2.9277049603818917" CI_START="-4.327704960381892" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-4.4" MEAN_2="-3.7" MODIFIED="2012-09-24 05:24:00 +0100" MODIFIED_BY="Julia A.E. Walters" ORDER="621" SD_1="14.2" SD_2="12.6" SE="1.8509038885391595" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.19" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="19" NOTES="&lt;p&gt;Willaert&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.63" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life: CRQ Dyspnoea (change at 4 weeks)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.19.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="3.649651919875218" CI_START="-7.0496519198752186" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.9" MODIFIED="2014-01-23 03:24:19 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="346" SD_1="4.5033" SD_2="7.2" SE="2.7294643993831467" STUDY_ID="STD-Willaert-2002" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.20" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="20" NOTES="&lt;p&gt;Willaert&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.56" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life: CRQ Fatigue (change at 4 weeks)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.20.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="1.7518156481720824" CI_START="-6.951815648172083" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="5.0" MODIFIED="2014-01-23 03:25:41 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="347" SD_1="4.5033" SD_2="5.4" SE="2.2203549057526817" STUDY_ID="STD-Willaert-2002" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.21" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="21" NOTES="&lt;p&gt;Willaert&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="37.87" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life: CRQ Mastery (change at 4 weeks)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.21.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="1.0923596556148598" CI_START="-8.092359655614858" EFFECT_SIZE="-3.4999999999999996" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="4.6" MODIFIED="2014-01-23 03:28:01 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="348" SD_1="5.1962" SD_2="5.4" SE="2.3430836953325707" STUDY_ID="STD-Willaert-2002" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.22" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="22" NOTES="&lt;p&gt;Willaert&lt;/p&gt;" NOTES_MODIFIED="2014-08-28 14:35:02 +0100" NOTES_MODIFIED_BY="Emma J Welsh" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.6" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life: CRQ Emotion (change at 4 weeks)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IVCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.22.01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="2.6598809515912123" CI_START="-11.059880951591213" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="7.2" MODIFIED="2014-01-23 03:29:52 +0000" MODIFIED_BY="Julia A.E. Walters" ORDER="349" SD_1="9.6995" SD_2="6.3" SE="3.5000035744029367" STUDY_ID="STD-Willaert-2002" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9268946821186472" CI_END="3.1653796374952883" CI_START="-0.09406227120407618" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.535658683145606" ESTIMABLE="YES" I2="31.66819386366543" I2_Q="0.0" ID="CMP-002.23" MODIFIED="2014-02-28 00:27:56 +0000" MODIFIED_BY="Julia A.E. Walters" NO="23" P_CHI2="0.23143710794814099" P_Q="1.0" P_Z="0.06477016688526721" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="148" UNITS="" WEIGHT="100.0" Z="1.8468411438647965">
<NAME>Duration of hospitalisation (days)</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.9268946821186472" CI_END="3.1653796374952883" CI_START="-0.09406227120407618" DF="2" EFFECT_SIZE="1.535658683145606" ESTIMABLE="YES" I2="31.66819386366543" ID="CMP-002.23.01" MODIFIED="2014-01-23 03:14:52 +0000" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.23143710794814099" P_Z="0.06477016688526721" STUDIES="3" TAU2="0.0" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0" Z="1.8468411438647965">
<NAME>Inpatient treatment</NAME>
<CONT_DATA CI_END="4.984621302055908" CI_START="-1.58462130205591" EFFECT_SIZE="1.6999999999999993" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="11.0" MODIFIED="2013-10-07 05:40:34 +0100" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="6.4" SD_2="3.9" SE="1.6758579892103032" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="20" WEIGHT="24.6181769463882"/>
<CONT_DATA CI_END="2.7807398929613014" CI_START="-1.3807398929612993" EFFECT_SIZE="0.7000000000000011" ESTIMABLE="YES" MEAN_1="11.9" MEAN_2="11.2" MODIFIED="2013-09-28 07:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="8.6" SD_2="6.7" SE="1.0616214937488193" STUDY_ID="STD-de-Jong-2007" TOTAL_1="107" TOTAL_2="103" WEIGHT="61.346658442142186"/>
<CONT_DATA CI_END="9.250152623356238" CI_START="0.549847376643763" EFFECT_SIZE="4.9" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="10.6" MODIFIED="2013-10-20 23:59:17 +0100" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="10.3" SD_2="2.8" SE="2.2195064081124376" STUDY_ID="STD-Willaert-2002" TOTAL_1="23" TOTAL_2="25" WEIGHT="14.03516461146961"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="24" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - hyperglycaemia</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="4" I2="0.0" ID="CMP-002.24.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-02 01:53:31 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<DICH_DATA CI_END="19.94240698639235" CI_START="1.198513027249428" EFFECT_SIZE="4.888888888888889" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="1.2997775751301495" LOG_CI_START="0.07864275896357571" LOG_EFFECT_SIZE="0.6892101670468626" MODIFIED="2013-09-28 07:13:49 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.7173006357310734" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="20" VAR="0.514520202020202" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="25" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effect - hypertension</NAME>
<GROUP_LABEL_1>IVCS</GROUP_LABEL_1>
<GROUP_LABEL_2>OCS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IVCS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OCS</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-06-02 01:53:46 +0100" MODIFIED_BY="Julia A.E. Walters" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Inpatient treatment</NAME>
<DICH_DATA CI_END="169.89878129926606" CI_START="0.3957650519079413" EFFECT_SIZE="8.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.230190263643018" LOG_CI_START="-0.4025625588755845" LOG_EFFECT_SIZE="0.9138138523837167" MODIFIED="2013-09-28 07:14:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DT - In Ceviker &amp;quot;Worsening of Previous Controlled Hypertension&amp;quot; - Included at the moment (possibly discuss)&lt;/p&gt;" NOTES_MODIFIED="2013-09-28 07:14:58 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="1.5464920402840814" STUDY_ID="STD-Ceviker-2014" TOTAL_1="20" TOTAL_2="20" VAR="2.391637630662021" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-08-28 15:08:48 +0100" MODIFIED_BY="Emma J Welsh">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-06-02 02:23:41 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for 2008-2014 literature searches.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAMxCAYAAAB/2dJ6AABn20lEQVR42uzdD4RV+f8H/i9ZSVYi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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-08-28 15:08:47 +0100" MODIFIED_BY="Emma J Welsh" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU4AAAOtCAIAAABhfhs7AAAzRElEQVR42u3dv24lxfb2cUtIiMCB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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-08-28 15:08:48 +0100" MODIFIED_BY="Emma J Welsh" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAAIgCAMAAAAP/QdFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-08-28 14:35:24 +0100" MODIFIED_BY="Emma J Welsh" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-08-28 15:08:48 +0100" MODIFIED_BY="Emma J Welsh" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_ROB_TABLE:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAukAAAKwCAMAAAASmxEGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-08-28 14:35:24 +0100" MODIFIED_BY="Emma J Welsh" NO="6" REF_ID="CMP-001.04" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">
<APPENDIX ID="APP-01" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<TITLE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-28 15:34:22 +0100" MODIFIED_BY="Julia A.E. Walters">
<P>#1 COPD[MeSH Terms]<BR/>#2 "adrenal cortex hormone*"<BR/>#3 steroid<BR/>#4 steroids<BR/>#5 glucocorticoid*<BR/>#6 corticoid*<BR/>#7 corticosteroid*<BR/>#8 beclomethasone<BR/>#9 betamethasone<BR/>#10 fluticasone<BR/>#11 cortisone<BR/>#12 dexamethasone<BR/>#13 hydrocortisone<BR/>#14 prednisolone<BR/>#15 prednisone<BR/>#16 methylprednisolone<BR/>#17 methylprednisone<BR/>#18 triamcinolone<BR/>#19 (#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)<BR/>#20 randomised controlled trial [pt]<BR/>#21 controlled clinical trial [pt]<BR/>#22 randomised [tiab]<BR/>#23 placebo [tiab]<BR/>#24 clinical trials as topic [mesh: noexp]<BR/>#25 randomly [tiab]<BR/>#26 trial [ti]<BR/>#27 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26)<BR/>#28 (animals [mh] NOT humans [mh])<BR/>#29 (#27 NOT #28)<BR/>#30 ("2012/01/01"[Date - Publication] : "3000"[Date - Publication])<BR/>#31 (#1 AND #19 AND #29 AND #30)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh" NO="2">
<TITLE MODIFIED="2014-08-28 14:35:02 +0100" MODIFIED_BY="Emma J Welsh">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-28 12:23:23 +0100" MODIFIED_BY="Emma J Welsh">
<P>#1 chronic AND obstructive AND pulmonary AND 'disease'/exp AND [embase]/lim AND [2010-2013]/py</P>
<P>#2 'triamcinolone'/exp OR 'methylprednisone'/exp OR 'methylprednisolone'/exp OR 'prednisone'/exp OR 'prednisolone'/exp OR 'hydrocortisone'/exp OR 'dexamethasone'/exp OR 'cortisone'/exp OR 'fluticasone'/exp OR 'betamethasone'/exp OR 'beclomethasone'/exp OR 'corticosteroid'/exp OR 'corticoid'/exp OR 'glucocorticoid'/exp OR 'steroids'/exp OR 'steroid'/exp OR 'adrenal'/exp AND cortex AND 'hormone'/exp AND [embase]/lim AND [2010-2013]/py</P>
<P>#1 AND #2 AND ([controlled clinical trial]/lim OR [randomised controlled trial]/lim) AND [humans]/lim AND [embase]/lim AND [2010-2013]/py</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;16 &lt;/span&gt;studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;20 studies&lt;/span&gt; included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;9 &lt;/span&gt;studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;290 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;290 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;288 of records identified through database searching (2008-2014)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;278 records excluded on title/abstract&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;span&gt;3 full-text articles excluded&lt;/span&gt;, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>